

Tuesday, December 05, 2017

Volume 48 No. 12



NOTICE – Items in this issue will be listed online weekly and printed monthly.

ACACIA COMMUNICATIONS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2017	2016
Total Revenues	298,563	335,985
Cost & expenses	266,453	259,739
Operating income	32,110	76,246
Other income (expense), net	(60)	(3,429)
Net before taxes	34,312	73,001
Income taxes	(24,560)	5,918
Net income	58,872	67,083
Earnings common share		
Primary	\$1.52	\$1.95
Fully Diluted	\$1.41	\$1.64
Common Shares:		
Full Diluted	41,660	25,183
Year-end	39,302	35,723

ACELRX PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2017	2016
Total Revenues	7,255	10,922
Cost & expenses	38,130	35,741
Operating income	(30,875)	(24,819)
Net before taxes	(41,621)	(33,509)
Income taxes	2	(34)
Net income	(41,623)	(33,475)
Earnings common share		
Primary	\$(0.91)	\$(0.74)
Fully Diluted	\$(0.91)	\$(0.74)
Common Shares:		
Full Diluted	45,701	45,306
Year-end	49,641	45,334

ACHAOGEN, INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2017	2016
Cost & expenses	93,528	68,325
Operating income	(84,222)	(37,286)
Interest expense	2,170	1,555
Other income (expense), net	(2,843)	(2,662)
Net income	(89,235)	(41,503)
Earnings common share		
Primary	\$(2.31)	\$(1.88)
Fully Diluted	\$(2.31)	\$(1.88)
Common Shares:		
Full Diluted	38,710	22,046
Year-end	42,361	27,451

ACHILLION PHARMACEUTICALS INC.

Secondary Offering On Nov. 15, 2017, Co. announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc. ("JJDC"), which shares constitute all of JJDC's equity position in Co., at a public offering price of \$2.75 per share. The offering is expected to close on Nov. 20, 2017, subject to the satisfaction of customary closing conditions. Co. will not sell any shares or receive any proceeds from the offering, and the total number of shares of its outstanding common stock will not change as a result of the offering.

ACLARIS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2017	2016
Total Revenues	684	
Cost & expenses	47,665	36,940
Operating income	(46,981)	(36,940)
Other income (expense), net	1,392	336
Net income	(45,589)	(36,604)
Balance for common	(45,589)	(36,604)
Earnings common share		

Primary	\$(1.68)	\$(1.76)
Fully Diluted	\$(1.68)	\$(1.76)
Common Shares:		
Full Diluted	27,180	20,753
Year-end	30,835	21,424

ADVANCED EMISSIONS SOLUTIONS INC

New Accountant On Nov. 16, 2017, Hein & Associates LLP resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Moss Adams LLP as its new independent public accounting firm.

ADVERUM BIOTECHNOLOGIES INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2017	2016
Cost & expenses	44,640	92,864
Operating income	(43,252)	(91,897)
Other income (expense), net	1,894	544
Net income	(41,358)	(91,353)
Earnings common share		
Primary	\$(0.97)	\$(2.66)
Fully Diluted	\$(0.97)	\$(2.66)
Common Shares:		
Full Diluted	42,849	34,382
Year-end	43,517	41,719

ADVISORY BOARD COMPANY (THE)

Interest Sale Completed On Nov. 17, 2017, Co. sold its wholly-owned subsidiary, Royall Acquisition Co., and certain of its assets related to Co.'s education business to Vista Equity Partners Fund VI, L.P. affiliates, Avatar Holdco, LLC and EAB Global, Inc., for \$1,550,000,000 in cash, subject to certain adjustments.

ADVISORY BOARD COMPANY (THE)

Merger Completed On Nov. 17, 2017, UnitedHealth Group Inc. ("UnitedHealth") wholly-owned subsidiary, OptumInsight, Inc. ("Optum"), through its wholly-owned subsidiary, Apollo Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Optum. As the result of the merger, each share of Co.'s common stock outstanding immediately prior to the Effective Time (other than shares of common stock of Co. held in Co.'s treasury, if any, or held by Co. or any wholly owned subsidiary of Co., if any, and shares of Co.'s common stock held by Optum or Merger Sub or any other direct or indirect wholly owned subsidiary of Optum, if any) was converted into the right to receive \$53.81 in cash, without interest (the "Merger Consideration"), consisting of (1) \$52.65 in cash, plus (2) an additional amount in cash equal to \$1.16, calculated in accordance with the Merger Agreement based on the per-share, after-tax value of Co.'s equity interests in Evolent Health, Inc. Pursuant to the Merger Agreement and by virtue of the Merger, at the Effective Time each share of common stock of Merger Sub outstanding immediately prior to the Effective Time was converted into one share of the common stock of Co., as the surviving corporation in the Merger, and constitutes the only outstanding shares of Co. In addition, each Co. stock option, other than those granted under Co.'s 2014 supplemental long-term incentive plan that are not vested in accordance with their terms at the Effective Time (such options, the "LTIP Options"), that was held by a grantee who is an active employee, other than an employee of the education business (each, an "Education Employee"), and that was outstanding immediately prior to the Effective Time, whether vested or unvested, was assumed and converted into an option to purchase a number of shares of UnitedHealth common stock, on the same terms and conditions as were applicable immediately prior to the Effective Time (except that any performance-based vesting conditions applicable to such option do not apply from and after the Effective Time), equal to the product of (1) the total number of shares of Co. common stock subject to such option, multiplied by (2) the quotient obtained by dividing the (A) Merger Consideration by (B)

the volume weighted average of the closing sale price per share of UnitedHealth common stock on the New York Stock Exchange for the five full consecutive trading days ending on and including the third business day prior to the Closing Date (the "Equity Award Conversion Ratio"), with any fractional shares rounded down to the next lower whole number of shares. The exercise price of such UnitedHealth options was equal to the quotient obtained by dividing (1) the exercise price per share applicable to Co. option immediately prior to the Effective Time by (2) the Equity Award Conversion Ratio, with any fractional shares rounded up to the next higher number of whole cents. Each LTIP Option that was held by a grantee who is an active employee, other than an Education Employee, and that was outstanding immediately prior to the Effective Time was assumed and converted into an option to purchase a number of shares of UnitedHealth common stock, on the same terms and conditions as were applicable immediately prior to the Effective Time (provided, however, that the compensation committee of Co.'s board of directors equitably adjusted the performance-based vesting conditions applicable to such award as of immediately prior to the Effective Time), equal to the product of (1) the total number of shares of Co. common stock subject to such LTIP Option, multiplied by (2) the Equity Award Conversion Ratio, with any fractional shares rounded down to the next lower whole number of shares, and with performance-vesting conditions equitably adjusted to reflect the Merger. The exercise price of such UnitedHealth options was equal to the quotient obtained by dividing the (1) exercise price per share applicable to the LTIP Option immediately prior to the Effective Time by (2) the Equity Award Conversion Ratio, with any fractional shares rounded up to the next higher number of whole cents. Each Co. stock option that was held by a non-employee member of Co.'s board of directors or a former employee, other than a former Education Employee, as of immediately prior to the Effective Time, and that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash equal to the excess, if any, of the Merger Consideration over the per-share exercise price for such option multiplied by the total number of shares of Co.'s common stock underlying such option, payable, less any required withholding taxes, within two business days following the Effective Time. Each Co. time-vested restricted stock unit and each Co. performance-vested restricted stock unit other than the LTIP PSUs that was held by a grantee who was an active employee, other than an Education Employee, and that was outstanding immediately prior to the Effective Time, whether vested or unvested, was assumed and converted into an equivalent UnitedHealth award denominated in shares of UnitedHealth common stock, on the same terms and conditions (except that any performance-based vesting conditions applicable to such awards will not apply from and after the Effective Time), equal to the product of (1) the total number of shares of Co. common stock subject to such awards, multiplied by (2) the Equity Award Conversion Ratio, with any fractional shares rounded down to the next lower whole number of shares. Each Co. time-vested restricted stock unit that was held by a non-employee member of Co.'s board of directors or a former employee, other than a former Education Employee, as of immediately prior to the Effective Time, and that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration multiplied by the total number of shares of Co.'s common stock underlying such restricted stock unit, payable, less any required withholding taxes, within two business days following the Effective Time.

AEGLEA BIOTHERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2017	2016
Cost & expenses	24,773	19,744
Operating income	(21,050)	(16,363)
Interest income	332	172
Other income (expense), net	(35)	(24)

Net income	(20,753)	(16,215)	Other income (expense), net	716	338	Income contin. oper.	(11,129,000)	(16,220,000)
Balance for common	(20,753)	(16,215)	Net before taxes	19,950	10,105	Net income	(11,349,000)	(25,571,000)
Earnings common share			Income taxes	(8,981)	2,927	Earnings common share		
Primary	\$(1.42)	\$(1.89)	Net income	28,931	7,178	Primary	\$(1.00)	\$(3.01)
Fully Diluted	\$(1.42)	\$(1.89)	Balance for common	28,917	7,168	Fully Diluted	\$(1.00)	\$(3.01)
Common Shares:			Earnings common share			Common Shares:		
Full Diluted	14,641	8,598	Primary	\$0.62	\$0.16	Full Diluted	11,349,000	8,505,000
Year-end	16,473	13,431	Fully Diluted	\$0.59	\$0.15	Year-end	15,148,000	8,810,000

AETHLON MEDICAL INC

Earnings, 6 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	2,396,422	3,750,602
Operating income	(2,396,422)	(3,358,529)
Other income (expense), net	(507,123)	(962,730)
Net income	(3,154,128)	(4,400,002)
Earnings common share		
Primary	\$(0.35)	\$(0.57)
Fully Diluted	\$(0.35)	\$(0.57)
Common Shares:		
Full Diluted	8,939,624	7,690,369
Year-end	9,618,909	7,711,811

AEVI GENOMIC MEDICINE INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	27,540	33,399
Operating income	(27,540)	(33,399)
Other income (expense), net	(15)	(6)
Net before taxes		(33,405)
Income taxes		16
Net income	(27,555)	(33,421)
Earnings common share		
Primary	\$(0.74)	\$(0.97)
Fully Diluted	\$(0.74)	\$(0.97)
Common Shares:		
Full Diluted	37,109	34,511
Year-end	37,110	37,098

AGROFRESH SOLUTIONS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	109,891,000	107,996,000
Cost & expenses	73,376,000	104,194,000
Operating income	5,180,000	(26,076,000)
Interest expense	27,495,000	43,850,000
Other income (expense), net	(40,000)	16,000
Foreign currency	10,584,000	682,000
Net before taxes	(11,771,000)	(69,228,000)
Income taxes	(11,895,000)	(26,239,000)
Net income	124,000	(42,989,000)
Earnings common share		
Primary	\$.....	\$(0.87)
Fully Diluted	\$.....	\$(0.87)
Common Shares:		
Full Diluted	50,134,591	49,385,733
Year-end	50,340,014	49,923,562

AIMMUNE THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	91,634	56,226
Operating income	(91,634)	(56,226)
Interest income	1,475	478
Net income	(90,159)	(55,748)
Earnings common share		
Primary	\$(1.79)	\$(1.33)
Fully Diluted	\$(1.79)	\$(1.33)
Common Shares:		
Full Diluted	50,254	41,831
Year-end	50,695	42,349

AKAMAI TECHNOLOGIES INC

Acquisition Completed On Nov. 27, 2017, Co. acquired Nominum Inc., a provider of domain name system (DNS) software solutions for service providers worldwide. Terms of the transaction were not disclosed.

ALARM.COM HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	250,144	191,312
Cost & expenses	216,581	176,545
Operating income	20,782	9,904
Interest expense	1,548	137

ALCENRA CAPITAL CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	9,748,740	12,472,578
Net income	14,279,366	16,290,031
Earnings common share		
Primary	\$1.03	\$1.21
Fully Diluted	\$1.03	\$1.21
Common Shares:		
Full Diluted	13,825,432	13,502,152
Year-end	14,245,220	13,490,636

ALLIANCE RESOURCE PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	1,312,989	1,404,053
Cost & expenses	867,760	916,678
Operating income	251,120	241,639
Interest income	82	8
Interest expense	28,904	23,386
Other income (expense), net	7,527	1,586
Net before taxes	229,825	219,847
Income taxes	(3)	4
Net income	229,828	219,843
Earnings common share		
Primary	\$2.32	\$2.08
Fully Diluted	\$2.32	\$2.08
Common Shares:		
Full Diluted	87,925	74,347
Year-end	130,704	74,375

ALMOST FAMILY INC

Merger Development On Nov. 15, 2017, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") with LHC Group, Inc. ("LHC Group"), and Hammer LHC Sub, Inc., a newly-formed and wholly-owned subsidiary of LHC Group ("Merger Sub"), providing for a "merger of equals" business combination of Co. and LHC Group. The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into Co. (the "Merger"), with Co. continuing as the surviving corporation and as a wholly-owned subsidiary of LHC Group. Pursuant to the terms and conditions of the Merger Agreement, the stockholders of Co. will be entitled to receive 0.9150 shares of LHC Group common stock for each share of Co. common stock, plus the cash equivalent of any fractional share. Upon the closing of the Merger, Co. stockholders will own approximately 41.5%, and the LHC Group stockholders will own approximately 58.5%, of the combined company. Also, each outstanding stock option of Co. will be converted into an option to purchase 0.9150 shares of LHC Group common stock at an exercise price per share equal to the quotient of the exercise price of Co. option divided by 0.9150, and the option shall otherwise remain subject to the same vesting terms and other conditions. In addition, each outstanding share of restricted stock of Co. will be converted into a restricted share of LHC Group subject to the same vesting terms and other conditions (except that the performance condition of performance-based stock awards will be deemed satisfied and the shares will vest solely on the basis of time). The transaction, which is expected to be completed in the first half of 2018, is subject to the receipt of regulatory approvals and other customary closing conditions as well as the approval of shareholders of both LHC Group and Co.

ALPHATEC HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	75,456,000	93,158,000
Cost & expenses	80,335,000	100,878,000
Operating income	(5,395,000)	(8,313,000)
Interest expense	5,669,000	3,118,000
Other income (expense), net	(8,000)	(9,751,000)
Net before taxes	(11,072,000)	(21,182,000)
Income taxes	57,000	(4,962,000)

ALPINE IMMUNE SCIENCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	1,603
Cost & expenses	11,788	24,078
Operating income	(10,185)	(24,078)
Interest expense	76
Other income (expense), net	6,539	328
Net before taxes	(3,461)
Income taxes	4
Net income	(3,465)	(23,750)
Balance for common	(3,465)	(23,750)
Earnings common share		
Primary	\$(0.87)	\$(6.12)
Fully Diluted	\$(0.87)	\$(6.12)
Common Shares:		
Full Diluted	3,990	3,869
Year-end	13,882	3,876

ALTAIR ENGINEERING INC**Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2016	2015
Revenue: software	223,818	205,567
Revenue: software related services	35,770	37,294
Total software	259,588	242,861
Revenue - client engineering services	47,702	45,075
Other revenue	5,950	6,193
Total revenues	313,240	294,129
Cost of revenue: software	31,962	27,406
Cost of revenue: software related services	27,653	30,079
Total software	59,615	57,485
Cost of revenue: client engineering services	38,106	36,081
Other cost of revenue	4,879	5,642
Total cost of revenue	102,600	99,208
Gross profit	210,640	194,921
Research & development	71,325	62,777
Sales & marketing	66,086	63,080
General & administrative	57,202	54,069
Amortization of intangible assets	3,322	2,624
Other operating income	2,742	2,576
Total operating expenses	195,193	179,974
Operating income (loss)	15,447	14,947
Interest expense	2,265	2,416
Foreign exchange gain (loss)	271	(973)
Other income	249	191
Other income (expenses), net	520	(782)
Income before income taxes - U.S.	(2,225)	(6,861)
Income before income taxes - Foreign	15,927	18,610
Income (loss) before provision for income taxes	13,702	11,749
Current Non-U.S. income taxes	9,413	9,893
Current U.S. State & local income taxes	202	56
Current income taxes	9,615	9,949
Deferred federal income taxes	(5,358)	(8,445)
Deferred Non-U.S. income taxes	(610)	(587)
Deferred U.S. State & local income taxes	(108)	(99)
Deferred income taxes	(6,076)	(9,131)

Provision for deferred (prepaid) income taxes	(825,869)	8,124	(52,214)
Total provision for (benefit from) income taxes	101,226	95,257	113,236
Net income (loss)	727,259	861,664	696,878
Weighted average shares outstanding - basic	346,371	308,736	312,660
Weighted average shares outstanding - diluted	350,484	312,308	316,872
Year end shares outstanding	368,636	308,171	312,061
Net earnings (loss) per share - basic	\$2.09	\$2.79	\$2.23
Net earnings (loss) per share - diluted	\$2.07	\$2.76	\$2.20
Dividends declared & paid per share	\$1.77	\$1.66	\$1.57
Total number of employees	1001115,300	1001110,000	1001119,700
Number of common stockholders	100122,261	100131,967	100142,056
Foreign currency translation adjustments	...	(6,006)	(12,925)

¹ Includes stock-based compensation expense - cost of sales: \$12,569,000; ² Includes stock-based compensation expense - cost of sales: \$7,808,000; ³ Includes stock-based compensation expense - cost of sales: \$8,983,000; ⁴ Includes stock-based compensation expense - research and development expense: \$51,258,000; ⁵ Includes stock-based compensation expense - research and development expense: \$27,039,000; ⁶ Includes stock-based compensation expense - research and development expense: \$26,617,000; ⁷ Includes stock-based compensation expense - selling, marketing, general and administrative expense: \$40,361,000; ⁸ Includes stock-based compensation expense - selling, marketing, general and administrative expense: \$28,574,000; ⁹ Includes stock-based compensation expense - selling, marketing, general and administrative expense: \$33,319,000; ¹⁰ As is; ¹¹ Approximately; ¹² As of November 17, 2017; ¹³ As of November 18, 2016; ¹⁴ As of November 20, 2015

Consolidated Balance Sheet, Years Ended (\$000):

	10/28/17	10/29/16 (revised)
Cash	226,160	67,877
Available-for-sale	751,678	693,255
Held-to-maturity	70,000	160,000
Cash & cash equivalents	1,047,838	921,132
Short-term investments	...	3,134,661
Accounts receivable, gross	696,166	482,726
Less: allowances	7,213	5,117
Accounts receivable, net	688,953	477,609
Raw materials	35,436	20,263
Work in process	376,476	232,196
Finished goods	138,904	124,096
Inventories	1,050,816	1,376,555
Prepaid income tax	3,522	6,405
Prepaid expenses & other current assets	60,209	58,501
Total current assets	2,351,338	4,974,863
Land & buildings	794,456	564,329
Machinery & equipment	2,368,215	1,994,115
Office equipment	66,493	58,785
Leasehold improvements	75,263	59,649
Property, plant & equipment, at cost	3,304,427	2,676,878
Less accumulated depreciation & amortization	2,197,123	2,040,762
Net property, plant & equipment	1,107,304	636,116
Deferred compensation plan investments	32,572	26,152
Other investments	24,838	21,937
Goodwill	12,217,455	1,679,116
Intangible assets, net	5,319,425	549,368

Deferred tax assets	32,322	36,005
Other assets	56,040	46,721
Total assets	21,141,294	7,970,278
Accounts payable	236,629	171,439
Deferred income on shipments to distributors, net	473,972	351,538
Income taxes payable	86,905	4,100
Debt, current	300,000	...
Accrued compensation & benefits	271,321	112,003
Accrued interest	59,400	26,411
Accrued special charges	37,348	12,374
Other accrued liabilities	130,757	105,069
Accrued liabilities	498,826	255,857
Total current liabilities	1,596,332	782,934
Long-term debt	7,551,084	1,732,177
Deferred income taxes	1,674,683	109,931
Deferred compensation plan liability	32,572	26,152
Other non-current liabilities	125,083	153,466
Total non-current liabilities	9,383,422	2,021,726
Common stock	61,441	51,363
Capital in excess of par value	5,250,519	402,270
Retained earnings	4,910,939	4,785,799
Foreign currency translation adjustment	(22,491)	(24,063)
Unrealized holding gains (loss) on available-for-sale securities	3	800
Unrealized holding losses on available-for-sale securities	(1)	(281)
Unrealized holding gains (losses) on derivatives	(10,879)	(18,884)
Pension plans	(27,991)	(31,386)
Accumulated other comprehensive income (loss)	(61,359)	(73,814)
Total shareholders' equity	10,161,540	5,165,618

¹ Includes stock-based compensation - inventories: \$5,373,000; ² Includes stock-based compensation - inventories: \$2,486,000

ANSYS INC.

Acquisition Completed On Nov. 15, 2017, Co. acquired 3DSIM, the developer of premier additive manufacturing simulation technology. Terms of the transaction were not disclosed.

ANTHERA PHARMACEUTICALS INC

Special Meeting of Stockholders On Nov. 20, 2017, Co. scheduled its Special Meeting of Stockholders on Jan. 5, 2018, at 11:00 a.m. (local time), at the offices of Goodwin Procter LLP, Three Embarcadero Center, San Francisco, CA 94111.

APPFOLIO INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	105,906	77,576
Cost & expenses	89,611	77,595
Operating income	6,948	(7,131)
Other income (expense), net	(93)	(34)
Net before taxes	7,232	(6,944)
Income taxes	93	48
Net income	7,139	(6,992)
Earnings common share		
Primary	\$0.21	\$(0.21)
Fully Diluted	\$0.20	\$(0.21)
Common Shares:		
Full Diluted	35,091	33,529
Year-end	33,942	33,693

APIAN CORP

Secondary Offering On Nov. 15, 2017, Co. announced the pricing of a follow-on offering of 3,800,000 shares of its Class A common stock at a price of \$20.25 per share, before underwriting discounts. All of the shares are being offered by certain selling stockholders. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to 570,000 additional shares of Class A common stock at the public offering price, less the underwriting discount. Co. will not receive any of

the proceeds from the sale but will bear the costs associated with the offering, other than underwriting discounts and commissions. The offering is expected to close on or about Nov. 20, 2017, subject to customary closing conditions.

APPROACH RESOURCES INC

New Accountant On Nov. 16, 2017, Hein & Associates LLP resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Moss Adams LLP as its new independent public accounting firm.

APTIO INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	136,152	116,249
Cost & expenses	155,253	137,037
Operating income	(19,101)	(20,788)
Foreign currency	173	(774)
Net before taxes	(18,117)	(23,308)
Income taxes	614	328
Net income	(18,731)	(23,636)
Balance for common	(18,731)	(23,636)
Earnings common share		
Primary	\$(0.48)	\$(1.78)
Fully Diluted	\$(0.48)	\$(1.78)
Common Shares:		
Full Diluted	39,240	13,307
Year-end	40,376	38,298

APTEVO THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	11,840	7,203
Cost & expenses	48,968	129,109
Operating income	(37,128)	(121,906)
Other income (expense), net	(1,356)	(417)
Net before taxes	(38,484)	(122,323)
Income taxes	(15,587)	(18,590)
Net income	16,733	(97,469)
Earnings common share		
Primary	\$0.79	\$(4.82)
Fully Diluted	\$0.79	\$(4.82)
Common Shares:		
Full Diluted	21,138	20,232
Year-end	21,427	20,246

AQUINOX PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	34,587,000	26,182,000
Interest income	720,000	391,000
Other income (expense), net	(48,000)	33,000
Net income	(33,915,000)	(25,758,000)
Earnings common share		
Primary	\$(1.45)	\$(1.48)
Fully Diluted	\$(1.45)	\$(1.48)
Common Shares:		
Full Diluted	23,444,181	17,372,616
Year-end	23,464,930	23,423,150

ARCHROCK PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	415,741	426,954
Cost & expenses	306,878	307,270
Deprec., depl. & amort.	108,947	115,951
Operating income	(84)	3,733
Net before taxes	(84)	3,733
Income taxes	2,970	469
Net income	(3,054)	3,264
Earnings common share		
Primary	\$(0.05)	\$0.05
Fully Diluted	\$(0.05)	\$0.05
Common Shares:		
Full Diluted	66,298	59,805
Year-end	71,608	61,252

ARDELYX INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	76,077	81,420
Operating income	(76,077)	(81,420)
Other income (expense), net	1,624	307
Net income	(74,453)	(81,113)
Earnings common share		
Primary	\$(1.57)	\$(2.15)

Fully Diluted	\$(1.57)	\$(2.15)
Common Shares:		
Full Diluted	47,404	37,706
Year-end	47,504	47,296

ARGOS THERAPEUTICS INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	228,449	781,828
Cost & expenses	60,343,031	37,381,199
Operating income	(60,114,582)	(36,599,371)
Interest income	50,485	24,399
Interest expense	1,089,971	1,482,943
Other income (expense), net	22,469,431	384,641
Net income	(38,684,637)	(37,673,274)
Earnings common share		
Primary	\$(0.82)	\$(1.30)
Fully Diluted	\$(0.82)	\$(1.30)
Common Shares:		
Full Diluted	47,036,779	28,903,427
Year-end	78,819,798	41,243,314

ARSANIS INC

Offering On Nov. 15, 2017, Co. announced a public offering and proposed to offer 4,000,000 shares of common stock. The estimated initial public offering price is \$10.00 per share. Co. granted the underwriters an option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any. Co. has applied to list its common stock on The NASDAQ Global Market under the symbol ASNS.

ARSANIS INC

Offering On Nov. 16, 2017, Co. announced a public offering pursuant to Common Stock, par value \$0.001 per share. Co. proposed to offer 2,176,873 shares at a proposed maximum offering price per share of \$7.58, which amounted to a proposed maximum aggregate offering price of \$16,503,129.72. The amount of registration fee is \$2,054.64.

ATARA BIOTHERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Cost & expenses	85,730	62,488
Operating income	(85,730)	(62,488)
Net before taxes	(84,176)	(60,804)
Income taxes	2	10
Net income	(84,178)	(60,814)
Earnings common share		
Primary	\$(2.84)	\$(2.12)
Fully Diluted	\$(2.84)	\$(2.12)
Common Shares:		
Full Diluted	29,597	28,670
Year-end	30,596	28,842

AUDENTES THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Cost & expenses	66,296	40,214
Operating income	(66,296)	(40,214)
Interest income	483	305
Other income (expense), net	(50)	(83)
Net income	(65,863)	(39,992)
Earnings common share		
Primary	\$(2.59)	\$(5.74)
Fully Diluted	\$(2.59)	\$(5.74)
Common Shares:		
Full Diluted	25,476	6,962
Year-end	29,734	21,703

AUDENTES THERAPEUTICS INC

Offering On Nov. 14, 2017, Co. announced a public offering pursuant to Common Stock, \$0.00001 par value. Co. proposed to offer 1,086,562 to be issued under the 2016 Equity Incentive Plan at a proposed maximum offering price per share of \$24.85, which amounted to a proposed maximum aggregate offering price of \$27,001,065.70. The amount of registration fee is \$3,361.63.

AVEXIS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	137,844,000	57,867,186
Operating income	(137,844,000)	(57,867,186)
Interest income	1,458,000	230,313
Net income	(136,386,000)	(57,636,873)
Earnings common share		
Primary	\$(4.67)	\$(2.75)
Fully Diluted	\$(4.67)	\$(2.75)

Common Shares:		
Full Diluted	29,228,847	20,958,421
Year-end	31,972,377	27,645,108

AVINGER INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	8,021	14,535
Cost & expenses	41,980	53,288
Operating income	(33,959)	(38,753)
Interest income	88	88
Interest expense	4,720	3,959
Other income (expense), net	9	(7)
Net income	(38,582)	(42,631)
Earnings common share		
Primary	\$(1.61)	\$(2.97)
Fully Diluted	\$(1.61)	\$(2.97)
Common Shares:		
Full Diluted	24,005	14,378
Year-end	31,539	22,800

AXSOME THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	20,720,187	19,917,948
Operating income	(20,720,187)	(19,917,948)
Other income (expense), net	207,114	
Net income	(21,512,891)	(19,872,715)
Earnings common share		
Primary	\$(0.97)	\$(1.04)
Fully Diluted	\$(0.97)	\$(1.04)
Common Shares:		
Full Diluted	22,270,885	19,149,579
Year-end	23,665,532	19,153,417

AYTU BIOSCIENCE INC**Earnings, 3 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	1,076,368	697,980
Cost & expenses	5,046,558	6,227,466
Operating income	(4,356,031)	(5,966,500)
Interest expense	188,745	415,381
Other income (expense), net	299,734	657,491
Net income	(4,245,042)	(5,724,390)
Earnings common share		
Primary	\$(1.76)	\$(23.37)
Fully Diluted	\$(1.76)	\$(23.37)
Common Shares:		
Full Diluted	2,415,402	244,937
Year-end	4,224,840	255,530

Consolidated Balance Sheet Items, as of (\$):

Assets:	2017	2016
Cash & equivalents	7,021,527	
Inventories	1,171,260	
Current assets	9,742,060	
Net property & equip.	567,000	
Total assets	21,245,920	
Liabilities:		
Current liabilities	3,508,186	
Stockholders' equity	6,352,941	
Net current assets	6,233,874	

B RILEY FINANCIAL INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	211,999	97,173
Cost & expenses	197,372	79,906
Operating income	14,627	17,267
Interest income	358	32
Interest expense	5,195	1,398
Other income (expense), net	(157)	
Net before taxes	9,633	15,901
Income taxes	(7,753)	6,184
Net income	17,386	9,717
Earnings common share		
Primary	\$0.80	\$0.51
Fully Diluted	\$0.76	\$0.50
Common Shares:		
Full Diluted	23,385	18,009
Year-end	26,462	19,043

B RILEY FINANCIAL INC

Offering On Nov. 16, 2017, Co.'s wholly-owned subsidiary, B. Riley FBR, Inc. ("B. Riley FBR"), announced that it has priced

its private placement of 18,750,000 shares of common stock of Select Interior Concepts, Inc. ("Select Interior") at \$12 per share resulting in aggregate gross proceeds of \$225,000,000. In conjunction with the transaction, Select Interior has granted B. Riley FBR a 30-day option to acquire up to 3,000,000 additional shares of common stock at the offering price, less underwriting discounts and commissions.

B RILEY FINANCIAL INC

Offering On Nov. 22, 2017, Co. announced a public offering pursuant to Common Stock, par value \$0.0001 per share. Co. proposed to offer 365,965 at a proposed maximum offering price per share of \$17.95, which amounted to a proposed maximum aggregate offering price of \$6,569,071.75. The amount of registration fee is \$817.85.

BEACON ROOFING SUPPLY INC**Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$000):**

	2017	2016	2015
Net sales	4,376,670	4,127,109	2,515,169
Cost of products sold	3,300,731	3,114,040	1,919,804
Gross profit	1,075,939	1,013,069	595,365
Total operating expenses	859,843	808,085	478,284
Income from operations	216,096	204,984	117,081
Interest expense, financing costs, & other	52,751	58,452	11,037
Income (loss) before provision for income taxes	163,345	146,532	106,044
Current federal income taxes	52,718	23,403	17,414
Current foreign income taxes	1,366	1,183	1,765
Current state income taxes	8,975	2,426	7,579
Total current income taxes	63,059	27,012	26,758
Deferred federal income taxes (benefit)	(656)	25,935	14,798
Deferred foreign income taxes (benefit)	...	321	(657)
Deferred state income taxes (benefit)	78	3,347	2,868
Total deferred income taxes (benefit)	(578)	29,603	17,009
Provision for income taxes	62,481	56,615	43,767
Net income (loss)	100,864	89,917	62,277
Weighted average shares outstanding			
- basic	60,316	59,424	49,578
Weighted average shares outstanding - diluted	61,344	60,418	50,173
Year end shares outstanding	67,701	59,891	49,791
Net income (loss) per share - basic	\$1.67	\$1.51	\$1.26
Net income (loss) per share - diluted	\$1.64	\$1.49	\$1.24
Total number of employees	5,406	5,042	3,366
Number of common stockholders	94	137	186
Foreign currency translation adjustments	...	1,024	(14,003)

□ Shares increased due to the effect of issuance of common stock withheld for taxes and in connection with Roofing Supply Group, LLC (RSG) acquisition; □ As is; □ As of October 31, 2017; □ As of October 31, 2016; □ As of November 1, 2015

Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):

	2017	2016 (revised)
Cash & cash equivalents	138,250	31,386
Accounts receivables, gross	716,356	641,777
Less: allowance for doubtful accounts	11,829	14,812
Accounts receivable, net	704,527	626,965
Inventories, net	551,924	480,736
Vendor rebates	193,071	149,052
Other prepaid expenses & other current assets	16,067	14,051
Total current assets	1,603,839	1,302,190
Land	2,796	2,925
Buildings & leasehold improvements	38,995	35,754
Equipment	293,489	263,947
Furniture & fixtures	23,140	20,155
Property & equipment, gross	358,420	322,781
Less: accumulated depreciation & amortization	202,291	174,212
Property & equipment, net	156,129	148,569
Goodwill	1,251,986	1,197,565
Intangible assets, net	429,069	464,024
Other assets, net	8,534	1,511
Total assets	3,449,557	3,113,859
Accounts payable	503,697	360,915
Accrued expenses	261,297	161,113
Current portions of long-term debt	14,141	14,811
Total current liabilities	779,135	536,839
Borrowings under revolving lines of credit, net	3,205	359,661
Long-term debt, net	721,268	722,929
Deferred income taxes, net	138,383	135,482
Long-term obligations under equipment financing & other, net of current portion	25,760	35,121
Total liabilities	1,667,751	1,790,032
Common stock	677	598
Additional paid-in capital	1,047,506	694,564
Retained earnings (accumulated deficit)	748,186	647,322
Foreign currency translation	(14,563)	(18,269)
Derivative financial instruments	...	(388)
Accumulated other comprehensive income (loss)	(14,563)	(18,657)
Total stockholders' equity	1,781,806	1,323,827

BEFUT GLOBAL INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	47,122	96,260
Cost & expenses	25,790	203,164
Operating income	21,332	(106,905)
Other income (expense), net	5	5
Net income	21,332	(106,905)
Earnings common share		
Primary	\$0.00	\$(0.00)
Fully Diluted	\$0.00	\$(0.00)
Common Shares:		
Full Diluted	190,830,375	29,715,640
Year-end	190,830,375	29,715,640

Consolidated Balance Sheet Items, as of (\$):

	2017
Assets:	
Cash & equivalents	194,661
Current assets	194,661
Net property & equip.	44,444
Total assets	839,155
Liabilities:	
Current liabilities	1,004,432
Stockholders' equity	(1,103,119)

Net current assets (809,771)

BELLEROPHON THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Cost & expenses	17,290	16,465
Operating income	(17,290)	(16,465)
Interest income	86	74
Other income (expense), net	(13,455)	...
Net income	(30,659)	(16,391)
Earnings common share		
Primary	\$(0.92)	\$(1.23)
Fully Diluted	\$(0.92)	\$(1.23)
Common Shares:		
Full Diluted	33,505	13,335
Year-end	54,960	14,507

BELLICUM PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	254	307
Cost & expenses	68,196	49,174
Operating income	(67,942)	(48,867)
Interest income	788	687
Interest expense	2,707	1,123
Net income	(69,861)	(49,303)
Earnings common share		
Primary	\$(2.24)	\$(1.83)
Fully Diluted	\$(2.24)	\$(1.83)
Common Shares:		
Full Diluted	31,205	26,920
Year-end	33,252	27,097

BENEFITFOCUS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	189,972	170,688
Cost & expenses	199,708	197,792
Operating income	(9,736)	(27,104)
Interest income	129	117
Other income (expense), net	(140)	(136)
Net before taxes	(18,858)	(32,944)
Income taxes	10	15
Net income	(18,868)	(32,959)
Earnings common share		
Primary	\$(0.61)	\$(1.12)
Fully Diluted	\$(0.61)	\$(1.12)
Common Shares:		
Full Diluted	30,974	29,442
Year-end	31,196	29,673

BIOVERATIV INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	839,800	631,200
Cost & expenses	510,500	423,100
Operating income	329,300	208,100
Other income (expense), net	3,800	(1,100)
Net before taxes	333,100	207,000
Income taxes	118,800	(3,700)
Net income	214,300	210,700
Earnings common share		
Primary	\$1.98	\$1.95
Fully Diluted	\$1.98	\$1.95
Common Shares:		
Full Diluted	108,400	108,000
Year-end	108,184	...

BLINK CHARGING CO**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	1,735,493	2,459,496
Cost & expenses	6,975,859	8,586,257
Operating income	(5,240,366)	(6,126,761)
Other income (expense), net	(93,478,969)	(2,713,883)
Gains or losses	(97,152)	(17,348)
Net income	(101,134,331)	(9,154,924)
Balance for common	(103,508,631)	(10,225,324)
Earnings common share		
Primary	\$(52.04)	\$(6.39)
Fully Diluted	\$(52.04)	\$(6.39)
Common Shares:		
Full Diluted	1,989,022	1,600,993
Year-end	4,812,632	1,609,530

BLUE BUFFALO PET PRODUCTS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Net Sales	937,627	854,682
Cost & expenses	711,197	693,787
Operating income	226,430	160,895
Interest income	787	361
Interest expense	8,979	11,233
Other income (expense), net	(32)	...
Net before taxes	218,206	150,023
Income taxes	78,297	54,584
Net income	139,909	95,439
Earnings common share		
Primary	\$0.71	\$0.49
Fully Diluted	\$0.70	\$0.48
Common Shares:		
Full Diluted	199,259	199,290
Year-end	195,252	196,515

BLUE HILLS BANCORP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Cost & expenses	53,527	50,333
Operating income	21,857	7,137
Net before taxes	21,857	7,137
Income taxes	6,661	2,482
Net income	15,196	4,655
Earnings common share		
Primary	\$0.63	\$0.19
Fully Diluted	\$0.62	\$0.19
Common Shares:		
Full Diluted	24,378	24,709
Year-end	26,869	26,997

BMC STOCK HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Net Sales	2,525,087	2,346,169
Cost & expenses	2,404,302	2,239,078
Operating income	76,283	63,343
Interest expense	18,960	24,020
Other income (expense), net	2,366	(8,928)
Net before taxes	59,689	30,395
Income taxes	19,906	9,933
Net income	39,783	20,462
Earnings common share		
Primary	\$0.60	\$0.31
Fully Diluted	\$0.59	\$0.31
Common Shares:		
Full Diluted	67,341	66,455
Year-end	66,900	66,400

BOB EVANS FARMS INC

Special General Meeting of Shareholders On Nov. 17, 2017, Co. scheduled its Special General Meeting of Shareholders on on January 9, 2018, at 9:00 am, local time, at the Dan Evans Training Center located at 8111 Smiths Mill Road, New Albany, OH 43054.

BREITBURN ENERGY PARTNERS LP

Bankruptcy Proceedings On Nov. 6, 2017, Co. filed with the U.S. Bankruptcy Court a monthly operating report for Sept. 2017. For the month, the Debtors reported a net loss of \$426,000,000 on \$44,900,000 in total revenue and paid \$10,700,000 in net reorganization items; \$5,200,000 in general and administrative expenses and \$20,000,000 in depreciation, depletion and amortization. Cash at the beginning of Sept. 2017 was \$1,300,000 and \$1,200,000 at month's end, with negative net cash flow of \$56,000.

BREITBURN ENERGY PARTNERS LP

Bankruptcy Proceedings On Nov. 15, 2017, Co. filed with the U.S. Bankruptcy Court First Amended Joint Chapter 11 Plan and related Disclosure Statement. According to the Disclosure Statement, "Holders of General Unsecured Claims (including Unsecured Noteholders that comply with the Rights Offering Procedures and are not Eligible Offerees or elect not to participate in the Rights Offering) will receive their pro rata share of [\$500,000 in Cash or [1% of the New Permian Corp. Shares]. Unsecured Noteholders that fail to comply with the Rights Offering Procedures will receive no distribution under the Plan. If a holder of an Allowed Unsecured Notes Claim that either is not an Eligible Offeree or elects not to participate in the Rights Offering does not comply with the requirements set forth in the Rights Offering Procedures, then such holder of an Allowed Unsecured Notes Claim shall be deemed to have forever and irrevocably relinquished and waived the right to receive a distribution under the Plan."

BREITBURN ENERGY PARTNERS LP

Bankruptcy Proceedings On Nov. 16, 2017, the U.S. Bankruptcy Court approved Co.'s motion to approve a sixth amendment to Co.'s post-petition financing arrangements. As previously reported, "Pursuant to this Motion, the Debtors seek authority to further amend their existing postpetition revolving loan facility that (a) extends the Existing DIP Facility's scheduled maturity date to Mar. 31, 2018; and (b) provides for the payment of certain fees to the agent and lenders thereunder (in such capacities, the 'DIP Agent' and 'DIP Lenders,' respectively) in consideration for the extension. The Debtors have recently filed their proposed plan of reorganization and accompanying disclosure statement, and a motion to, among other things, approve the Disclosure Statement and solicitation procedures, and to schedule a confirmation hearing. The Plan has the support of the Debtors' principal creditor constituencies. Although it is possible that the Plan may be confirmed and become effective before the Existing DIP Facility's scheduled maturity date of Dec. 31, 2017, in view of potential objections and scheduling it is very possible that these chapter 11 cases will continue past Dec. 31, 2017. Accordingly, the Debtors and the DIP Agent on behalf of the DIP Lenders have engaged in good faith and arms' length negotiations on the Sixth Amendment to continue the Existing DIP Facility (including the letters of credit sub-facilities thereunder) on terms that were previously approved by the Court."

BREITBURN ENERGY PARTNERS LP

Bankruptcy Proceedings On Nov. 17, 2017, the U.S. Bankruptcy Court issued an order selecting a mediator and governing mediation procedures in Co.'s case. The order states, "The Court authorizes and appoints the Honorable Robert D. Drain (the 'Mediator') to serve as Mediator in these Chapter 11 Cases and to conduct a single mediation session as set forth herein. The Mediator is authorized to mediate any issues related to the Plan except for the issue relating to the cancellation of debt income ('CODI') raised by the Equity Committee. The joint mediation session shall take place (subject to change by the Mediator) on Nov. 21, 2017, at a time and place to be fixed by the Mediator."

BREITBURN ENERGY PARTNERS LP

Bankruptcy Proceedings On Nov. 21, 2017, the U.S. Bankruptcy Court scheduled a Nov. 21, 2017 hearing to consider Co.'s motion for an exclusivity extension.

BREITBURN ENERGY PARTNERS LP

Bankruptcy Proceedings On Nov. 27, 2017, the U.S. Bankruptcy Court approved Co.'s motion to extend the exclusive period during which Co. can file a Chapter 11 plan and solicit acceptances thereof through and including Jan. 15, 2018. As previously reported, "After extensive negotiations with various creditor constituencies holding competing interests, the Debtors filed their joint chapter 11 on Oct. 11, 2017. The Plan provides for a comprehensive restructuring and addresses 11 classes of claims against and interests in the Debtors. Importantly, the Plan is the result of the Debtors interfacing and engaging in arms' length negotiations and reaching a consensus with their key economic stakeholders holding more than \$2,000,000,000 of their funded debt. More specifically, the prosecution, confirmation, and consummation of the Plan is supported by (i) the Debtors' Revolving Credit Facility Lenders holding approximately \$750,000,000 in Revolving Credit Facility Claims; (ii) the Debtors' Second Lien Group holding claims in excess of \$790,000,000; and (iii) holders of more than 68% of the Debtors' Unsecured Notes, or approximately \$785,000,000 in principal amount. The efforts of the Debtors and these major parties in interest should not be undermined at the eleventh hour of these chapter 11 cases by the distractions of competing plans. In view of the broad support for the Plan, the limited amount of time between the hearing on the Disclosure Statement and the expiration of the current Exclusive Solicitation Period, and the diligence with which the Debtors have pursued Plan confirmation, the Debtors submit that ample cause exists for the requested extension of the Exclusive Solicitation Period."

BREITBURN ENERGY PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	430,559	320,969
Cost & expenses	756,399	598,686
Operating income	(525,429)	(524,483)
Interest expense	61,973	126,888
Other income (expense), net	(219,369)	(77,541)
Gains or losses		(2,021)
Net before taxes	(806,771)	(730,933)
Income taxes	(516)	(554)
Net income	(806,255)	(730,379)
Balance for common	(806,243)	(747,587)
Earnings common share		

Primary	\$(3.77)	\$(3.50)
Fully Diluted	\$(3.77)	\$(3.50)
Common Shares:		
Full Diluted	213,789	213,743
Year-end	213,800	213,800

BROCADE COMMUNICATIONS SYSTEMS INC

Merger Completed On Nov. 17, 2017, Broadcom Ltd. ("Ultimate Parent") indirect wholly-owned subsidiary, LSI Corp. ("Parent"), through its wholly-owned subsidiary, Bobcat Merger Sub, Inc. ("Merger Sub"), merged with an into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each share of common stock, par value \$0.001 per share, of Co. ("Co. Common Stock") that was issued and outstanding immediately prior to such time (other than shares of Co. Common Stock that were (i) owned directly by Ultimate Parent, Parent, Merger Sub or any other direct or indirect subsidiary of Ultimate Parent, (ii) held in treasury of Co., (iii) held by any subsidiary of Co. or (iv) held by any stockholders of Co. who were entitled to demand and properly demanded appraisals of such shares pursuant to their statutory rights of appraisal in accordance with the General Corporation Law of the State of Delaware) was canceled and converted into the right to receive cash in an amount equal to \$12.75 per share, without interest, less any required tax withholding (the "Merger Consideration"). In addition, each stock option to purchase Co. Common Stock (an "Option") with a per share exercise price less than the Merger Consideration (an "In-the-Money Option") that was outstanding and vested as of immediately prior to the Effective Time was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment ("cashed out"), and each restricted stock unit award covering Co. Common Stock (an "RSU Award") that was not assumed (as described below) also was cashed out. The amount of the cash payment for each cashed out Option and cashed out RSU Award equaled the number of shares of Co. Common Stock subject to such award multiplied by (i) with respect to a cashed out Option, the excess of the Merger Consideration over the exercise price per share of such Option, or (ii) with respect to a cashed out RSU Award, the Merger Consideration (the "Cash Out Payment"). each outstanding and unvested In-the-Money Option, each outstanding Option that was not an In-the-Money Option, and each outstanding RSU Award, as of immediately prior to the Effective Time, and, in each case, held by an employee or other service provider of Co. or its subsidiaries who provides service to Co. or its subsidiaries as of immediately following the Effective Time (a "Continuing Service Provider") was assumed by Ultimate Parent and converted automatically into an option (with respect to an assumed Option) or restricted share unit award (with respect to an assumed RSU Award) covering ordinary shares in the capital of Ultimate Parent ("Ultimate Parent Ordinary Shares") having, subject to applicable law, the same terms and conditions as the assumed Option or RSU Award, as applicable (each, an "Assumed Award"), except that (i) each such Assumed Award covers that number of Ultimate Parent Ordinary Shares equal to the number of shares of Co. Common Stock subject to such Assumed Award immediately prior to the Effective Time multiplied by 0.0486 (the "Exchange Ratio"), which ratio was determined as the Merger Consideration divided by the volume weighted average price for an Ultimate Parent Ordinary Share for the twenty trading days prior to the closing date of the Merger (the "Closing Date"), and (ii) with respect to an Option that was assumed, the per share exercise price equals the exercise price per share of such Option divided by the Exchange Ratio (the "Assumption Treatment"). all other Options not assumed or cashed out pursuant to the Merger Agreement (which includes any Options held by individuals who are not Continuing Service Providers that have a per share exercise price equal to or greater than the Merger Consideration) were cancelled as of immediately prior to the Effective Time in exchange for no consideration. Each RSU Award that was subject to performance criteria immediately prior to the Closing Date (a "PSU Award") was treated in accordance with the terms of the applicable PSU Award agreement, including that (i) the PSU Award's performance period was deemed to end on the Closing Date, (ii) the number of units eligible to vest based on performance achievement over the shortened performance period under the PSU Award ("Eligible Units") was determined as of the Closing Date, (iii) 50% of the Eligible Units vested as of immediately prior to the Effective Time, and (iv) the Eligible Units under the PSU Award were treated in the same manner as an RSU Award (whether cashed out or assumed) at the Effective Time, provided that any such Eligible Units that were subject to the Assumption Treatment are scheduled to vest on the one (1) year anniversary of the Closing Date based on continued service through such date, subject to any accelerated vesting as may be specified under any plan, agreement or other arrangement ap-

plicable to such PSU Award. The aggregate consideration paid by Ultimate Parent in the Merger was approximately \$6,100,000,000, without giving effect to the related transaction fees and expenses.

BROOKS AUTOMATION INC**Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$000):**

	2017	2016 (revised)	2015 (revised)
Products revenue	533,624	421,783	457,411
Services revenue	159,261	138,540	95,297
Total revenue	692,885	560,323	552,708
Cost of products revenue	323,812	267,974	298,348
Cost of services revenue	101,669	94,268	65,255
Total cost of revenue	425,481	362,242	363,603
Gross profit (loss)	267,404	198,081	189,105
Research & development expenses	47,004	51,543	52,232
Selling, general & administrative expenses	153,061	130,261	115,270
Restructuring charges	3,226	12,039	4,713
Total operating expenses	203,291	193,843	172,215
Operating income (loss)	64,113	4,238	16,890
Interest income	464	452	899
Interest expense	408	157	395
Gain on settlement of equity method investment	1,847
Other income (expense), net	(645)	(579)	421
Income (loss) before income taxes & earnings (losses) of equity method investments - domestic	26,428	(8,186)	(1,321)
Income (loss) before income taxes & earnings (losses) of equity method investments - foreign	38,943	12,140	19,136
Income (loss) before income taxes & earnings (losses) of equity method investments	65,371	3,954	17,815
Current federal income taxes provision (benefit)	...	(145)	10
Current state income taxes provision (benefit)	473	(186)	56
Current foreign income taxes provision (benefit)	11,150	5,868	5,537
Total current income taxes provision (benefit)	11,623	5,537	5,603
Deferred federal income taxes provision (benefit)	538	68,300	(1,773)
Deferred state income taxes provision (benefit)	31	4,000	(104)
Deferred foreign income taxes provision (benefit)	(52)	(2,027)	(296)
Total deferred income taxes provision (benefit)	517	70,273	(2,173)
Income tax provision (benefit)	12,140	75,810	3,430
Income before income taxes & earnings (losses)			

of equity method investments	53,231	(71,856)	14,385
Equity in earnings (losses) of equity method investments ..	9,381	2,380	(164)
Net income (loss)	62,612	(69,476)	14,221
Weighted average shares outstanding			
- basic	69,575	68,507	67,411
Weighted average shares outstanding			
- diluted	70,485	68,507	68,549
Year end shares outstanding	69,833	68,758	67,631
Net income (loss) per share - basic	\$0.90	\$(1.01)	\$0.21
Net income (loss) per share - diluted	\$0.89	\$(1.01)	\$0.21
Dividends declared per share	\$0.40	\$0.40	\$0.40
Number of full time employees	1,661	1,310	1,426
Number of common stockholders	556	593	615
Foreign currency translation adjustments		8,844	(9,557)

□ Reclassified to conform with 2017 presentation; □ As is; □ As of November 2, 2017; □ As of November 15, 2016; □ As of October 30, 2015

Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):

	2017	2016	(revised)
Cash & cash equivalents	101,622	85,086	
Marketable securities	28	39	
Accounts receivable, gross	122,868	108,713	
Less allowance for doubtful accounts	1,959	2,241	
Less allowance for sales returns	(81)	(100)	
Accounts receivable, net	120,828	106,372	
Raw materials & purchased parts	73,819	60,979	
Work-in-process	10,548	16,090	
Finished goods	22,028	15,503	
Inventories	106,395	92,572	
Prepaid expenses & other current assets	23,138	15,265	
Total current assets	352,011	299,334	
Buildings & land	46,641	45,772	
Computer equipment & software	56,544	65,989	
Machinery & equipment	61,173	54,896	
Furniture & fixtures	4,376	5,704	
Leasehold improvements	18,938	17,128	
Capital projects in progress	3,013	5,428	
Property, plant & equipment, gross	190,685	194,917	
Less accumulated depreciation & amortization	132,223	140,032	
Property, plant & equipment, net	58,462	54,885	
Long-term marketable securities	2,642	6,096	
Long-term deferred tax assets	1,692	1,982	
Goodwill	233,638	202,138	
Intangible assets, net	83,520	81,843	
Equity method investments	28,593	27,273	
Other assets	6,070	12,354	
Total assets	766,628	685,905	
Accounts payable	49,100	41,128	
Deferred revenue	24,292	14,966	
Accrued warranty & retrofit costs	8,054	6,324	
Accrued compensation & benefits	27,065	21,254	
Accrued restructuring costs	1,708	5,939	

Accrued income taxes payable	11,417	7,554	
Accrued expenses & other current liabilities	25,142	22,628	
Total current liabilities	146,778	119,793	
Long-term tax reserves	1,687	2,681	
Long-term deferred tax liabilities	3,748	2,913	
Long-term pension liabilities	1,979	2,557	
Other long-term liabilities	4,792	4,271	
Total liabilities	158,984	132,215	
Common stock	833	821	
Additional paid-in capital	1,874,918	1,855,703	
Currency translation adjustments	15,168	15,389	
Unrealized gains (losses) on available-for-sale securities	(1)	(3)	
Pension liability adjustments	46	(220)	
Accumulated other comprehensive income (loss)	15,213	15,166	
Treasury stock, at cost	200,956	200,956	
Retained earnings (accumulated deficit)	(1,082,364)	(1,117,044)	
Total stockholders' equity	607,644	553,690	
Total equity	607,644	553,690	

CAESARS ENTERTAINMENT CORP

Acquisition Development On Nov. 16, 2017, Co. announced that it has entered into a definitive agreement to acquire Centaur Holdings, LLC ("Centaur") for \$1,700,000,000 in cash, including \$1,625,000,000 at closing and \$75,000,000 in deferred consideration. As a result of the transaction, Co. will add Hoosier Park Racing and Casino in Anderson, IN, and the Indiana Grand Racing and Casino ("Indiana Grand") in Shelbyville, IN, to its Total Rewards network. The transaction is subject to receipt of regulatory approvals and other customary closing conditions and is expected to close in the first half of 2018.

CALITHERA BIOSCIENCES, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2017	2016
Total Revenues	18,701	18,701
Cost & expenses	36,845	28,730
Operating income	(18,144)	(28,730)
Interest income	1,292	246
Net income	(16,852)	(28,484)
Earnings common share		
Primary	\$(0.53)	\$(1.50)
Fully Diluted	\$(0.53)	\$(1.50)
Common Shares:		
Full Diluted	32,072	18,963
Year-end	35,477	20,100

CANCER GENETICS, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2017	2016
Total Revenues	21,598,000	19,819,000
Cost & expenses	30,700,000	33,046,000
Operating income	(9,102,000)	(13,227,000)
Interest income	37,000	21,000
Interest expense	797,000	344,000
Other income (expense), net	(4,087,000)	523,000
Net before taxes	(13,949,000)	(13,949,000)
Income taxes	(970,000)	
Net income	(12,979,000)	(13,027,000)
Earnings common share		
Primary	\$(0.65)	\$(0.88)
Fully Diluted	\$(0.65)	\$(0.88)
Common Shares:		
Full Diluted	20,059,000	14,868,000
Year-end	24,252,000	18,870,000

CANTABIO PHARMACEUTICALS INC

Earnings, 6 mos. to Sep 30 (Consol. - \$):

	2017	2016
Cost & expenses	564,265	554,651
Operating income	(564,265)	(554,651)

Interest expense	187,423	7,864
Gains or losses	54,000	
Foreign currency		3,100
Net income	(697,688)	(559,415)
Earnings common share		
Primary	\$(0.03)	\$(0.02)
Fully Diluted	\$(0.03)	\$(0.02)
Common Shares:		
Full Diluted	27,145,000	26,805,000
Year-end	27,400,000	26,805,270

CARDAX INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2017	2016
Total Revenues	496,088	11,160
Cost & expenses	1,682,586	1,423,574
Deprec., depl. & amort.	22,189	22,055
Operating income	(1,208,687)	(1,434,469)
Other income (expense), net	12,598	47,082
Net income	(1,197,035)	(1,387,926)
Earnings common share		
Primary	\$(0.01)	\$(0.02)
Fully Diluted	\$(0.01)	\$(0.02)
Common Shares:		
Full Diluted	92,513,317	73,949,386
Year-end	121,345,130	80,972,876

CARDIOVASCULAR SYSTEMS, INC

Offering On Nov. 17, 2017, Co. announced a public offering pursuant to Common Stock issuable under the Registrant's 2017 Equity Incentive Plan. Co. proposed to offer 2,550,000 shares at a proposed maximum offering price per share of \$23.565, which amounted to a proposed maximum aggregate offering price of \$60,090,750. The amount of registration fee is \$7,481.30.

CAREDX INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2017	2016
Total Revenues	35,821	29,771
Cost & expenses	51,828	48,242
Operating income	(16,007)	(18,471)
Other income (expense), net	(4,595)	(5,113)
Net before taxes	(24,768)	(24,935)
Income taxes	(837)	(888)
Net income	(23,931)	(24,047)
Earnings common share		
Primary	\$(1.09)	\$(1.61)
Fully Diluted	\$(1.09)	\$(1.61)
Common Shares:		
Full Diluted	21,765	14,894
Year-end	22,564	21,226

CARLYLE GROUP LP (THE)

Acquisition Development On Nov. 20, 2017, Co. announced that it has agreed to acquire Centerstone Insurance & Financial Services, Inc. d/b/a BenefitMall, a provider of employee benefits and payroll services to small and medium sized businesses across the U.S., from an investor group led by Austin Ventures. The transaction is subject to customary conditions and is expected to close by year-end 2017. Financial terms were not disclosed.

CATABASIS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2017	2016
Total Revenues	250	
Cost & expenses	21,882	26,885
Operating income	(21,632)	(26,885)
Interest income	128	183
Interest expense	381	662
Other income (expense), net	18	82
Net income	(21,867)	(27,282)
Earnings common share		
Primary	\$(1.03)	\$(1.77)
Fully Diluted	\$(1.03)	\$(1.77)
Common Shares:		
Full Diluted	21,164	15,408
Year-end	22,895	18,639

CAVIUM INC

Merger Development On Nov. 20, 2017, Marvell Technology Group Ltd. ("Marvell") entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among Marvell, Kauai Acquisition Corp., an indirect wholly owned subsidiary of Marvell ("Merger Sub"), and Co. Pursuant to the Merger Agreement, Merger Sub will be merged with and into Co. (the

"Merger"), with Co. continuing as an indirect wholly owned subsidiary of Marvell. Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger, each share of common stock, \$0.001 par value per share, of Co. (each, a "Co. Share") issued and outstanding immediately prior to the effective time of the Merger (other than (i) Co. Shares held by Co. (or held in Co.'s treasury) or held by Marvell, Merger Sub or any other subsidiary of Marvell or held, directly or indirectly, by any subsidiary of Co. or (ii) Co. Shares with respect to which appraisal rights are properly exercised and not withdrawn under Delaware law) will be converted into the right to receive 2.1757 common shares, \$0.002 par value per share, of Marvell (each, a "Marvell Share") and \$40.00 in cash, without interest. This represents a transaction value of approximately \$6,000,000,000. The transaction was unanimously approved by the boards of directors of both companies and is expected to close in mid-calendar 2018, subject to regulatory approval as well as other customary closing conditions, including the adoption by Co. shareholders of the merger agreement and the approval by Marvell shareholders of the issuance of Marvell common shares in the transaction.

CBTX INC

Offering On Nov. 15, 2017, Co. announced a public offering pursuant to Common Stock, \$0.01 par value per share. Co. proposed to offer (i) 660,000 CBTX, Inc. 2017 Omnibus Incentive Plan at a proposed maximum offering price per share of \$28.52, which amounted to a proposed maximum aggregate offering price of \$18,823,200. The amount of registration fee is \$2,343.49; (ii) 168,000 CBFH, Inc. 2014 Stock Option Plan at a proposed maximum offering price per share of \$18.85, which amounted to a proposed maximum aggregate offering price of \$3,166,800. The amount of registration fee is \$394.27; and (iii) 157,314 VB Texas, Inc. 2006 Stock Option Plan at a proposed maximum offering price per share of \$10.46, which amounted to a proposed maximum aggregate offering price of \$1,645,505. The amount of registration fee is \$204.87.

CCOM GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Net Sales	68,371,062	65,498,808
Cost & expenses	67,116,271	64,381,722
Operating income	1,254,791	1,117,086
Interest expense	488,618	451,732
Other income (expense), net	155,622	141,257
Net before taxes	921,795	806,611
Income taxes	200,604	352,507
Net income	721,191	454,104
Earnings common share		
Primary	\$0.08	\$0.05
Fully Diluted	\$0.08	\$0.05
Common Shares:		
Full Diluted	9,439,540	9,439,540
Year-end	9,154,928	9,154,928

CELSIUS HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	27,023,123	16,508,097
Cost & expenses	29,933,699	18,984,920
Operating income	(2,910,576)	(2,476,823)
Interest expense	122,195	171,250
Net income	(3,032,771)	(2,648,073)
Balance for common	(3,306,514)	(2,924,337)
Earnings common share		
Primary	\$(0.08)	\$(0.08)
Fully Diluted	\$(0.08)	\$(0.08)
Common Shares:		
Full Diluted	43,990,367	38,530,195
Year-end	45,679,093	38,666,451

CEREBAIN BIOTECH CORP**Earnings, 3 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	359,380	488,111
Operating income	(431,483)	(4,189,967)
Other income (expense), net	(31,668)	(3,664,347)
Net income	(431,483)	(4,189,967)
Earnings common share		
Primary	\$(0.05)	\$(0.59)
Fully Diluted	\$(0.05)	\$(0.59)
Common Shares:		
Full Diluted	8,003,532	7,147,869
Year-end	8,319,347	7,206,347

Consolidated Balance Sheet Items, as of (\$):

	2017
Assets:	
Cash & equivalents	1,110
Current assets	139,194
Total assets	139,194
Liabilities:	
Current liabilities	1,914,506
Long-term debt	2,748,227
Stockholders' equity	(4,523,539)
Net current assets	(1,775,312)

CHEMBIO DIAGNOSTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	18,027,354	13,613,965
Cost & expenses	22,425,638	18,612,166
Operating income	(4,398,284)	(4,998,201)
Interest income	24,956	9,729
Net before taxes	(4,988,472)	(4,988,472)
Income taxes	5,800,818	5,800,818
Net income	(4,373,328)	(10,789,290)
Earnings common share		
Primary	\$(0.36)	\$(1.06)
Fully Diluted	\$(0.36)	\$(1.06)
Common Shares:		
Full Diluted	12,293,781	10,150,737
Year-end	12,318,570	12,026,847

CHEROKEE INC. (DE)

Postpone of Special Meeting On Nov. 20, 2017, Co. announced special meeting of Cherokee's stockholders, previously scheduled to be held on Nov. 28, 2017 at 8:00 a.m. (Pacific Time), has been postponed to a future date to be determined by Co.'s Board of Directors. Further, under certain circumstances, the Special Meeting may be cancelled in its entirety.

CHIAMA INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	20,978,000	53,367,000
Operating income	(20,978,000)	(53,367,000)
Other income (expense), net	556,000	389,000
Net before taxes	(20,422,000)	(52,978,000)
Income taxes	301,000	238,000
Net income	(20,723,000)	(53,216,000)
Earnings common share		
Primary	\$(0.85)	\$(2.19)
Fully Diluted	\$(0.85)	\$(2.19)
Common Shares:		
Full Diluted	24,361,479	24,305,916
Year-end	24,376,827	24,359,584

CHINA XD PLASTICS CO., LTD

Annual Meeting Development On Nov. 20, 2017, 2017, Co. scheduled its annual Meeting of Shareholders for Wednesday, Dec. 3, 2017, at 8:00 pm U.S. Eastern Standard Time, on the 19th Floor, Tower B of Wang Xin Building, No. 28, Xiaoyun Road, Chaoyang District, Beijing, China.

CHINA YCT INTERNATIONAL GROUP INC**Earnings, 6 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	23,320,051	16,539,265
Operating income	7,681,598	4,767,714
Interest income	56,302	32,149
Gains or losses	573,092	
Net before taxes	8,310,992	4,799,863
Income taxes	2,077,748	1,228,628
Net income	6,233,244	3,571,235
Earnings common share		
Primary	\$0.20	\$0.12
Fully Diluted	\$0.20	\$0.12
Common Shares:		
Full Diluted	29,789,168	29,759,891
Year-end	29,789,168	29,764,168

CHS INC**Annual Report****Consolidated Income Statement, Years Ended Aug. 31**

	2017	2016	2015
Revenues	31,934,751	30,347,203	34,582,442
Cost of goods sold	30,985,510	29,387,910	33,091,676
Gross profit	949,241	959,293	1,490,766
Marketing, general & administrative			

expenses	604,359	601,261	642,309
Reserve & impairment charges	456,679	47,836	133,045
Operating earnings (loss)	(111,797)	310,196	715,412
Gain (loss) on investments	(4,569)	9,252	5,239
Interest income (expense), net	(171,239)	(113,704)	(70,659)
Other income (loss)	95,415	38,357	10,326
Equity loss (income) from investments	137,338	175,777	107,850
Income before income taxes	(54,852)	419,878	768,168
Current federal provision (benefit) for income taxes	(1,767)	3,386	(47,695)
Current state provision (benefit) for income taxes	2,695	3,972	3,891
Current foreign provision (benefit) for income taxes	(7,088)	12,729	1,335
Total current provision (benefit) for income taxes	(6,160)	20,087	(42,469)
Deferred federal provision (benefit) for income taxes	(162,223)	(30,758)	29,348
Deferred state provision (benefit) for income taxes	(15,977)	8,512	(2,799)
Deferred foreign provision (benefit) for income taxes	2,285	(1,932)	3,755
Total deferred provision (benefit) for income taxes	(175,915)	(24,178)	30,304
Income taxes	(182,075)	(4,091)	(12,165)
Net income	127,223	423,969	780,333
Net income (loss) attributable to noncontrolling interests	634	223	712
Net income attributable to CHS Inc.	127,857	424,192	781,045
Total number of employees	11,626	12,157	12,511

Reclassified to conform with 2017 presentation; As is

Consolidated Balance Sheet, Years Ended Aug. 31 (\$000):

	2017	2016
Cash & cash equivalents	181,379	279,313
Trade accounts receivable	1,234,500	1,804,646
CHS Capital, LLC short-term notes receivable	164,807	858,805
Deferred purchase price receivable	202,947	
Receivables - other	493,104	380,956
Less allowances & reserves	225,726	163,644
Receivables, net	1,869,632	2,880,763
Grain & oilseed	1,145,285	937,258
Energy	755,886	729,695
Crop nutrients	248,699	217,521
Feed & farm supplies	353,130	417,431
Processed grain & oilseed	49,723	48,930
Other inventories	23,862	19,864
Inventories	2,576,585	2,370,699
Derivative assets	232,017	543,821
Margin deposits	206,062	310,276
Supplier advance payments	249,234	347,600
Other current assets	299,618	202,708
Total current assets	5,614,527	6,935,180
Investments	3,750,993	3,795,976
Land & land improvements	357,829	266,016
Buildings	1,030,478	1,040,943
Machinery & equipment	6,950,435	6,747,865
Office & other property,		

plant & equipment	235,361	250,879
Construction in progress	327,682	523,817
Property, plant & equipment, gross	8,901,785	8,829,520
Less accumulated depreciation & amortization	3,545,351	3,341,197
Property, plant & equipment, net	5,356,434	5,488,323
Goodwill	154,055	160,414
Customer lists, trademarks & other intangible assets	33,330	44,766
Notes receivable	51,596	358,096
Deferred purchase price receivable	345,655	...
Long-term derivative assets	196,913	...
Prepaid pension & other benefits	122,433	120,693
Capitalized major maintenance	105,006	169,054
Cash value of life insurance	118,677	112,193
Other assets	124,137	127,440
Total assets	15,973,756	17,312,135
Notes payable	1,988,215	2,731,479
Current portion of long-term debt	156,345	214,329
Customer margin deposits & credit balances	157,914	208,991
Customer advance payments	413,163	412,823
Accounts payable	1,951,292	1,819,049
Derivative liabilities	316,018	513,599
Accrued expenses	437,527	422,494
Dividends & equities payable	12,121	198,031
Total current liabilities	5,432,595	6,520,795
Private placement debt	1,643,886	1,775,924
Bank financing	445,000	345,000
Capital lease obligations	33,075	105,708
Other notes & contracts	62,652	76,147
Deferred financing costs	(4,820)	(5,574)
Total long-term debt	2,179,793	2,297,205
Less current portion	156,345	214,329
Long-term debt	2,023,448	2,082,876
Long-term deferred tax liability	333,221	487,762
Other liabilities	278,667	354,452
Preferred stock	2,264,038	2,244,132
Equity certificates	4,341,649	4,237,174
Pension & other postretirement, net	(135,046)	(165,146)
Unrealized net gain on available for sale investments, net	10,041	5,656
Cash flow hedges, net	(6,954)	(9,196)
Foreign currency translation adjustment, net	(51,711)	(43,040)
Accumulated other comprehensive income (loss)	(183,670)	(211,726)
Capital reserves	1,471,217	1,582,380
Total CHS Inc. equities	7,893,234	7,851,960
Noncontrolling interests	12,591	14,290
Total equities	7,905,825	7,866,250

□ Reclassified to conform with 2017 presentation

CINEDIGM CORP

Earnings, 6 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	31,518	46,355
Cost & expenses	21,621	22,374
Operating income	(895)	4,767
Other income (expense), net	(3,324)	331
Net before taxes	(12,235)	(4,948)
Income taxes	382	110
Net income	(12,617)	(5,058)
Balance for common	(12,778)	(5,200)
Earnings common share		
Primary	\$(1.07)	\$(0.75)
Fully Diluted	\$(1.07)	\$(0.75)

Common Shares:		
Full Diluted	11,959	6,931
Year-end	13,745	8,542

CISCO SYSTEMS INC

Earnings, 3 mos. to (Consol. - \$000):

	10/28/17	10/29/16
Net Sales	12,136,000	12,352,000
Cost & expenses	9,319,000	9,397,000
Operating income	2,756,000	2,877,000
Other income (expense), net	(6,000)	14,000
Gains or losses	68,000	(35,000)
Net before taxes	2,962,000	2,953,000
Income taxes	568,000	631,000
Net income	2,394,000	2,322,000
Earnings common share		
Primary	\$0.48	\$0.46
Fully Diluted	\$0.48	\$0.46
Common Shares:		
Full Diluted	4,994,000	5,066,000
Year-end	4,951,000	5,024,000

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2017	
Cash & equivalents		11,043,000
Inventories		1,693,000
Current assets		84,080,000
Net property & equip.		3,202,000
Total assets		130,522,000
Liabilities:		
Current liabilities		29,284,000
Long-term debt		25,684,000
Stockholders' equity		65,550,000
Net current assets		54,796,000

CITRIX SYSTEMS INC

Co. Repurchasing Certain Securities On Nov. 13, 2017, Co.'s its board of directors has authorized Co. to repurchase up to an additional \$1,700,000,000 of Citrix common stock, for a total repurchase authorization in excess of \$2,000,000,000. Citrix reiterated its plan to return \$2,000,000,000 of capital to shareholders by buying shares on the open market or through accelerated stock repurchase ("ASR") transactions through the end of 2018.

CLEARSIDE BIOMEDICAL INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	290	515
Cost & expenses	42,377	16,356
Operating income	(42,087)	(15,841)
Other income (expense), net	(395)	(355)
Net income	(42,482)	(16,196)
Earnings common share		
Primary	\$(1.68)	\$(1.54)
Fully Diluted	\$(1.68)	\$(1.54)
Common Shares:		
Full Diluted	25,300	10,502
Year-end	25,342	20,546

COGINT INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	161,038,000	132,643,000
Cost & expenses	190,709,000	151,916,000
Operating income	(40,131,000)	(28,385,000)
Interest expense	7,098,000	5,561,000
Other income (expense), net	(1,273,000)	
Net before taxes	(35,219,000)	
Income taxes	(11,519,000)	
Net income	(47,229,000)	(23,700,000)
Earnings common share		
Primary	\$(0.86)	\$(0.56)
Fully Diluted	\$(0.86)	\$(0.56)
Common Shares:		
Full Diluted	54,665,776	42,100,504
Year-end	56,065,613	50,663,171

COHERUS BIOSCIENCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	1,556	189,262
Cost & expenses	187,226	231,733
Operating income	(185,670)	(42,471)
Other income (expense), net	3,605	(3,762)
Net income	(189,217)	(51,844)
Earnings common share		

Primary	\$(3.68)	\$(1.25)
Fully Diluted	\$(3.68)	\$(1.25)
Common Shares:		
Full Diluted	51,378	41,097
Year-end	57,945	43,627

COMMERCEHUB INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	74,390	67,671
Cost & expenses	62,964	62,784
Operating income	11,426	4,887
Interest income		273
Interest expense	604	405
Net before taxes	10,822	4,755
Income taxes	4,130	1,611
Net income	6,692	3,144
Earnings common share		
Primary	\$0.16	\$0.07
Fully Diluted	\$0.15	\$0.07
Common Shares:		
Full Diluted	45,081	43,559
Year-end	43,317	42,848

COMTECH TELECOMMUNICATIONS CORP.

Annual Meeting Development On Nov. 16, 2017, 2017, Co. scheduled its Annual Meeting of Shareholders for Dec. 5, 2017, at 10 a.m. at Co.'s corporate headquarters located at 68 South Service Road, Lower Level Auditorium, Melville, NY, 11747.

CONATUS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	26,572,397	
Cost & expenses	39,715,377	20,654,079
Operating income	(13,142,980)	(20,654,079)
Interest expense	473,354	52,500
Other income (expense), net	(71,779)	1,645
Net income	(13,040,010)	(20,609,939)
Earnings common share		
Primary	\$(0.46)	\$(0.96)
Fully Diluted	\$(0.46)	\$(0.96)
Common Shares:		
Full Diluted	28,104,199	21,527,993
Year-end	30,005,462	25,173,339

CONFORMIS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	57,364	58,226
Cost & expenses	101,519	100,386
Operating income	(44,155)	(42,160)
Interest income	367	409
Interest expense	1,397	104
Net before taxes	(41,579)	(41,821)
Income taxes	143	27
Net income	(41,722)	(41,848)
Earnings common share		
Primary	\$(0.97)	\$(1.01)
Fully Diluted	\$(0.97)	\$(1.01)
Common Shares:		
Full Diluted	43,182	41,333
Year-end	45,293	42,759

CONIFER HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	70,287	68,222
Cost & expenses	92,549	72,956
Operating income	(22,262)	(4,734)
Net before taxes	(22,262)	(4,734)
Income taxes	(410)	(607)
Net income	(21,763)	(4,016)
Earnings common share		
Primary	\$(2.85)	\$(0.53)
Fully Diluted	\$(2.85)	\$(0.53)
Common Shares:		
Full Diluted	7,648	7,614
Year-end	8,518	7,631

CONTROL4 CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	176,386	151,435
Cost & expenses	169,313	151,791

Operating income	7,073	(356)
Interest income	224	17
Other income (expense), net	183	(306)
Net before taxes	7,480	(645)
Income taxes	(2,441)	(9,585)
Net income	9,921	8,940
Earnings common share		
Primary	\$0.40	\$0.38
Fully Diluted	\$0.38	\$0.37
Common Shares:		
Full Diluted	26,393	24,149
Year-end	25,266	23,639

CORBUS PHARMACEUTICALS HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):		
	2017	2016
Cost & expenses	24,141,085	13,948,378
Operating income	(21,700,890)	(12,412,624)
Foreign currency	(77,071)	(16,196)
Net income	(21,727,922)	(12,428,400)
Earnings common share		
Primary	\$(0.44)	\$(0.31)
Fully Diluted	\$(0.44)	\$(0.31)
Common Shares:		
Full Diluted	48,946,335	40,059,364
Year-end	50,223,010	43,987,361

CORD BLOOD AMERICA INC

Earnings, 9 mos. to Sep 30(Consol. - \$):		
	2017	2016
Total Revenues	2,240,069	2,554,571
Cost & expenses	1,867,066	2,478,653
Operating income	373,003	75,918
Other income (expense), net	20,719	27,344
Net income	448,965	100,127
Earnings common share		
Primary	\$(0.45)	\$(0.01)
Fully Diluted	\$(0.45)	\$(0.01)
Common Shares:		
Full Diluted	1,272,066	146,272,066
Year-end	1,272,066	146,272,066

CORVUS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):		
	2017	2016
Cost & expenses	44,335	25,726
Operating income	(44,335)	(25,726)
Interest income	601	
Net income	(43,734)	(25,289)
Earnings common share		
Primary	\$(2.14)	\$(1.83)
Fully Diluted	\$(2.14)	\$(1.83)
Common Shares:		
Full Diluted	20,426	13,798
Year-end	20,944	20,912

CPI CARD GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):		
	2017	2016
Net Sales	189,898	241,320
Cost & expenses	181,061	206,827
Operating income	3,654	29,891
Interest expense	15,530	15,109
Other income (expense), net	12	17
Net before taxes	(11,296)	14,607
Income taxes	(3,893)	5,194
Net income	(7,403)	9,413
Earnings common share		
Primary	\$(0.13)	\$0.17
Fully Diluted	\$(0.13)	\$0.17
Common Shares:		
Full Diluted	55,559	56,232
Year-end	55,661	55,293

CSI COMPRESSCO LP

Earnings, 9 mos. to Sep 30(Consol. - \$000):		
	2017	2016
Total Revenues	212,465	228,495
Cost & expenses	188,200	297,982
Deprec., depl. & amort.	51,860	55,016
Operating income	(27,595)	(124,503)
Net before taxes	(27,595)	(124,503)
Income taxes	2,191	1,497
Net income	(29,786)	(126,000)
Earnings common share		
Primary	\$(0.85)	\$(3.72)

Fully Diluted	\$(0.85)	\$(3.72)
Common Shares:		
Full Diluted	34,467	33,216
Year-end	35,496	33,262

CSW INDUSTRIALS INC

Earnings, 6 mos. to Sep 30(Consol. - \$000):		
	2017	2016
Total Revenues	188,396	164,238
Cost & expenses	162,118	149,860
Operating income	26,278	14,378
Interest expense	1,338	1,490
Other income (expense), net	(56)	1,291
Net before taxes	24,884	14,179
Income taxes	9,068	6,242
Net income	15,816	7,937
Earnings common share		
Primary	\$1.00	\$0.51
Fully Diluted	\$0.99	\$0.50
Common Shares:		
Full Diluted	15,935	15,771
Year-end	15,907	15,712

CUMBERLAND PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):		
	2017	2016
Total Revenues	29,500,843	23,944,120
Cost & expenses	30,867,276	22,786,960
Operating income	(3,178,022)	(475,760)
Interest income	216,849	160,248
Interest expense	70,646	77,777
Net before taxes	(3,031,819)	(393,289)
Income taxes	4,196,192	(159,282)
Net income	(7,228,011)	(234,007)
Earnings common share		
Primary	\$(0.45)	\$(0.01)
Fully Diluted	\$(0.45)	\$(0.01)
Common Shares:		
Full Diluted	15,973,737	16,268,579
Year-end	15,781,736	16,195,631

CURAEIS TECHNOLOGIES INC

Earnings, 9 mos. to Sep 30(Consol. - \$):		
	2017	2016
Total Revenues	23,000	20,000
Cost & expenses	3,499,000	2,958,000
Operating income	(3,476,000)	(2,938,000)
Other income (expense), net	2,000	1,000
Net income	(3,999,000)	(2,957,000)
Balance for common		
Primary	\$(0.09)	\$(0.09)
Fully Diluted	\$(0.09)	\$(0.09)
Common Shares:		
Full Diluted	47,768,000	45,901,000
Year-end	48,663,265	46,556,765

CUTERA INC

Offering On Nov. 14, 2017, Co. announced a public offering pursuant to Common Stock, par value \$0.001 per share. Co. proposed to offer 1,600,000 shares at a proposed maximum offering price per share of \$39.28, which amounted to a proposed maximum aggregate offering price of \$62,848,000. The amount of registration fee is \$7,824.58.

CYTOX THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):		
	2017	2016
Total Revenues	44,550	8,771
Cost & expenses	89,562	54,127
Operating income	(45,012)	(45,356)
Other income (expense), net	(101)	(46)
Net before taxes	(43,713)	(44,860)
Income taxes	7	7
Net income	(43,720)	(44,867)
Earnings common share		
Primary	\$(1.19)	\$(1.24)
Fully Diluted	\$(1.19)	\$(1.24)
Common Shares:		
Full Diluted	36,757	36,168
Year-end	37,095	36,393

DATATRAK INTERNATIONAL INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	5,595,639	6,935,947
Cost & expenses	5,240,485	5,872,926
Deprec., depl. & amort.	480,718	166,494
Operating income	(125,564)	896,527
Interest income	2,039	594
Interest expense	129,440	23,119
Gains or losses		(6,025)
Net before taxes		867,977
Income taxes		11,389
Net income	(252,965)	856,588
Earnings common share		
Primary	\$(0.14)	\$0.52
Fully Diluted	\$(0.14)	\$0.47
Common Shares:		
Full Diluted	1,837,518	1,825,891
Year-end	2,267,286	1,720,842

DECISION DIAGNOSTICS CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):		
	2017	2016
Net Sales	1,181,074	725,484
Cost & expenses	2,600,300	3,351,233
Operating income	(1,419,226)	(2,625,749)
Other income (expense), net	(34,515)	(1,163,152)
Gains or losses	(176,137)	1,000,000
Net income	(1,800,471)	(2,967,357)
Balance for common		
Primary	\$(0.02)	\$(0.04)
Fully Diluted	\$(0.02)	\$(0.04)
Common Shares:		
Full Diluted	92,209,047	66,451,145
Year-end	101,271,675	81,955,005

DEEP DOWN INC

Earnings, 9 mos. to Sep 30(Consol. - \$):		
	2017	2016
Total Revenues	14,458,000	19,489,000
Cost & expenses	15,112,000	20,193,000
Operating income	(892,000)	(1,017,000)
Other income (expense), net	94,000	
Gains or losses	574,000	1,070,000
Net before taxes	(178,000)	2,000
Income taxes	15,000	16,000
Net income	(193,000)	(14,000)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	15,074,000	15,534,000
Year-end	13,436,243	15,181,642

DEEP DOWN INC

New Accountant On Nov. 16, 2017, Hein & Associates LLP resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Moss Adams LLP as its new independent public accounting firm.

DERMIRA INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):		
	2017	2016
Cost & expenses	249,848	82,856
Operating income	(246,650)	(82,737)
Interest expense	4,184	
Net income	(247,249)	(81,701)
Earnings common share		
Primary	\$(6.15)	\$(2.54)
Fully Diluted	\$(6.15)	\$(2.54)
Common Shares:		
Full Diluted	40,172	32,178
Year-end	41,674	35,604

DESTINATION XL GROUP INC

Earnings, 9 mos. to (Consol. - \$000):		
	10/28/17	10/29/16
Net Sales	332,454	327,637
Cost & expenses	320,340	306,841
Deprec., depl. & amort.	25,055	22,363
Operating income	(12,941)	(1,567)
Interest expense	2,497	2,346
Net before taxes	(15,438)	(3,913)
Income taxes	64	126
Net income	(15,502)	(4,039)
Earnings common share		

Primary	\$(0.32)	\$(0.08)	income tax				Furniture & fixtures	3,473,000	2,803,000
Fully Diluted	\$(0.32)	\$(0.08)	provision (benefit) ...	(1,454,000)	1,260,000	(297,000)	Property, equipment & improvements, at cost	39,944,000	37,519,000
Common Shares:			Deferred foreign				Less accumulated depreciation & amortization	27,143,000	23,478,000
Full Diluted	48,966	49,532	income tax				Property, equipment, & improvements, net	12,801,000	14,041,000
Year-end	48,670	50,804	provision (benefit) ...	(654,000)	(145,000)	(203,000)	Identifiable intangible		

DETREX CORP.

Merger Development On Nov. 14, 2017, Co. and Italmatch Chemicals Group ("Italmatch") jointly announced that they have entered into a definitive agreement and plan of merger ("Merger Agreement") pursuant to which a newly formed subsidiary of Italmatch will acquire Co. for \$27.00 a share in cash. Under the terms of the Merger Agreement dated Nov. 10, 2017, each share of Co. common stock outstanding immediately prior to the merger will be converted into and exchanged for the right to receive \$27.00 in cash. The merger consideration represents a 8% premium over the closing bid price of Co.'s common stock as quoted on the website of OTC Markets Group on Nov. 9, 2017, and a 9% premium over the average price for the 30-day period ended Nov. 9, 2017, and a 16% premium over the average price for the 90-day period ended Nov. 9, 2017. The Boards of Directors of both companies unanimously approved this transaction. The proposed merger is expected to close by Dec. 31, 2017, subject to the approval by the holders of at least two-thirds of the issued and outstanding shares of common stock of Co. and the satisfaction or waiver of customary closing conditions.

DIGI INTERNATIONAL INC**Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$):**

	2017	2016	2015
		(revised)	(revised)
Revenue - hardware product	166,480,000	196,101,000	195,497,000
Revenue - service & solutions	15,154,000	6,904,000	8,350,000
Total revenue	181,634,000	203,005,000	203,847,000
Cost of hardware product	85,369,000	97,776,000	99,842,000
Cost of service & solutions	7,647,000	4,662,000	5,571,000
Amortization	1,444,000	887,000	1,313,000
Total cost of sales	94,460,000	103,325,000	106,726,000
Gross profit	87,174,000	99,680,000	97,121,000
Sales & marketing expenses	33,955,000	33,847,000	37,574,000
Research & development expenses	28,566,000	30,955,000	29,949,000
General & administrative expenses	13,331,000	17,026,000	18,306,000
Restructuring charges (benefit), net	2,515,000	747,000	403,000
Total operating expenses	78,367,000	82,575,000	86,232,000
Operating income (loss)	8,807,000	17,105,000	10,889,000
Interest income	656,000	545,000	218,000
Interest expense	48,000	291,000	4,000
Other income (expense), net	76,000	(669,000)	2,014,000
Total other income (expense), net	684,000	(415,000)	2,228,000
Income before income taxes - United States	5,170,000	9,841,000	6,934,000
Income before income taxes - international	4,321,000	6,849,000	6,183,000
Income (loss) from continuing operations, before income taxes	9,491,000	16,690,000	13,117,000
Current federal income tax provision (benefit) ...	312,000	(141,000)	1,452,000
Current state income tax provision (benefit) ...	165,000	139,000	453,000
Current foreign income tax provision (benefit) ...	1,756,000	2,099,000	2,279,000
Deferred U.S.			

Income from continuing operations	9,366,000	13,478,000	9,433,000
Income (loss) from discontinued operations, after income taxes	3,230,000	(2,845,000)
Net income (loss)	9,366,000	16,708,000	6,588,000
Weighted average shares outstanding - basic	26,432,000	25,760,000	24,645,000
Weighted average shares outstanding - diluted	27,099,000	26,311,000	25,227,000
Year end shares outstanding	26,571,415	26,040,378	25,046,950
Earnings (loss) per share from continuing operations, basic	\$0.35	\$0.52	\$0.38
Earnings (loss) per share from discontinued operations, basic	\$0.13	\$(0.12)
Net earnings (loss) per share - basic	\$0.35	\$0.65	\$0.27
Earnings (loss) per share from continuing operations, diluted	\$0.35	\$0.51	\$0.37
Earnings (loss) per share from discontinued operations, diluted	\$0.12	\$(0.11)
Net earnings (loss) per share - diluted	\$0.35	\$0.64	\$0.26
Total number of employees	514	515	515
Number of common stockholders	118	129	129
Foreign currency translation adjustments	(2,107,000)	(4,323,000)

Reclassified to conform with 2017 presentation; Restated to reflect the discontinued operation of Company's wholly owned subsidiary, Etherios Inc. ; As of November 17, 2017; As of December 9, 2016; On November 23, 2015

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

	2017	2016
		(revised)
Cash & cash equivalents	78,222,000	75,727,000
Marketable securities	32,015,000	58,382,000
Accounts receivable, gross	31,365,000	30,885,000
Less allowance for doubtful accounts	341,000	209,000
Less reserve for future returns & pricing adjustments	(2,169,000)	(1,991,000)
Accounts receivable, net	28,855,000	28,685,000
Raw materials	24,050,000	21,116,000
Work in process	484,000	802,000
Finished goods	5,704,000	4,358,000
Inventories, net	30,238,000	26,276,000
Receivable from sale of business	1,998,000	2,997,000
Other current assets	3,032,000	3,578,000
Total current assets	174,360,000	195,645,000
Marketable securities, long-term	4,753,000	3,541,000
Land	1,800,000	1,800,000
Buildings	10,522,000	10,522,000
Improvements	3,445,000	3,239,000
Equipment	17,133,000	15,778,000
Purchased software	3,571,000	3,377,000

Property, equipment & improvements, at cost	39,944,000	37,519,000
Less accumulated depreciation & amortization	27,143,000	23,478,000
Property, equipment, & improvements, net	12,801,000	14,041,000
Identifiable intangible assets, net	11,800,000	4,041,000
Goodwill	131,995,000	109,448,000
Deferred tax assets	9,211,000	7,295,000
Receivable from sale of business	1,959,000
Other assets	269,000	196,000
Total assets	345,189,000	336,166,000
Accounts payable	6,240,000	8,569,000
Accrued compensation	4,325,000	10,787,000
Accrued warranty	987,000	1,033,000
Accrued professional fees	928,000	753,000
Accrued restructuring	1,343,000	361,000
Unearned revenue	1,656,000	...
Other current liabilities	2,501,000	2,305,000
Total current liabilities	17,980,000	23,808,000
Income taxes payable	877,000	1,490,000
Deferred tax liabilities	534,000	616,000
Contingent consideration on acquired business	6,000,000	9,447,000
Other noncurrent liabilities	654,000	776,000
Total liabilities	26,045,000	36,137,000
Common stock	330,000	325,000
Additional paid-in capital	245,528,000	237,492,000
Retained earnings (accumulated deficit)	150,478,000	141,112,000
Accumulated other comprehensive income (loss)	(22,659,000)	(24,691,000)
Treasury stock, at cost	54,533,000	54,209,000
Total stockholders' equity	319,144,000	300,029,000

Reclassified to conform with 2017 presentation

DIGIRAD CORP**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2017	2016
Total Revenues	87,421,000	94,333,000
Cost & expenses	90,801,000	90,990,000
Operating income	(5,114,000)	1,608,000
Other income (expense), net	(946,000)	(414,000)
Net before taxes	(6,902,000)	102,000
Income taxes	6,845,000	(12,222,000)
Net income	(13,747,000)	12,324,000
Earnings common share		
Primary	\$(0.69)	\$0.63
Fully Diluted	\$(0.69)	\$0.62
Common Shares:		
Full Diluted	19,974,000	20,026,000
Year-end	20,052,984	19,679,640

DIMENSION THERAPEUTICS INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2017	2016
Total Revenues	12,467	7,339
Cost & expenses	55,298	43,323
Operating income	(42,831)	(35,984)
Net income	(42,748)	(35,976)
Earnings common share		
Primary	\$(1.71)	\$(1.44)
Fully Diluted	\$(1.71)	\$(1.44)
Common Shares:		
Full Diluted	25,014	24,901
Year-end	25,209	25,044

DIMENSION THERAPEUTICS INC

Merger Completed On Nov. 7, 2017, Ultragenyx Pharmaceutical Inc. ("Ultragenyx") wholly-owned subsidiary, Mystic River Merger Sub Inc. ("Purchaser"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Ultragenyx. As the result of the merger, each share issued and outstanding of Co.'s common stock, par value \$0.0001 per share, immediately prior to the Effective Time was

converted into the right to receive \$6.00 per Share, (the "Offer Price"), in cash, without interest thereon and subject to any required tax withholding, other than (i) Shares held by Co. as treasury stock, or by Ultragenyx or Purchaser or (ii) Shares held by stockholders who properly exercised appraisal rights under the DGCL. The aggregate consideration paid by Ultragenyx was approximately \$152,300,000, not including related transaction fees and expenses.

DOLLAR TREE INC

Earnings, 9 mos. to (Consol. - \$000):

	10/28/17	10/29/16
Net Sales	15,884,900	15,083,700
Cost & expenses	14,651,400	13,965,400
Operating income	1,233,500	1,118,300
Interest expense	220,200	286,700
Other income (expense), net	(800)	100
Net before taxes	1,012,500	831,700
Income taxes	338,300	257,300
Net income	674,200	574,400
Earnings common share		
Primary	\$2.85	\$2.44
Fully Diluted	\$2.84	\$2.43
Common Shares:		
Full Diluted	237,500	236,700
Year-end	237,097	236,000

DRONE AVIATION HOLDING CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	474,634	1,073,672
Cost & expenses	7,715,816	8,270,242
Operating income	(7,241,182)	(7,196,570)
Interest expense	1,558,389	3,149
Other income (expense), net	1,149,647	86,024
Net income	(7,649,924)	(7,113,695)
Balance for common	(7,649,924)	(7,113,695)
Earnings common share		
Primary	\$(0.86)	\$(1.13)
Fully Diluted	\$(0.86)	\$(1.13)
Common Shares:		
Full Diluted	8,880,168	6,285,681
Year-end	9,182,470	8,807,220

DXP ENTERPRISES, INC.

New Accountant On Nov. 16, 2017, Hein & Associates LLP resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Moss Adams LLP as its new independent public accounting firm.

EDGEWATER TECHNOLOGY INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	86,796,000	96,748,000
Cost & expenses	89,935,000	90,718,000
Operating income	(5,515,000)	3,011,000
Other income (expense), net	(200,000)	(1,761,000)
Net before taxes	(5,715,000)	1,250,000
Income taxes	(1,996,000)	657,000
Net income	(3,719,000)	593,000
Earnings common share		
Primary	\$(0.28)	\$0.05
Fully Diluted	\$(0.28)	\$0.04
Common Shares:		
Full Diluted	13,497,000	14,080,000
Year-end	13,959,000	12,340,000

EDITAS MEDICINE INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	93,552	63,359
Operating income	(83,491)	(58,204)
Other income (expense), net	458	(22)
Net income	(84,135)	(57,807)
Balance for common	(84,135)	(57,854)
Earnings common share		
Primary	\$(2.13)	\$(1.86)
Fully Diluted	\$(2.13)	\$(1.86)
Common Shares:		
Full Diluted	39,559	31,041
Year-end	41,840	35,609

EIGER BIOPHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	30,935	33,211
Operating income	(30,935)	(33,211)
Interest income	321	
Interest expense	1,129	685
Other income (expense), net	188	(423)
Net income	(31,555)	(34,319)
Earnings common share		
Primary	\$(3.77)	\$(6.58)
Fully Diluted	\$(3.77)	\$(6.58)
Common Shares:		
Full Diluted	8,367	5,218
Year-end	10,516	8,357

EL POLLO LOCO HOLDINGS INC

Earnings, 9 mos. to (Consol. - \$000):

	09/27/17	09/28/16
Total Revenues	306,499	287,644
Cost & expenses	276,364	243,145
Operating income	16,489	32,703
Interest expense	2,471	2,441
Other income (expense), net	(107)	(411)
Net before taxes	13,911	29,851
Income taxes	5,254	11,930
Net income	8,657	17,921
Earnings common share		
Primary	\$0.23	\$0.47
Fully Diluted	\$0.22	\$0.46
Common Shares:		
Full Diluted	39,101	39,020
Year-end	38,653	38,474

ELEVEN BIOTHERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	425	29,156
Cost & expenses	23,087	22,668
Operating income	(22,662)	6,488
Interest expense		247
Other income (expense), net	180	(819)
Net income	(22,482)	5,422
Earnings common share		
Primary	\$(0.91)	\$0.27
Fully Diluted	\$(0.91)	\$0.26
Common Shares:		
Full Diluted	24,663	20,796
Year-end	24,698	24,155

ENERGY & TECHNOLOGY CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	2,112,773	1,286,190
Cost & expenses	2,883,834	1,915,421
Operating income	(853,637)	(712,206)
Interest expense	139,509	298,203
Other income (expense), net	167,213	
Gains or losses	(1,514)	(2,182)
Net income	(827,447)	(1,012,591)
Earnings common share		
Common Shares:		
Full Diluted	165,560,766	165,560,766
Year-end	165,560,766	165,560,766

ENGLOBAL CORP.

New Accountant On Nov. 16, 2017, Hein & Associates LLP resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Moss Adams LLP as its new independent public accounting firm.

ENTEGRA FINANCIAL CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	32,310	28,959
Operating income	8,337	6,775
Net before taxes	8,337	6,775
Income taxes	2,464	2,751
Net income	5,873	4,024
Earnings common share		
Primary	\$0.91	\$0.62
Fully Diluted	\$0.90	\$0.62
Common Shares:		
Full Diluted	6,542	6,500
Year-end	6,459	6,466

ENTELLUS MEDICAL INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	64,575	53,512
Cost & expenses	94,934	73,279
Operating income	(32,672)	(19,878)
Interest income	286	228
Interest expense	2,029	1,686
Other income (expense), net	(82)	(42)
Net before taxes	(34,497)	(21,378)
Income taxes	(14,876)	34
Net income	(19,621)	(21,412)
Earnings common share		
Primary	\$(0.87)	\$(1.14)
Fully Diluted	\$(0.87)	\$(1.14)
Common Shares:		
Full Diluted	22,595	18,827
Year-end	25,448	18,863

EV ENERGY PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	165,690,000	132,453,000
Cost & expenses	180,694,000	119,498,000
Deprec., depl. & amort.	70,221,000	91,492,000
Operating income	(85,225,000)	(78,537,000)
Interest expense	30,501,000	32,554,000
Other income (expense), net	1,149,000	49,281,000
Gains or losses	20,588,000	(17,192,000)
Net before taxes	(93,989,000)	(79,002,000)
Income taxes	(109,000)	(1,779,000)
Net income	(93,880,000)	(77,223,000)
Earnings common share		
Primary	\$(1.86)	\$(1.54)
Fully Diluted	\$(1.86)	\$(1.54)
Common Shares:		
Full Diluted	49,353,000	49,046,000
Year-end	49,368,869	49,055,214

EXA CORP

Merger Completed On Nov. 17, 2017, Dassault Systemes S.E. indirect wholly-owned subsidiary, Dassault Systemes Simulia Corp. ("Parent"), through its wholly-owned subsidiary, 3DS Acquisition 3 Corp. ("Purchaser") merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each issued and outstanding shares of common stock, par value \$0.001 per share, of Co. (the "Shares"), other than Shares outstanding immediately prior to the Effective Time owned by Co., Parent or Purchaser, or by stockholders who have validly exercised their appraisal rights under Delaware law, was canceled and converted into the right to receive \$24.25 in cash, payable net to the holder thereof in cash, without interest (the "Offer Price"), subject to any withholding of taxes required by applicable law. In addition, each option to acquire Shares granted under a Co. equity plan that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested or exercisable, became fully vested and exercisable immediately prior to the Effective Time. Each option granted under a Co. equity plan that was outstanding and unexercised as of the Effective Time and that had an exercise price per Share that was less than the Offer Price was automatically canceled at the Effective Time in exchange for the right to receive an amount in cash equal to the product of the excess of the Offer Price over the applicable exercise price per Share of such option and the aggregate number of Shares issuable upon exercise of such option, less any required withholding taxes. Each option granted under a Co. equity plan that was outstanding and unexercised as of the Effective Time and that had an exercise price per Share that was equal to or greater than the Offer Price was canceled effective as of the Effective Time for no consideration. Pursuant to the Merger Agreement, each restricted stock unit granted by Co. under a Co. equity plan that was outstanding as of immediately prior to the Effective Time became fully vested and was canceled as of the Effective Time, in exchange for the right to receive an amount in cash equal to the product of the Offer Price and the aggregate number of vested Shares subject to such restricted stock unit. The aggregate consideration paid to Co.'s stockholders in the Offer and Merger was approximately \$372,000,000, without giving effect to related transaction fees and expenses.

EXPEDIA INC

Offering On Nov. 17, 2017, Co. announced a public offering pursuant to 3.800% Senior Notes due 2028. Co. proposed to offer \$1,000,000,000 at a proposed maximum offering price per unit of 100%, which amounted to a proposed maximum aggregate offering price of \$1,000,000,000. The amount of registration fee is \$124,500.

Year-end	1,381,595	1,381,595
Consolidated Balance Sheet Items, as of (\$):		
Assets:		
		2017
Cash & equivalents	169,145	
Inventories	19,714,744	
Current assets	31,755,632	
Net property & equip.	27,733,219	
Total assets	63,274,926	
Liabilities:		
Current liabilities	13,346,085	
Long-term debt	17,346,201	
Stockholders' equity	9,351,091	
Net current assets	18,409,547	

FIBROCELL SCIENCE INC

Offering On Nov. 17, 2017, Co. announced a public offering pursuant to (i) Common stock, \$0.001 par value per share, which amounted to a proposed maximum aggregate offering price of \$23,322,000.00. The amount of registration fee is \$2,903.59; and (ii) Common stock issuable upon exercise of the underwriter's warrants, which amounted to a proposed maximum aggregate offering price of \$1,166,100.00. The amount of registration fee is \$145.18.

FIDUS INVESTMENT CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	25,528,000	24,125,000
Operating income	26,019,000	18,829,000
Net before taxes	26,019,000	18,829,000
Income taxes	29,000	69,000
Net income	25,990,000	18,760,000
Earnings common share		
Primary	\$1.12	\$1.06
Fully Diluted	\$1.12	\$1.06
Common Shares:		
Full Diluted	23,201,533	17,616,540
Year-end	24,492,880	19,212,425

FIRST HARTFORD CORP

Annual Meeting Development On Nov. 16, 2017, 2017, Co. scheduled its annual Meeting of Shareholders for Wednesday, Jan. 17, 2018 at 10:00 a.m. local time, The Hartford Club U 46 Prospect Street, Hartford, CT.

FIRSTHAND TECHNOLOGY VALUE FUND INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	1,043,461	616,806
Cost & expenses	3,099,817	3,441,292
Net income	(2,056,356)	(2,824,486)
Earnings common share		
Primary	\$(0.28)	\$(0.37)
Common Shares:		
Year-end	7,430,697	7,430,697

FIVE PRIME THERAPEUTICS, INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	147,760	90,232
Operating income	(121,470)	(67,803)
Net before taxes	(119,308)	(65,982)
Income taxes	1,703	(20,391)
Net income	(121,011)	(45,591)
Earnings common share		
Primary	\$(4.34)	\$(1.70)
Fully Diluted	\$(4.34)	\$(1.70)
Common Shares:		
Full Diluted	27,883	26,794
Year-end	28,072	28,442

FLEX PHARMA INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	991,671	711,759
Cost & expenses	27,624,337	32,613,724
Operating income	(26,632,666)	(31,901,965)
Interest income	227,535	308,877
Net income	(26,405,131)	(31,593,088)
Balance for common	(26,405,131)	(31,593,088)
Earnings common share		
Primary	\$(1.54)	\$(1.96)
Fully Diluted	\$(1.54)	\$(1.96)
Common Shares:		
Full Diluted	17,131,887	16,104,510
Year-end	17,541,377	17,970,590

FOGO DE CHAO INC

Earnings, 9 mos. to (Consol. - \$000):

	10/01/17	10/02/16
Total Revenues	225,517	207,419
Cost & expenses	190,690	169,515
Operating income	20,735	26,314
Interest income	1,909	1,534
Interest expense	3,709	3,307
Other income (expense), net	12	(14)
Net before taxes	18,947	24,527
Income taxes	6,195	7,977
Net income	12,752	16,550
Earnings common share		
Primary	\$0.47	\$0.60
Fully Diluted	\$0.46	\$0.58
Common Shares:		
Full Diluted	28,840	28,846
Year-end	28,235	28,126

FRESHPET INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	115,682,698	98,992,060
Cost & expenses	120,051,266	102,758,001
Operating income	(4,368,568)	(3,765,941)
Other income (expense), net	(515,473)	(93,036)
Net before taxes	(5,714,973)	(4,349,074)
Income taxes	62,261	45,000
Net income	(5,777,234)	(4,394,074)
Balance for common	(5,777,234)	(4,394,074)
Earnings common share		
Primary	\$(0.17)	\$(0.13)
Fully Diluted	\$(0.17)	\$(0.13)
Common Shares:		
Full Diluted	34,316,161	33,603,535
Year-end	34,835,698	33,839,791

FUNKO INC**Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2016	2015
Net sales	426,717	56,565
Cost of sales	280,396	44,485
Selling, general & administrative expense	77,525	13,894
Acquisition transaction costs	1,140	7,559
Depreciation & amortization	23,509	3,370
Total operating expenses	382,570	69,308
Income (loss) from operations	44,147	(12,743)
Interest expense, net	17,267	2,818
Net income (loss)	26,880	(15,561)
Year end units		
outstanding	231	212
Number of full time employees	465	...
Number of part time employees	7	...

□ Period from October 31, 2015 through December 31, 2015; □ As is, □ As of June 30, 2017

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2016	2015
Cash & cash equivalents	6,161	24,411
Accounts receivable, gross	86,342	48,147
Allowance for doubtful accounts	2,735	205
Accounts receivable, net	83,607	47,942
Inventory	43,616	49,629
Prepaid deposits for inventory & molds	10,473	4,467
Prepaid royalties, net	6,903	6,851
Other prepaid expenses & current assets	1,664	1,050
Prepaid expenses & other current assets	19,040	12,368
Total current assets	152,424	134,550

Tooling & Molds	28,942	17,896
Leasehold improvements	4,970	2,420
Computer equipment, software, & other	2,346	1,335
Furniture, fixtures, & warehouse equipment	4,220	2,498
Construction in progress	5,452	1,068
Property, plant & equipment, gross	45,930	25,217
Less: Accumulated depreciation	20,457	9,893
Property & equipment, net	25,473	15,324
Goodwill	97,453	97,453
Intangible assets, net	243,796	256,741
Other assets	3,091	1,462
Total assets	522,237	505,330
Line of credit	6,729	...
Current portion of long-term debt, net of unamortized discount		
	7,130	5,626
Accounts payable	23,653	9,490
Accrued royalties	21,284	13,564
Accrued payroll & compensation	4,768	2,524
Deferred revenue	3,754	2,951
Accrued shipping costs	2,811	1,719
Accrued interest	86	1,110
Other current liabilities	2,327	2,974
Accrued expense & other current liabilities	13,746	11,278
Current portion of contingent consideration		
	25,000	38,879
Total current liabilities	97,542	78,837
Long-term debt	203,894	164,220
Contingent consideration	...	18,463
Deferred rent	3,424	254
Class A units	219,311	204,311
Additional paid-in-capital		
	58,090	46,290
Retained earnings (accumulated deficit)		
	(60,024)	(7,045)
Total members' equity	217,377	243,556

FUTURE FINTECH GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	10,179,416	26,256,579
Cost & expenses	23,748,629	25,353,455
Operating income	(13,569,213)	903,124
Interest income	2,032	160,370
Interest expense	738,705	1,688,263
Other income (expense), net	3,013,337	534,450
Minority interest	2,767,477	127,278
Net before taxes	(11,292,549)	(90,319)
Income taxes	258,260	884,282
Income contin. oper.	(14,318,286)	...
Net income	(14,460,412)	(1,101,879)
Earnings common share		
Primary	\$(3.04)	\$(0.28)
Fully Diluted	\$(3.00)	\$(0.28)
Common Shares:		
Full Diluted	4,814,052	3,887,435
Year-end	5,173,187	4,061,090

GELTECH SOLUTIONS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	954,100	920,741
Cost & expenses	3,381,863	3,737,950
Operating income	(2,427,763)	(2,817,209)
Interest income	9	8
Interest expense	636,839	516,281
Other income (expense), net	...	(227,251)
Gains or losses	...	(72,765)
Net income	(3,064,593)	(3,633,498)
Earnings common share		
Primary	\$(0.05)	\$(0.07)
Fully Diluted	\$(0.05)	\$(0.07)
Common Shares:		
Full Diluted	58,816,056	50,562,616
Year-end	70,520,807	52,305,513

GEMPHIRE THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	26,557	7,468
Operating income	(26,557)	(7,468)
Other income (expense), net	(5)	(5)
Net income	(26,669)	(7,372)
Earnings common share		
Primary	\$(2.60)	\$(1.65)
Fully Diluted	\$(2.60)	\$(1.65)
Common Shares:		
Full Diluted	10,253	4,704
Year-end	10,633	9,270

GIGGLES N' HUGS INC

Earnings, 9 mos. to (Consol. - \$):

	10/01/17	09/25/16
Net Sales	1,890,505	2,338,755
Cost & expenses	3,074,002	3,148,814
Operating income	(1,183,497)	(810,059)
Other income (expense), net	(51,843)	(205,128)
Gains or losses		220,082
Net before taxes	(1,312,259)	(1,219,457)
Income taxes	2,650	(616)
Net income	(1,314,909)	(1,218,841)
Earnings common share		
Primary	\$(0.01)	\$(0.03)
Fully Diluted	\$(0.01)	\$(0.03)
Common Shares:		
Full Diluted	125,101,775	43,661,733
Year-end	144,777,251	47,772,769

GLADSTONE LAND CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	18,310,000	12,396,000
Cost & expenses	4,759,000	3,852,000
Operating income	8,428,000	4,800,000
Interest expense	6,984,000	4,297,000
Other income (expense), net	(1,185,000)	(113,000)
Gains or losses	(78,000)	
Net income	181,000	390,000
Earnings common share		
Primary	\$0.01	\$0.04
Fully Diluted	\$0.01	\$0.04
Common Shares:		
Full Diluted	11,512,968	10,001,466
Year-end	13,485,025	10,024,875

GLOBAL BLOOD THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	77,330	55,668
Operating income	(77,330)	(55,668)
Interest income	1,856	407
Net income	(75,772)	(55,261)
Earnings common share		
Primary	\$(1.81)	\$(1.72)
Fully Diluted	\$(1.81)	\$(1.72)
Common Shares:		
Full Diluted	41,832	32,075
Year-end	43,376	36,516

GLOBAL WATER RESOURCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	23,408	22,585
Cost & expenses	12,621	12,960
Operating income	5,623	4,874
Interest income	14	12
Interest expense	3,889	10,595
Other income (expense), net	1,296	1,796
Net before taxes	3,044	(3,913)
Income taxes	1,227	(1,353)
Net income	1,817	(2,560)
Earnings common share		
Primary	\$0.09	\$(0.13)
Fully Diluted	\$0.09	\$(0.13)
Common Shares:		
Full Diluted	19,632	19,001
Year-end	19,631	19,581

GLOWPOINT INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	11,417,000	14,950,000
Cost & expenses	12,496,000	15,219,000
Operating income	(2,449,000)	(1,778,000)
Other income (expense), net	9,045,000	
Net before taxes	5,616,000	(2,913,000)
Income taxes	(230,000)	108,000
Net income	5,846,000	(3,021,000)
Balance for common	5,837,000	(3,030,000)
Earnings common share		
Primary	\$0.16	\$(0.09)
Fully Diluted	\$0.15	\$(0.09)
Common Shares:		
Full Diluted	38,078,000	35,480,000
Year-end	36,130,000	35,855,000

GLYCOMIMETICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues		18,500
Cost & expenses	24,396,418	23,573,715
Operating income	(24,396,418)	(23,555,215)
Other income (expense), net	373,208	73,974
Net income	(24,023,210)	(23,481,241)
Earnings common share		
Primary	\$(0.86)	\$(1.14)
Fully Diluted	\$(0.86)	\$(1.14)
Common Shares:		
Full Diluted	27,814,781	20,638,129
Year-end	32,737,799	23,063,430

GOPRO INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	844,945	644,860
Cost & expenses	950,094	991,261
Operating income	(105,149)	(346,401)
Interest expense	9,152	1,815
Other income (expense), net	705	1,360
Net before taxes	(113,596)	(346,856)
Income taxes	13,429	(43,562)
Net income	(127,025)	(303,294)
Earnings common share		
Primary	\$(0.92)	\$(2.18)
Fully Diluted	\$(0.92)	\$(2.18)
Common Shares:		
Full Diluted	138,450	138,875
Year-end	136,752	136,601

GRANITE CITY FOOD & BREWERY LTD

Earnings, 9 mos. to (Consol. - \$):

	09/26/17	09/27/16
Net Sales	107,372,495	114,170,594
Cost & expenses	103,542,988	107,020,656
Deprec., depl. & amort.	6,038,607	5,444,177
Operating income	(2,209,100)	1,705,761
Net before taxes	(5,379,158)	(1,390,171)
Income taxes	49,442	60,614
Net income	(5,428,600)	(1,450,785)
Earnings common share		
Primary	\$(0.38)	\$(0.10)
Fully Diluted	\$(0.38)	\$(0.10)
Common Shares:		
Year-end	14,360,981	14,360,981

GREEN BANCORP INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	93,267	134,519
Operating income	48,339	(5,273)
Net before taxes	48,339	(5,273)
Income taxes	16,822	(1,757)
Net income	31,517	(3,516)
Earnings common share		
Primary	\$0.85	\$(0.10)
Fully Diluted	\$0.85	\$(0.10)
Common Shares:		
Full Diluted	37,273	36,659
Year-end	37,096	36,683

GREEN PLAINS PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	78,743	75,487
Cost & expenses	28,419	29,367

Operating income	46,543	41,900
Interest income	61	62
Interest expense	3,941	1,295
Net before taxes	42,663	40,667
Income taxes	135	304
Net income	42,528	40,363
Earnings common share		
Primary	\$1.31	\$1.24
Fully Diluted	\$1.31	\$1.24
Common Shares:		
Full Diluted	15,914	15,902
Year-end	31,809	31,800

GSI TECHNOLOGY INC

Earnings, 6 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	20,334	26,304
Cost & expenses	23,657	25,535
Operating income	(3,323)	769
Interest income	196	146
Other income (expense), net	5	88
Net before taxes	(3,122)	1,003
Income taxes	130	117
Net income	(3,252)	886
Earnings common share		
Primary	\$(0.16)	\$0.04
Fully Diluted	\$(0.16)	\$0.04
Common Shares:		
Full Diluted	20,922	21,349
Year-end	21,074	20,325

GULF RESOURCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	104,160,873	120,907,839
Cost & expenses	70,030,152	80,954,199
Operating income	34,130,721	39,953,640
Interest income	398,382	356,828
Interest expense	124,068	134,150
Net before taxes	34,405,035	40,176,318
Income taxes	9,152,597	9,996,622
Net income	25,252,438	30,179,696
Earnings common share		
Primary	\$0.54	\$0.65
Fully Diluted	\$0.54	\$0.65
Common Shares:		
Full Diluted	46,833,030	46,560,937
Year-end	46,803,791	46,793,791

HABIT RESTAURANTS INC

Earnings, 9 mos. to (Consol. - \$000):

	09/26/17	09/27/16
Total Revenues	246,607	209,958
Cost & expenses	225,735	188,349
Deprec., depl. & amort.	13,492	10,779
Operating income	7,380	10,830
Other income (expense), net	(688)	
Net before taxes	6,311	10,374
Income taxes	1,397	3,038
Net income	4,914	7,336
Earnings common share		
Primary	\$0.17	\$0.20
Fully Diluted	\$0.17	\$0.20
Common Shares:		
Full Diluted	20,311	16,358
Year-end	20,340	26,003

HAYNES INTERNATIONAL, INC.

Annual Report

Consolidated Income Statement, Years Ended Sept. 30 (\$000):

	2017	2016	2015
Net revenues	395,209	406,359	487,635
Cost of sales	365,499	358,779	393,971
Gross profit	29,710	47,580	93,664
Selling, general & administrative expense	42,393	39,684	42,572
Research & technical expense	3,855	3,698	3,598
Operating income (loss)	(16,538)	4,198	47,494
Interest income	186	108	94

Interest expense	865	555	412	Total current assets	355,168	366,260	Full Diluted	11,693	7,724
Income (loss) before income taxes				Land & land improvements	9,345	7,207	Year-end	16,401	14,586
- U.S.	(25,090)	(4,160)	36,327	Buildings & improvements	44,705	37,343			
Income (loss) before income taxes - foreign	7,873	7,911	10,849	Machinery & equipment	289,035	262,717			
Income (loss) before income taxes	(17,217)	3,751	47,176	Construction in process	5,692	28,562			
Current provision for income taxes - U.S. federal	933	(4,427)	11,207	Property, plant & equipment, gross	348,777	335,829			
Current provision (benefit) for income taxes - foreign	1,652	1,368	1,690	Less accumulated depreciation	156,221	136,647			
Current provision for income taxes - state	401	(141)	686	Property, plant & equipment, net	192,556	199,182			
Total current provision (benefit) for income taxes	2,986	(3,200)	13,583	Deferred income taxes-long term portion	58,133	71,010			
Deferred provision (benefit) for income taxes - U.S. federal	(8,781)	4,582	(79)	Other assets	5,107	1,798			
Deferred provision (benefit) for income taxes - foreign	...	(105)	690	Goodwill	4,789	4,789			
Deferred provision (benefit) for income taxes - state	(1,427)	(2,954)	2,368	Other intangible assets, net	6,066	6,562			
Valuation allowance	195	408	128	Total assets	621,819	649,601			
Total deferred provision (benefit) for income taxes	(10,013)	1,931	3,107	Accounts payable	32,802	29,925			
Provision (benefit) for income taxes	(7,027)	(1,269)	16,690	Employee compensation	7,791	7,394			
Net income (loss)	(10,190)	5,020	30,486	Taxes, other than income taxes	2,422	2,264			
Weighted average shares outstanding-basic	12,397	12,361	12,332	Utilities	909	992			
Weighted average shares outstanding-diluted	12,397	12,366	12,344	Professional fees	746	615			
Year end shares outstanding	12,510	12,491	12,446	Capital lease obligation, current	926	383			
Net income (loss) per share-basic	\$(0.83)	\$0.40	\$2.45	Other accrued expenses	1,314	1,232			
Net income (loss) per share-diluted	\$(0.83)	\$0.40	\$2.45	Income taxes payable	195	...			
Dividends per common share	\$0.88	\$0.88	\$0.88	Accrued pension & postretirement benefits	5,095	5,095			
Number of full time employees	1,124	1,123	1,147	Deferred revenue-current portion	2,500	7,488			
Number of stockholders	53	47	48	Total current liabilities	54,700	55,388			
Foreign currency translation adjustments	(4,167)	(7,001)	(4,167)	Future capital lease rental payments	4,275	4,331			
				Finance lease rental payments	4,017	3,700			
				Environmental post-closure monitoring & maintenance activities	633	683			
				Less amounts due within one year	1,029	458			
				Long-term obligations (less current portion)	7,896	8,256			
				Deferred revenue (less current portion)	20,329	22,829			
				Deferred income taxes	1,741	1,578			
				Accrued pension benefits (less current portion)	90,957	130,134			
				Accrued postretirement benefits (less current portion)	112,424	120,117			
				Total liabilities	288,047	338,302			
				Common stock	13	12			
				Additional paid-in capital	248,733	246,625			
				Retained earnings (accumulated deficit)	159,366	180,565			
				Treasury stock	1,646	1,380			
				Pension plan	(43,012)	(74,742)			
				Postretirement plan	(21,691)	(29,585)			
				Foreign exchange	(7,991)	(10,196)			
				Accumulated other comprehensive income (loss)	(72,694)	(114,523)			
				Total stockholders' equity (deficiency)	333,772	311,299			

□ Reclassified to conform with 2017 presentation; □ As is; □ Approximately; □ As of November 1, 2017; □ As of November 1, 2016; □ As of November 1, 2015

Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):

	2017	2016	2015
Cash & cash equivalents	46,328	59,297	59,297
Restricted cash	...	5,446	...
Accounts receivable, gross	62,222	62,014	62,014
Less allowance for doubtful accounts	620	402	402
Accounts receivable	61,602	61,612	61,612
Raw materials	18,731	21,587	21,587
Work-in-process	130,019	118,822	118,822
Finished goods	94,331	94,772	94,772
Other inventories	1,376	1,377	1,377
Inventories	244,457	236,558	236,558
Income taxes receivable	...	538	...
Other current assets	2,781	2,809	2,809

□ Reclassified to conform with 2017 presentation

HEALTH INSURANCE INNOVATIONS, INC Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016	2015
Total Revenues	180,986	133,092	133,092
Cost & expenses	152,307	116,007	116,007
Operating income	25,721	14,718	14,718
Other income (expense), net	(27)	(474)	(474)
Net before taxes	25,696	14,191	14,191
Income taxes	4,220	2,501	2,501
Net income	21,476	11,690	11,690
Earnings common share			
Primary	\$1.31	\$0.62	\$0.62
Fully Diluted	\$1.21	\$0.61	\$0.61
Common Shares:			

HIGHPOWER INTERNATIONAL INC. Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	164,972,338	119,972,281
Cost & expenses	152,837,801	116,046,491
Operating income	12,134,537	3,925,790
Other income (expense), net	1,552,300	2,052,102
Gains or losses	1,664,377	...
Net before taxes	14,425,029	4,925,978
Income taxes	2,197,392	978,882
Net income	12,227,637	3,947,096
Earnings common share		
Primary	\$0.78	\$0.29
Fully Diluted	\$0.77	\$0.29
Common Shares:		
Full Diluted	15,563,012	15,104,914
Year-end	15,476,000	15,109,019

HOLOGIC INC Annual Report Consolidated Income Statement, Years Ended (\$):

	09/30/17	09/24/16	09/26/15
		(revised)	(revised)
Product sales	2,538,000,000	2,379,000,000	2,270,400,000
Service & other revenues	520,800,000	453,700,000	434,600,000
Total revenues	3,058,800,000	2,832,700,000	2,705,000,000
Product	881,800,000	756,800,000	755,500,000
Amortization of intangible assets	297,100,000	293,400,000	299,700,000
Service & other revenues	258,900,000	219,200,000	217,100,000
Gross profit	1,621,000,000	1,563,300,000	1,432,700,000
Research & development expense	232,800,000	232,100,000	214,900,000
Selling & marketing expense	498,600,000	415,100,000	363,000,000
General & administrative expense	343,300,000	267,300,000	261,000,000
Amortization of intangible assets	62,500,000	89,700,000	110,200,000
Gain on sale of business	899,700,000
Restructuring & divestiture charges	13,300,000	10,500,000	28,500,000
Total operating expenses	250,800,000	1,014,700,000	977,600,000
Income (loss) from operations	1,370,200,000	548,600,000	455,100,000
Interest income	3,800,000	700,000	1,300,000
Interest expense	153,200,000	155,300,000	205,500,000
Debt extinguishment gains (losses)	(3,200,000)	(5,300,000)	(62,700,000)
Other income (expense), net	12,900,000	26,600,000	(11,000,000)
Income (loss) before income taxes	1,105,800,000	310,700,000	158,300,000
Income (loss) before income taxes - foreign	124,700,000	104,600,000	18,900,000
Income (loss) before income taxes	1,230,500,000	415,300,000	177,200,000
Federal provision (benefit) for income taxes - current	701,100,000	209,000,000	185,200,000
Federal provision (benefit) for income taxes - deferred	(276,900,000)	(122,700,000)	(137,000,000)
Total federal provision (benefit) for income taxes	424,200,000	86,300,000	48,200,000
State provision (benefit) for income taxes - current	53,100,000	16,600,000	3,500,000
State provision (benefit) for			

income taxes -			
deferred	(15,900,000)	(22,700,000)	(11,000,000)
Total state			
provision (benefit)			
for income taxes	37,200,000	(6,100,000)	(7,500,000)
Foreign provision			
(benefit) for			
income taxes -			
current	13,900,000	14,700,000	5,700,000
Foreign provision			
(benefit) for			
income taxes -			
deferred	(300,000)	(10,400,000)	(800,000)
Total foreign			
provision (benefit)			
for income taxes	13,600,000	4,300,000	4,900,000
Provision (benefit)			
for income taxes	475,000,000	84,500,000	45,600,000
Net income (loss)	755,500,000	330,800,000	131,600,000
Weighted average			
shares outstanding			
- basic	279,811,000	280,213,000	280,566,000
Weighted average			
shares outstanding			
- diluted	285,653,000	286,156,000	289,537,000
Year end shares			
outstanding	275,293,000	277,726,000	282,495,000
Net income (loss)			
per common share -			
basic	\$2.70	\$1.18	\$0.47
Net income (loss)			
per common share -			
diluted	\$2.64	\$1.16	\$0.45
Number of full time			
employees	6,233	5,333	5,290
Number of common			
stockholders	1,077	1,142	1,189
Foreign currency			
translation			
adjustments		(10,400,000)	

□ Approximately; □ As of November 14, 2017; □ As of November 11, 2016; □ As of November 13, 2015

Consolidated Balance Sheet, Years Ended (\$):			
	09/30/17	09/24/16	(revised)
Cash & cash equivalents	540,600,000	548,400,000	
Accounts receivable,			
gross	543,300,000	459,700,000	
Less: reserves	9,800,000	12,700,000	
Accounts receivable, net	533,500,000	447,000,000	
Raw materials	95,700,000	96,400,000	
Work-in-process	45,000,000	51,700,000	
Finished goods	190,900,000	126,600,000	
Inventories	331,600,000	274,700,000	
Prepaid income taxes	22,400,000	16,900,000	
Prepaid expense & other			
current assets	50,500,000	39,600,000	
Total current assets	1,478,600,000	1,326,600,000	
Equipment & software	422,400,000	381,900,000	
Equipment under customer			
usage agreements	368,700,000	334,600,000	
Buildings & improvements	172,000,000	186,100,000	
Leasehold improvements	60,600,000	65,600,000	
Land	46,300,000	51,900,000	
Furniture & fixtures	20,800,000	18,400,000	
Property, plant &			
equipment, at cost	1,090,800,000	1,038,500,000	
Less: accumulated			
depreciation &			
amortization	599,600,000	578,300,000	
Property, plant &			
equipment, net	491,200,000	460,200,000	
Intangible assets, net	2,741,600,000	2,643,400,000	
Goodwill	3,171,200,000	2,803,100,000	
Life insurance contracts	41,000,000	36,000,000	
Capitalized software	12,300,000	10,000,000	
Manufacturing access fees	7,100,000	9,600,000	
Cost-method equity			
investments	3,000,000	3,500,000	
Deferred tax assets	9,100,000	9,300,000	
Other assets	24,500,000	15,300,000	
Total assets	7,979,600,000	7,317,000,000	

Term loan	121,300,000	83,800,000
Revolver	345,000,000	...
Securitization program	200,000,000	200,000,000
Convertible notes	484,500,000	12,200,000
Current portion of		
long-term debt	1,150,800,000	296,000,000
Accounts payable	166,600,000	156,900,000
Accrued compensation &		
employee benefits	176,700,000	176,400,000
Accrued income taxes &		
other taxes	66,900,000	38,400,000
Other accrued expenses	131,700,000	72,800,000
Accrued expenses	375,300,000	287,600,000
Deferred revenue	171,200,000	161,400,000
Current portion of		
capital lease obligations	1,600,000	...
Total current liabilities	1,865,500,000	901,900,000
Term loan	1,190,500,000	1,308,200,000
Senior notes	981,600,000	977,700,000
Convertible notes	...	763,500,000
Long-term debt, net of		
current portion	2,172,100,000	3,049,400,000
Capital lease		
obligations, net of		
current portion	22,700,000	...
Deferred income tax		
liabilities	973,600,000	982,600,000
Deferred revenue	20,800,000	15,900,000
Reserve for income tax		
uncertainties	88,300,000	167,600,000
Accrued lease obligation		
- long-term	34,100,000	34,800,000
Pension liabilities	10,000,000	11,200,000
Other long-term		
liabilities	7,800,000	10,900,000
Other long-term		
liabilities	140,200,000	224,500,000
Common stock	2,900,000	2,900,000
Additional		
paid-in-capital	5,630,800,000	5,560,300,000
Retained earnings		
(accumulated deficit)	(2,382,700,000)	(3,138,200,000)
Treasury stock, at cost	450,100,000	250,000,000
Foreign currency		
translation	(18,500,000)	(26,100,000)
Marketable securities	(400,000)	(300,000)
Pension plans	(1,600,000)	(2,500,000)
Hedged interest rate		
caps, net	4,300,000	(3,400,000)
Accumulated other		
comprehensive income		
(loss)	(16,200,000)	(32,300,000)
Total stockholders'		
equity (deficit)	2,784,700,000	2,142,700,000

□ Reclassified to conform with 2017 presentation

HORTONWORKS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	186,804	132,502
Cost & expenses	339,848	326,482
Operating income	(153,044)	(193,980)
Other income (expense), net	(2,134)	87
Net before taxes	(155,178)	(193,893)
Income taxes	1,101	742
Net income	(156,279)	(194,635)
Earnings common share		
Primary	\$(2.41)	\$(3.47)
Fully Diluted	\$(2.41)	\$(3.47)
Common Shares:		
Full Diluted	64,747	56,141
Year-end	69,413	59,920

I.D. SYSTEMS, INC. (DE)

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	29,791,000	27,596,000
Cost & expenses	32,707,000	31,880,000
Operating income	(2,916,000)	(4,284,000)
Interest income	169,000	218,000
Interest expense	248,000	222,000
Other income (expense), net	(1,000)	1,000
Net income	(2,996,000)	(4,287,000)

Earnings common share

Primary	\$(0.21)	\$(0.33)
Fully Diluted	\$(0.21)	\$(0.33)
Common Shares:		
Full Diluted	14,311,000	12,946,000
Year-end	18,316,000	13,766,000

IEG HOLDINGS CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	1,288,694	1,627,879
Cost & expenses	3,759,266	4,818,020
Operating income	(2,475,067)	(3,197,186)
Other income (expense), net	(623,920)	11,426
Gains or losses	(153,514)	...
Net income	(3,252,501)	(3,185,760)
Balance for common	(3,252,501)	(3,218,995)
Earnings common share		
Primary	\$(0.30)	\$(0.44)
Fully Diluted	\$(0.30)	\$(0.44)
Common Shares:		
Full Diluted	10,901,436	7,332,923
Year-end	12,335,293	9,672,723

IMPINJ INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	98,437	78,632
Cost & expenses	105,932	79,465
Operating income	(7,495)	(833)
Other income (expense), net	(341)	(845)
Net before taxes	(7,836)	(1,678)
Income taxes	152	98
Net income	(7,988)	(1,776)
Balance for common	(7,988)	(8,034)
Earnings common share		
Primary	\$(0.39)	\$(1.01)
Fully Diluted	\$(0.39)	\$(1.01)
Common Shares:		
Full Diluted	20,604	7,991
Year-end	20,955	18,780

INC RESEARCH HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	1,595,381	1,204,525
Cost & expenses	1,542,679	1,049,321
Operating income	(43,886)	111,559
Interest income	765	139
Interest expense	33,818	9,317
Other income (expense), net	(704)	(850)
Gains or losses	(9,298)	8,439
Foreign currency	(6,264)	(18,789)
Net before taxes	(93,205)	91,181
Income taxes	30,217	16,042
Net income	(123,422)	75,139
Earnings common share		
Primary	\$(1.90)	\$1.39
Fully Diluted	\$(1.90)	\$1.35
Common Shares:		
Full Diluted	65,097	55,836
Year-end	104,219	53,580

INOTEK PHARMACEUTICALS CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	22,535	29,640
Operating income	(22,535)	(29,640)
Interest income	574	285
Interest expense	2,666	525
Net income	(24,627)	(29,880)
Earnings common share		
Primary	\$(0.91)	\$(1.12)
Fully Diluted	\$(0.91)	\$(1.12)
Common Shares:		
Full Diluted	27,008	26,660
Year-end	27,223	26,931

INOVALON HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	334,739	331,495
Cost & expenses	267,131	266,551
Deprec., depl. & amort.	38,514	25,794

Operating income	29,094	39,150
Interest income	4,045	4,424
Interest expense	4,549	3,806
Gains or losses	(381)	538
Net before taxes	28,209	40,306
Income taxes	10,840	13,883
Net income	17,369	26,423
Balance for common	16,905	26,308
Earnings common share		
Primary	\$0.12	\$0.17
Fully Diluted	\$0.12	\$0.17
Common Shares:		
Full Diluted	143,327	152,122
Year-end	145,897	152,554

INSIGHT ENTERPRISES INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Net Sales	4,919,548	4,017,932
Cost & expenses	4,785,821	3,909,770
Operating income	133,727	108,162
Other income (expense), net	(980)	(979)
Foreign currency	(972)	(1,042)
Net before taxes	118,824	100,568
Income taxes	42,309	36,978
Net income	76,515	63,590
Earnings common share		
Primary	\$2.14	\$1.75
Fully Diluted	\$2.11	\$1.74
Common Shares:		
Full Diluted	36,186	36,596
Year-end	35,792	35,477

INSPIR THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	2,604,000	2,625,000
Operating income	(2,604,000)	(2,625,000)
Other income (expense), net	3,442,000	421,000
Net income	(5,641,000)	(2,201,000)
Earnings common share		
Primary	\$(1.77)	\$(1.58)
Fully Diluted	\$(1.77)	\$(1.58)
Common Shares:		
Full Diluted	3,183,289	1,392,079
Year-end	9,075,589	1,392,079

INTEGRITY APPLICATIONS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	125,881	482,177
Cost & expenses	8,021,937	4,816,337
Operating income	(7,896,056)	(4,334,160)
Other income (expense), net	273,360	110,471
Foreign currency	(30,154)	(33,329)
Net income	(7,672,266)	(4,272,506)
Balance for common	(8,671,416)	(4,813,168)
Earnings common share		
Primary	\$(1.40)	\$(0.84)
Fully Diluted	\$(1.40)	\$(0.84)
Common Shares:		
Full Diluted	6,207,844	5,746,838
Year-end	6,521,993	5,912,702

INTEL CORP

Offering On Nov. 14, 2017, Co. announced a public offering pursuant to Common Stock, par value \$0.001 per share, issuable under the Intel Corporation 2006 Equity Incentive Plan, Common Stock, par value \$0.001 per share, issuable in respect of stock options under the Mobileye N.V. 2014 Equity Incentive Plan, Common Stock, par value \$0.001 per share, issuable in respect of restricted stock units under the Mobileye N.V. 2014 Equity Incentive Plan and Common Stock, par value \$0.001 per share, issuable in respect of stock options under the Mobileye N.V. 2003 Share Option Plan, Amended and Restated July 27, 2014. Co. proposed to offer (i) 33,000,000 Common Stock, par value \$0.001 per share, issuable under the Intel Corporation 2006 Equity Incentive Plan at a proposed maximum offering price per share of \$45.74, which amounted to a proposed maximum aggregate offering price of \$1,509,420,000.00. The amount of registration fee is \$187,922.79; (ii) 8,328,464 Common Stock, par value \$0.001 per share, issuable in respect of stock options under the Mobileye N.V. 2014 Equity Incentive Plan at a proposed maximum offering price

per share of \$28.50, which amounted to a proposed maximum aggregate offering price of \$237,361,224.00. The amount of registration fee is \$29,551.47; (iii) 1,074,892 Common Stock, par value \$0.001 per share, issuable in respect of restricted stock units under the Mobileye N.V. 2014 Equity Incentive Plan at a proposed maximum offering price per share of \$45.74, which amounted to a proposed maximum aggregate offering price of \$49,165,560.08. The amount of registration fee is \$6,121.11; and (iv) 124,230 Common Stock, par value \$0.001 per share, issuable in respect of stock options under the Mobileye N.V. 2003 Share Option Plan, Amended and Restated July 27, 2014 at a proposed maximum offering price per share of \$4.01, which amounted to a proposed maximum aggregate offering price of \$498,162.30. The amount of registration fee is \$62.02.

INTERLINK ELECTRONICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	8,797	9,105
Cost & expenses	6,895	6,636
Operating income	1,902	2,469
Other income (expense), net	13	35
Net before taxes	1,915	2,504
Income taxes	650	535
Net income	1,265	1,969
Earnings common share		
Primary	\$0.17	\$0.27
Fully Diluted	\$0.17	\$0.27
Common Shares:		
Full Diluted	7,418	7,406
Year-end	7,336	7,328

INTERMOLECULAR INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	26,655	36,821
Cost & expenses	37,598	49,585
Operating income	(10,943)	(12,764)
Other income (expense), net	243	204
Net before taxes	(10,518)	(12,437)
Income taxes	1	7
Net income	(10,519)	(12,444)
Earnings common share		
Primary	\$(0.21)	\$(0.25)
Fully Diluted	\$(0.21)	\$(0.25)
Common Shares:		
Full Diluted	49,543	49,367
Year-end	49,560	49,521

INTERNATIONAL ISOTOPES INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	7,218,602	5,897,236
Operating income	(1,697,869)	(1,095,564)
Interest income	2,011	274
Interest expense	391,524	348,426
Other income (expense), net	(887,678)	78,183
Net income	(2,975,060)	(1,365,533)
Earnings common share		
Primary	\$(0.46)	\$(0.72)
Fully Diluted	\$(0.46)	\$(0.72)
Common Shares:		
Full Diluted	406,375,721	402,892,423
Year-end	406,755,371	404,987,914

INTERSECT ENT, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	66,772	54,477
Cost & expenses	80,865	75,528
Operating income	(14,093)	(21,051)
Net income	(13,211)	(20,406)
Earnings common share		
Primary	\$(0.46)	\$(0.72)
Fully Diluted	\$(0.46)	\$(0.72)
Common Shares:		
Full Diluted	28,978	28,356
Year-end	29,385	28,562

INTERSECTIONS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	119,631,000	133,392,000
Cost & expenses	125,211,000	129,532,000
Operating income	(9,669,000)	(92,000)
Other income (expense), net	(1,392,000)	(419,000)
Net before taxes	(12,956,000)	(2,213,000)

Income taxes	(23,000)	(69,000)
Income contin. oper.	(12,933,000)	(2,144,000)
Net income	(15,382,000)	(17,682,000)
Earnings common share		
Primary	\$(0.65)	\$(0.76)
Fully Diluted	\$(0.65)	\$(0.76)
Common Shares:		
Full Diluted	23,818,000	23,178,000
Year-end	24,122,000	

INTUIT INC

Annual Meeting Development On Nov. 22, 2017, 2017, Co. scheduled its annual Meeting of Shareholders for Thursday, Jan. 18, 2018, at 8:00 a.m. Pacific Standard Time at Co.'s offices at 2750 Coast Avenue, Building 6, Mountain View, CA 94043.

INTUIT INC**Earnings, 3 mos. to Oct 31(Consol. - \$000):**

	2017	2016
Total Revenues	886,000	778,000
Cost & expenses	942,000	838,000
Operating income	(57,000)	(61,000)
Gains or losses	2,000	(1,000)
Net before taxes	(59,000)	(72,000)
Income taxes	(42,000)	(42,000)
Net income	(17,000)	(30,000)
Earnings common share		
Primary	\$(0.07)	\$(0.12)
Fully Diluted	\$(0.07)	\$(0.12)
Common Shares:		
Full Diluted	256,000	258,000
Year-end	255,667	257,068

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2017
Cash & equivalents	529,000
Current assets	1,415,000
Net property & equip.	1,016,000
Total assets	4,064,000
Liabilities:	
Current liabilities	2,117,000
Long-term debt	425,000
Stockholders' equity	1,203,000
Net current assets	(702,000)

INVO BIOSCIENCE, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	200,790	41,384
Cost & expenses	644,202	1,881,503
Operating income	(443,412)	(1,840,119)
Other income (expense), net	(40,869)	
Net income	(500,695)	(1,847,843)
Earnings common share		
Primary	\$(0.11)	\$(0.11)
Fully Diluted	\$(0.11)	\$(0.11)
Common Shares:		
Full Diluted	141,103,908	138,713,059
Year-end	141,681,268	140,596,646

INVUITY INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	28,391	23,106
Cost & expenses	57,014	52,713
Operating income	(28,623)	(29,607)
Interest income	162	
Interest expense	1,559	1,514
Other income (expense), net	(2,491)	61
Net income	(32,511)	(31,060)
Earnings common share		
Primary	\$(1.91)	\$(2.19)
Fully Diluted	\$(1.91)	\$(2.19)
Common Shares:		
Full Diluted	17,016	14,174
Year-end	17,124	16,905

IOVANCE BIOTHERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	66,806,000	37,717,000
Operating income	(66,806,000)	(37,717,000)
Net income	(66,210,000)	(37,206,000)
Balance for common	(66,210,000)	(86,660,000)
Earnings common share		
Primary	\$(1.06)	\$(1.64)

Fully Diluted	\$(1.06)	\$(1.64)
Common Shares:		
Full Diluted	62,697,000	52,963,000
Year-end	71,954,843	61,948,389

IRIDEX CORP.**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/17	10/01/16
Total Revenues	31,350	33,628
Cost & expenses	39,020	35,117
Operating income	(7,670)	(1,489)
Other income (expense), net	(19)	(83)
Net before taxes	(7,689)	(1,572)
Income taxes	23	(674)
Net income	(7,712)	(898)
Earnings common share		
Primary	\$(0.67)	\$(0.09)
Fully Diluted	\$(0.67)	\$(0.09)
Common Shares:		
Full Diluted	11,544	10,083
Year-end	11,579	10,146

JAKKS PACIFIC INC.

Annual Meeting Development On Nov. 13, 2017, Co. announced that its Annual Meeting of Stockholders will be held on Dec. 22, 2017 at 8:00 a.m. local time, at Sherwood Country Club, 320 West Stafford Road, Thousand Oaks, CA 91361.

JOINT CORP (NEW)**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	18,234,516	14,742,668
Cost & expenses	19,633,672	22,120,893
Deprec., depl. & amort.	1,550,013	1,908,238
Operating income	(2,949,169)	(9,286,463)
Other income (expense), net	(33,589)	5,200
Net before taxes	(2,982,758)	(9,281,263)
Income taxes	79,277	132,144
Net income	(3,062,035)	(9,413,407)
Earnings common share		
Primary	\$(0.23)	\$(0.74)
Fully Diluted	\$(0.23)	\$(0.74)
Common Shares:		
Full Diluted	13,144,764	12,657,435
Year-end	13,485,600	12,719,399

KANDI TECHNOLOGIES GROUP, INC

Annual Meeting Development On Nov. 15, 2017, 2017, Co. scheduled its annual Meeting of Shareholders for Dec. 28, 2017, at 7:00 a.m. E.T. (8:00 p.m. local time) at Co.'s executive office, located at Building 11, West Floor 1, 1 Jiaogong Road, Xihu District, Hangzhou City, Zhejiang Province, China, 310012.

KCAP FINANCIAL INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	13,331,068	13,712,694
Net income	8,356,404	14,395,816
Earnings common share		
Primary	\$0.23	\$0.39
Fully Diluted	\$0.23	\$0.39
Common Shares:		
Full Diluted	37,202,011	37,142,002
Year-end	37,317,815	37,160,770

KEMPHARM INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Cost & expenses	25,216	26,646
Operating income	(25,216)	(26,646)
Other income (expense), net	(2,381)	25,002
Net before taxes	(32,832)	(6,591)
Income taxes	(12)	(11)
Net income	(32,820)	(6,580)
Earnings common share		
Primary	\$(2.24)	\$(0.45)
Fully Diluted	\$(2.24)	\$(0.45)
Common Shares:		
Full Diluted	14,651	14,580
Year-end	14,657	14,647

KIMBALL ELECTRONICS INC**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Net Sales	253,204	226,451
Cost & expenses	243,614	213,629
Operating income	9,590	12,822
Interest income	18	23
Interest expense	116	39
Other income (expense), net	(21)	804
Gains or losses	1,364	(25)
Net before taxes	10,835	13,585
Income taxes	2,355	3,463
Net income	8,480	10,122
Earnings common share		
Primary	\$0.32	\$0.36
Fully Diluted	\$0.31	\$0.36
Common Shares:		
Full Diluted	27,028	28,095
Year-end	26,839	27,848

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2017	2016
Cash & equivalents	38,316	38,316
Inventories	164,632	164,632
Current assets	408,894	408,894
Net property & equip.	136,915	136,915
Total assets	575,502	575,502
Liabilities:		
Current liabilities	214,098	214,098
Stockholders' equity	348,972	348,972
Net current assets	194,796	194,796

KINSALE CAPITAL GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	136,034	101,262
Cost & expenses	108,738	72,026
Operating income	27,296	29,236
Net before taxes	27,296	29,236
Income taxes	8,319	9,940
Net income	18,977	19,296
Earnings common share		
Primary	\$0.90	\$0.24
Fully Diluted	\$0.88	\$0.24
Common Shares:		
Full Diluted	21,461	20,741
Year-end	21,029	20,969

KONA GRILL INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Net Sales	136,592	125,931
Cost & expenses	134,581	120,320
Operating income	(9,266)	(4,727)
Interest expense	1,214	263
Other income (expense), net	(472)	
Net before taxes	(10,952)	(4,990)
Income taxes	71	56
Net income	(11,023)	(5,046)
Earnings common share		
Primary	\$(1.09)	\$(0.46)
Fully Diluted	\$(1.09)	\$(0.46)
Common Shares:		
Full Diluted	10,126	10,897
Year-end	10,105	10,542

KULICKE & SOFFA INDUSTRIES, INC.**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	09/30/17	10/01/16	10/03/15
Net revenue	809,041	627,192	536,471
Cost of sales	433,995	340,463	277,379
Gross profit	375,046	286,729	259,092
Selling, general & administrative expenses	141,382	141,816	131,808
Research & development expenses	100,203	92,374	90,033
Impairment charges	35,207		
Total operating expenses	276,792	234,190	221,841
Income (loss) from operations	98,254	52,539	37,251
Interest income	6,491	3,318	1,637
Interest expense	1,059	1,107	1,183

Income (loss) before income taxes			
- United States operations	(4,114)	(12,600)	4,178
Income (loss) before income taxes - foreign operations	107,800	67,350	33,527
Income (loss) from operations before income taxes	103,686	54,750	37,705
Current federal income taxes (benefit)	(3,975)	871	1,459
Current state income taxes	64	53	76
Current foreign income taxes (benefit)	13,290	21,841	4,707
Deferred federal income taxes (benefit)	(15,374)	(13,423)	(20,250)
Deferred state income taxes (benefit)	40	12	(10)
Deferred foreign income taxes (benefit)	(2,180)	(1,716)	1,084
Income tax expense (benefit)	(8,135)	7,638	(12,934)
Share of results of equity-method investee, net of tax	190		
Net income (loss)	112,011	47,112	50,639
Weighted average shares outstanding - basic	70,906	70,477	75,414
Weighted average shares outstanding - diluted	72,063	70,841	75,659
Year end shares outstanding	70,197	70,420	71,240
Net income (loss) per share - basic	\$1.58	\$0.67	\$0.67
Net income (loss) per share - diluted	\$1.55	\$0.67	\$0.67
Number of full-time employees	2,778	2,389	2,373
Number of part-time employees	277	206	118
Number of common stockholders	226	240	253
Foreign currency translation adjustments		624	(3,360)

□ As is; □ Approximately; □ As of November 14, 2017; □ As of November 15, 2016; □ As of November 16, 2015

Consolidated Balance Sheet, Years Ended (\$000):

	09/30/17	10/01/16
Cash & cash equivalents	392,410	423,907
Restricted cash	530	
Short-term investments	216,000	124,000
Accounts & notes receivable, gross	198,559	130,961
Less: allowance for doubtful accounts	79	506
Accounts & notes receivable, net	198,480	130,455
Raw materials & supplies	44,239	26,876
Work in process	40,827	24,333
Finished goods	61,596	57,166
Inventory reserves	24,639	21,080
Inventories, net	122,023	87,295
Prepaid expenses & other current assets	23,939	15,285
Total current assets	953,382	780,942
Land	2,182	
Buildings & building improvements	50,910	34,472
Leasehold improvements	9,882	19,963

Data processing equipment & software	34,700	32,975
Machinery, equipment, furniture & fixtures	68,143	54,730
Property, plant & equipment, gross	165,817	142,140
Less: accumulated depreciation	98,055	91,798
Property, plant & equipment, net	67,762	50,342
Goodwill	56,318	81,272
Intangible assets, net	62,316	50,810
Deferred income taxes	27,771	16,822
Equity investments	1,502	...
Other assets	2,056	2,256
Total assets	1,171,107	982,444
Accounts payable	51,354	41,813
Accrued wages & benefits	47,411	24,248
Accrued customer obligations	50,497	13,077
Accrued commissions & professional fees	8,555	10,908
Accrued deferred rent	1,930	2,920
Accrued severance	3,828	1,296
Other accrued expenses	20,093	11,505
Income taxes payable	16,780	12,830
Total current liabilities	200,448	118,597
Financing obligation	16,074	16,701
Deferred income taxes	26,779	27,697
Other liabilities	14,870	12,931
Total liabilities	258,171	175,926
Common stock	506,515	498,676
Treasury stock, at cost	157,604	139,407
Retained earnings (accumulated deficit)	561,986	449,975
Gain (loss) from foreign currency translation adjustments	2,422	462
Unrecognized actuarial net gain (loss), Switzerland pension plan, net of tax	(1,736)	(2,726)
Unrealized gain (loss) on hedging	1,353	(462)
Accumulated other comprehensive income (loss)	2,039	(2,726)
Total shareholders' equity (deficit)	912,936	806,518

□ Reclassified to conform with 2017 presentation

KURA ONCOLOGY INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	25,082	20,889
Operating income	(585)	(690)
Interest income	449	369
Other income (expense), net	585	690
Net income	(24,686)	(20,213)
Earnings common share		
Primary	\$(1.16)	\$(1.09)
Fully Diluted	\$(1.16)	\$(1.09)
Common Shares:		
Full Diluted	21,217	18,549
Year-end	29,127	19,045

LAM RESEARCH CORP

Co. Repurchasing Certain Securities On Nov. 14, 2017, Co.'s Board of Directors has approved a \$2,000,000,000 share repurchase authorization, with execution planned over the next 12 to 18 months; and a 11% increase of Co.'s quarterly dividend.

LANDMARK INFRASTRUCTURE PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	6,369,000	5,719,000
Operating income	10,074,000	851,000
Interest expense	12,931,000	10,282,000
Other income (expense), net	(111,000)	(5,439,000)
Gains or losses		275,000
Net before taxes	10,074,000	...
Income taxes	72,000	...
Net income	10,002,000	1,126,000
Balance for common	5,024,000	...

Earnings common share		
Primary	\$0.22	\$0.02
Fully Diluted	\$0.22	\$(0.02)
Common Shares:		
Full Diluted	22,755,000	15,529,000
Year-end	19,749,563	19,073,357

LANTHEUS HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	250,137	227,503
Cost & expenses	207,491	183,056
Operating income	42,646	44,447
Interest expense	14,147	20,799
Other income (expense), net	(678)	(768)
Foreign currency	554	(330)
Net before taxes	28,375	22,550
Income taxes	2,116	657
Net income	26,259	21,893
Earnings common share		
Primary	\$0.71	\$0.71
Fully Diluted	\$0.67	\$0.71
Common Shares:		
Full Diluted	38,971	31,049
Year-end	37,498	35,715

LATTICE SEMICONDUCTOR CORP

Earnings, 9 mos. to (Consol. - \$000):

	09/30/17	10/01/16
Total Revenues	290,695	308,946
Cost & expenses	311,817	309,395
Operating income	(46,899)	(25,741)
Other income (expense), net	(1,412)	3,558
Equity earnings	692	1,085
Net before taxes	(62,423)	(37,440)
Net income	(63,349)	(45,935)
Earnings common share		
Primary	\$(0.52)	\$(0.38)
Fully Diluted	\$(0.52)	\$(0.38)
Common Shares:		
Full Diluted	122,393	119,596
Year-end	123,138	121,000

LEMAITRE VASCULAR INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Net Sales	74,714	65,863
Cost & expenses	59,933	53,436
Operating income	14,781	12,427
Interest income	100	55
Foreign currency	(103)	(74)
Net before taxes	14,778	12,408
Income taxes	1,885	4,415
Net income	12,893	7,993
Earnings common share		
Primary	\$0.68	\$0.43
Fully Diluted	\$0.65	\$0.42
Common Shares:		
Full Diluted	19,970	19,103
Year-end	19,262	20,034

LHC GROUP INC

Merger Development On Nov. 15, 2017, Almost Family, Inc. ("Almost") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Co., and Hammer Merger Sub, Inc., a newly-formed and wholly-owned subsidiary of Co. ("Merger Sub"), providing for a "merger of equals" business combination of Almost and Co. The Merger Agreement provides that, upon the terms and subject to the conditions set forth therein, Merger Sub will be merged with and into Almost (the "Merger"), with Almost continuing as the surviving corporation and as a wholly-owned subsidiary of Co. Pursuant to the terms and conditions of the Merger Agreement, the stockholders of Almost will be entitled to receive 0.9150 shares of Co. common stock for each share of Almost common stock, plus the cash equivalent of any fractional share. Upon the closing of the Merger, Almost stockholders will own approximately 41.5%, and Co.'s stockholders will own approximately 58.5% of the combined company. Also, each outstanding stock option of Almost will be converted into an option to purchase 0.9150 shares of Co. common stock at an exercise price per share equal to the quotient of the exercise price of Almost option divided by 0.9150, and the option shall otherwise remain subject to the same vesting terms and other conditions. In addition, each outstanding share of restricted stock of Almost will be

converted into a restricted share of Co. subject to the same vesting terms and other conditions (except that the performance condition of performance-based stock awards will be deemed satisfied and the shares will vest solely on the basis of time). The transaction, which is expected to be completed in the first half of 2018, is subject to the receipt of regulatory approvals and other customary closing conditions as well as the approval of shareholders of both Co. and Almost.

LIBERTY INTERACTIVE CORP

Securities Registration On Nov. 15, 2017, Co. announced a public offering pursuant to Series A QVC Group common stock. Co. proposed to offer 58,561,895, which amounted to a proposed maximum aggregate offering price of \$1,324,918,488. The amount of registration fee is \$1,317.

LIFEAPPS BRANDS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	3,093	11,168
Cost & expenses	171,865	179,841
Deprec., depl. & amort.	675	9,574
Operating income	(169,447)	(178,247)
Net income	(169,447)	(178,247)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	25,311,186	20,500,239
Year-end	25,311,186	20,515,731

LIFETIME BRANDS INC

Offering On Nov. 16, 2017, Co. announced a public offering pursuant to Common Stock, \$.01 par value per share. Co. proposed to offer 437,500 at a proposed maximum offering price per share of \$16.35, which amounted to a proposed maximum aggregate offering price of \$7,153,125. The amount of registration fee is \$890.56.

LIGHTWAVE LOGIC INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	4,032,323	3,041,967
Operating income	(4,032,323)	(3,041,967)
Other income (expense), net	(128,557)	(260,142)
Net income	(4,160,693)	(3,301,918)
Earnings common share		
Primary	\$(0.06)	\$(0.05)
Fully Diluted	\$(0.06)	\$(0.05)
Common Shares:		
Full Diluted	70,128,995	65,816,072
Year-end	72,194,057	67,048,161

LINCOLN EDUCATIONAL SERVICES CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	194,452	212,991
Cost & expenses	206,942	223,139
Operating income	(12,490)	(10,148)
Interest income	47	141
Interest expense	6,597	4,629
Other income (expense), net	...	5,109
Net before taxes	(19,040)	(9,527)
Income taxes	150	150
Net income	(19,190)	(9,677)
Earnings common share		
Primary	\$(0.80)	\$(0.41)
Fully Diluted	\$(0.80)	\$(0.41)
Common Shares:		
Full Diluted	23,866	23,433
Year-end	30,630	30,768

LINCOLN ELECTRIC HOLDINGS, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Net Sales	1,877,246	1,710,786
Cost & expenses	1,575,048	1,505,583
Operating income	302,198	205,203
Interest income	3,349	1,225
Interest expense	18,333	11,828
Other income (expense), net	5,294	4,636
Net before taxes	292,508	199,236
Income taxes	69,218	54,264
Net income	223,290	144,972
Earnings common share		
Primary	\$3.40	\$2.13
Fully Diluted	\$3.35	\$2.11

Common Shares:		
Full Diluted	66,679	68,784
Year-end	65,756	66,029

Full Diluted	30,074	25,156
Year-end	32,732	26,521

Total number of employees	11,000	10,300	10,300
Number of class A common stockholders	611	631	1,172
Foreign currency translation adjustments		(17,744)	(77,387)

LONESTAR RESOURCES US INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	62,634,000	44,537,000
Cost & expenses	54,278,000	57,694,000
Operating income	(32,171,000)	(51,458,000)
Other income (expense), net	9,791,000	25,347,000
Net before taxes	(42,196,000)	(45,755,000)
Income taxes	(15,339,000)	(10,354,000)
Net income	(26,857,000)	(35,401,000)
Balance for common	(28,977,000)	(35,401,000)
Earnings common share		
Primary	\$(1.33)	\$(4.64)
Fully Diluted	\$(1.33)	\$(4.64)
Common Shares:		
Full Diluted	21,822,015	7,629,896
Year-end	21,824,515	8,024,515

LOXO ONCOLOGY, INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	130,289	45,776
Operating income	(130,289)	(45,776)
Interest income	2,041	572
Net income	(128,248)	(45,204)
Earnings common share		
Primary	\$(4.68)	\$(2.19)
Fully Diluted	\$(4.68)	\$(2.19)
Common Shares:		
Full Diluted	27,391	20,660
Year-end	29,916	21,678

LUMOS NETWORKS CORP

Merger Completed On Nov. 17, 2017, MTN Infrastructure TopCo, Inc. ("Parent"), affiliate of EQT Infrastructure investment strategy ("EQT Infrastructure") an alternative investments firm, wholly-owned subsidiary, MTN Infrastructure BidCo, Inc., merged with and into Co., with Co. continuing as a wholly-owned subsidiary of Parent. As the result of the merger, each outstanding share of Co.'s common stock, par value \$0.01 per share, outstanding immediately before the Effective Time was cancelled and converted into the right to receive \$18.00 in cash (the "Merger Consideration"), without interest.

MANKIND CORP

Special Meeting of Stockholders On Nov. 7, 2017, Co. announced that a Special Meeting of Stockholders will be held on Dec. 13, 2017 at 10:00 a.m. local time, at Co.'s office, at 30930 Russell Ranch Road, Suite 301, Westlake Village, CA 91362.

MATCH GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	951,754	823,240
Cost & expenses	694,073	585,493
Operating income	232,854	202,624
Other income (expense), net	(25,453)	4,389
Net before taxes	149,831	145,141
Income taxes	(214,039)	41,615
Net income	359,223	98,024
Earnings common share		
Primary	\$1.38	\$0.39
Fully Diluted	\$1.21	\$0.36
Common Shares:		
Full Diluted	297,307	268,710
Year-end	273,019	

MATTERSIGHT CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	32,861	29,539
Cost & expenses	38,929	41,874
Operating income	(10,942)	(16,630)
Other income (expense), net	(1,472)	89
Net before taxes	(14,767)	(17,832)
Income taxes	4	27
Net income	(14,771)	(17,859)
Balance for common	(15,209)	(18,299)
Earnings common share		
Primary	\$(0.51)	\$(0.73)
Fully Diluted	\$(0.51)	\$(0.73)
Common Shares:		

MATTHEWS INTERNATIONAL CORP

Annual Report

Consolidated Income Statement, Years Ended Sept. 30

(\$000):

	2017	2016	2015
Sales	1,515,608	1,480,464	1,426,068
Cost of sales	952,221	924,010	896,693
Gross profit (loss)	563,387	556,454	529,375
Selling expense	144,174	140,924	143,299
Administrative expense	306,610	296,715	281,053
Operating profit (loss)	112,603	118,815	105,023
Investment income	2,468	2,061	175
Interest expense	26,371	24,344	20,610
Other income (deductions), net	7,587	(1,298)	5,064
Income (loss) before income taxes	96,287	95,234	89,652
Current federal provision (benefit) for income taxes	1,542	18,733	655
Current state provision (benefit) for income taxes	628	1,829	1,466
Current foreign provision (benefit) for income taxes	10,459	12,482	10,599
Total current provision (benefit) for income taxes	12,629	33,044	12,720
Deferred federal provision (benefit) for income taxes	11,887	(3,066)	13,279
Deferred state provision (benefit) for income taxes	905	(2,412)	645
Deferred foreign provision (benefit) for income taxes	(3,067)	1,507	(280)
Total deferred provision (benefit) for income taxes	9,725	(3,971)	13,644
Provision (benefit) for income taxes	22,354	29,073	26,364
Net income (loss)	73,933	66,161	63,288
Net loss (income) attributable to noncontrolling interests	435	588	161
Net income attributable to Matthews International Corporation shareholders	74,368	66,749	63,449
Less: dividends & undistributed earnings allocated to participating securities			10
Net income available to Matthews International Corporation shareholders	74,368	66,749	63,439
Weighted average shares outstanding - basic	32,240	32,642	32,939
Weighted average shares outstanding - diluted	32,570	32,904	33,196
Year end shares outstanding	32,149	32,142	32,875
Net earnings (loss) per share - basic	\$2.31	\$2.04	\$1.93
Net earnings (loss) per share - diluted	\$2.28	\$2.03	\$1.91
Dividends per common share	\$0.68	\$0.60	\$0.54

Reclassified to conform with 2016 presentation; ⁽¹⁾ Approximately; ⁽²⁾ As is; ⁽³⁾ As of October 31, 2017; ⁽⁴⁾ As of October 31, 2016; ⁽⁵⁾ As of October 31, 2015

Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):

2017

(revised) 2016

Cash & cash equivalents	57,515	55,711
Accounts receivable, gross	331,188	306,431
Allowance for doubtful accounts	11,622	11,516
Accounts receivable, net	319,566	294,915
Raw materials	29,396	29,597
Work in process	61,917	54,357
Finished goods	80,132	78,518
Inventories, net	171,445	162,472
Other current assets	46,533	61,086
Total current assets	595,059	574,184
Investments	37,667	31,365
Buildings	104,604	102,153
Machinery & equipment	412,980	378,650
Less accumulated depreciation	335,346	305,613
Land	16,845	19,705
Construction in progress	36,450	24,597
Property, plant & equipment, net	235,533	219,492
Deferred income taxes	2,456	775
Other assets	51,758	19,895
Goodwill	897,794	851,489
Other intangible assets, net	424,382	393,841
Total assets	2,244,649	2,091,041
Long-term debt, current maturities	29,528	27,747
Trade accounts payable	66,607	58,118
Accrued compensation	62,210	63,737
Accrued income taxes	21,386	15,527
Other current liabilities	105,401	94,219
Total current liabilities	285,132	259,348
Revolving credit facilities	551,126	608,000
Securitization facility	95,825	
Senior secured term loan	232,479	246,449
Notes payable to banks	21,831	5,301
Short-term borrowings	4,735	8,617
Capital lease obligations	5,134	4,187
Less current maturities	29,528	27,747
Long-term debt	881,602	844,807
Accrued pension	103,273	110,941
Postretirement benefits	19,273	22,143
Deferred income taxes	139,430	107,038
Other liabilities	25,680	37,430
Total liabilities	1,454,390	1,381,707
Class A common stock	36,334	36,334
Additional paid-in capital	123,432	117,088
Retained earnings	948,830	896,224
Cumulative foreign currency translation	(112,907)	(122,259)
Fair value of derivatives, net	2,415	(3,559)
Minimum pension liabilities, net	(43,623)	(56,050)
Accumulated other comprehensive income (loss)	(154,115)	(181,868)
Treasury stock, at cost	164,774	159,113
Total shareholders' equity - Matthews International Corporation	789,707	708,665
Noncontrolling interests	552	669
Total shareholders' equity	790,259	709,334

□ Reclassified to conform with 2017 presentation; □ Net of tax - Fair value of derivatives: 1,544,000; □ Net of tax - Fair value of derivatives: \$2,275,000; □ Net of tax - Minimum pension liability: \$27,114,000; □ Net of tax - Minimum pension liability: \$35,426,000

MCBC HOLDINGS INC**Earnings, 3 mos. to (Consol. - \$000):**

	10/01/17	10/02/16
Net Sales	65,049	60,689
Cost & expenses	53,958	49,027
Operating income	11,064	11,635
Interest expense	491	611
Net before taxes	10,573	11,024
Income taxes	3,527	4,041
Net income	7,046	6,983
Earnings common share		
Primary	\$0.38	\$0.38
Fully Diluted	\$0.38	\$0.38
Common Shares:		
Full Diluted	18,687	18,593
Year-end	18,678	18,631

Consolidated Balance Sheet Items, as of (\$000):

	2017	2016
Assets:		
Cash & equivalents	12,680	11,569
Inventories	33,578	33,578
Current assets	14,627	14,627
Net property & equip.	94,990	94,990
Total assets		
Liabilities:		
Current liabilities	43,005	29,376
Long-term debt	19,028	19,028
Stockholders' equity	(9,427)	(9,427)
Net current assets		

MERCADOLIBRE INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	961,117,000	588,121,000
Cost & expenses	840,235,000	471,737,000
Operating income	120,882,000	116,384,000
Foreign currency	(19,475,000)	(5,062,000)
Net before taxes	118,741,000	117,707,000
Income taxes	37,241,000	32,690,000
Net income	81,500,000	85,017,000
Earnings common share		
Primary	\$1.85	\$1.93
Fully Diluted	\$1.85	\$1.93
Common Shares:		
Full Diluted	44,157,364	44,157,215
Year-end	44,157,364	44,157,341

MERITAGE HOSPITALITY GROUP INC**Earnings, 9 mos. to (Consol. - \$):**

	10/01/17	10/02/16
Cost & expenses	208,503,605	161,720,054
Deprec., depl. & amort.	6,057,694	4,139,952
Operating income	12,777,279	8,511,538
Interest expense	3,753,833	2,277,196
Other income (expense), net ..	2,359,567	300,644
Net before taxes	11,383,013	6,534,986
Income taxes	3,906,814	1,964,289
Net income	7,476,199	4,570,697
Earnings common share		
Common Shares:		
Year-end	6,119,741	5,895,554

MGP INGREDIENTS INC (NEW)**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Net Sales	259,255	237,118
Cost & expenses	226,878	205,741
Operating income	32,377	31,377
Interest expense	934	980
Other income (expense), net ..	11,033	2,260
Net before taxes	42,476	32,657
Income taxes	13,292	9,758
Net income	29,184	22,899
Balance for common	28,378	22,188
Earnings common share		
Primary	\$1.70	\$1.33
Fully Diluted	\$1.70	\$1.33
Common Shares:		
Full Diluted	16,735	16,626

Year-end

16,724 16,657

MICROSEMI CORP**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	10/01/17	□10/02/16 (revised)	□09/27/15 (revised)
Net sales	1,811,800	1,655,000	1,245,600
Cost of sales	654,300	717,900	561,300
Gross profit	1,157,500	937,100	684,300
Selling, general & administrative expenses	330,700	352,400	249,500
Research & development costs	341,600	309,100	200,300
Amortization of intangible assets	191,700	161,200	96,500
Restructuring & severance charges	23,200	60,700	15,400
Total operating expenses	887,200	883,400	561,700
Operating income (loss)	270,300	53,700	122,600
Interest expense, net	97,700	120,100	27,300
Other income (expenses)	(36,500)	41,000	1,600
Total other income (expenses), net	(134,200)	(79,100)	(25,700)
Income (loss) before income taxes - domestic	(110,400)	(112,500)	(14,900)
Income (loss) before income taxes - foreign	246,500	87,100	111,800
Income (loss) before income taxes ..	136,100	(25,400)	96,900
Current federal income tax expense (benefit)	800
Current state income tax expense ..	600	200	200
Current foreign income tax expense ..	12,200	4,300	4,200
Deferred federal income tax expense (benefit)	2,500	4,100	4,600
Deferred state income tax expense (benefit)	400	200	...
Deferred foreign income tax expense (benefit)	(56,700)	(1,600)	3,300
Provision for (benefit from) income taxes	(40,200)	7,200	12,300
Net income (loss)	176,300	(32,600)	84,600
Weighted average shares outstanding - basic	114,900	107,000	94,200
Weighted average shares outstanding - diluted	117,100	107,000	95,900
Year end shares outstanding	116,300	113,600	95,100
Net earnings (loss) per share-basic	\$1.54	\$(0.31)	\$0.90
Net earnings (loss) per share-diluted	\$1.51	\$(0.31)	\$0.88
Total number of employees	□4,500	□4,400	□3,700
Number of common stockholders	□919	□994	□653
Foreign currency translation adjustments	2,700	4,800	(1,600)

□ 53 weeks; □ As is; □ Approximately; □ As of November 10, 2017; □ As of November 4, 2016; □ As of November 5, 2015

Consolidated Balance Sheet, Years Ended (\$000):

	10/01/17	□10/02/16 (revised)
Cash & cash equivalents	144,900	189,500

Accounts receivable, gross	311,700	286,900
Allowances	43,800	41,700
Accounts receivable, net	267,900	245,200
Raw materials	42,500	32,800
Work in progress	120,600	112,800
Finished goods	76,000	67,500
Inventories	239,100	213,100
Assets held for sale	13,900
Other current assets	75,000	73,200
Total current assets	726,900	734,900
Buildings	41,800	37,200
Machinery & equipment	498,800	439,300
Furniture & fixtures	9,000	8,900
Leasehold improvements	63,100	62,600
Accumulated depreciation	427,800	382,200
Land	1,500	1,500
Construction in progress	11,200	7,600
Property & equipment, net	197,600	174,900
Goodwill	2,497,300	2,479,400
Intangible assets, net	752,300	934,600
Deferred income taxes, net	67,200	37,300
Other assets	81,800	61,900
Total assets	4,323,100	4,423,000
Accounts payable	164,900	112,800
Accrued payroll, bonus & employee benefits	32,700	53,800
Accrued interest	24,200	31,200
Deferred revenue	24,000	15,100
Accrued restructuring & severance	16,800	4,600
Accrued licenses	13,600	26,000
Accrued outside services	11,900	12,800
Accrued income, property & sales taxes	11,900	1,100
Accrued warranties	5,600	7,500
Accrued commissions	3,300	4,300
Accrued leases & rent	1,400	2,500
Customer deposits	1,300	1,100
Other accrued expenses	6,700	6,100
Accrued liabilities	153,400	166,100
Current maturity of credit facility	61,100	40,700
Total current liabilities	379,400	319,600
Long term debt	1,735,600	2,138,500
Deferred income taxes	103,800	120,200
Unrecognized tax benefits	71,100	70,600
Deferred rent	13,500	17,200
Pension & retirement	14,400	14,200
Restructuring	3,500	4,200
Other long-term liabilities	7,500	9,600
Common stock	23,300	22,700
Capital in excess of par value of common stock	1,443,700	1,357,800
Retained earnings (accumulated deficit)	526,900	350,600
Accumulated other comprehensive income (loss)	400	(2,200)
Total stockholders' equity	1,994,300	1,728,900

□ Reclassified to conform with 2017 presentation

MICROVISION INC.

Offering On Nov. 17, 2017, Co. announced a public offering pursuant to Common Stock; Preferred Stock; Warrants. Co. proposed to offer \$60,000,000, which amounted to a proposed maximum aggregate offering price of \$60,000,000. The amount of registration fee is \$7,470.

MID-CON ENERGY PARTNERS LP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	46,176	32,492
Cost & expenses	46,454	30,342
Deprec., depl. & amort.	13,850	17,550
Operating income	(14,128)	(15,400)
Interest expense	4,615	5,981
Other income (expense), net	57	(131)
Net income	(18,678)	(21,503)
Earnings common share		

Primary	\$(0.69)	\$(0.73)	Balance for common	(38,557)	(27,411)	expense	524,238	474,053	331,475
Fully Diluted	\$(0.69)	\$(0.73)	Earnings common share			Depreciation & amortization	51,993	44,069	31,566
Common Shares:			Primary	\$(1.21)	\$(1.04)	Asset impairment	7,132	7,716	4,672
Full Diluted	29,972	29,807	Fully Diluted	\$(1.21)	\$(1.04)	Acquisition related costs	13,742
Year-end	30,091	29,912	Common Shares:			Other expense (income), net	1,667	913	691
			Full Diluted	31,952	26,332	Total operating expenses	585,030	526,751	382,146
			Year-end	35,733	27,031	Income (loss) from operations	66,384	44,677	(12,942)

MINERVA NEUROSCIENCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	31,637,670	20,953,340
Operating income	(31,637,670)	(20,953,340)
Interest expense	509,526	797,376
Gains or losses	508,116	136,960
Foreign currency	(46,215)	(27,552)
Net income	(31,685,295)	(21,641,308)
Earnings common share		
Primary	\$(0.84)	\$(0.71)
Fully Diluted	\$(0.84)	\$(0.71)
Common Shares:		
Full Diluted	37,676,686	30,393,293
Year-end	38,700,693	34,807,213

MITCHAM INDUSTRIES INC

New Accountant On Nov. 16, 2017, Hein & Associates LLP resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Moss Adams LLP as its new independent public accounting firm.

MOBILEIRON INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	127,660	118,454
Cost & expenses	175,922	174,940
Operating income	(48,262)	(56,486)
Other income (expense), net	701	184
Net before taxes	(47,561)	(56,302)
Income taxes	881	672
Net income	(48,442)	(56,974)
Earnings common share		
Primary	\$(0.52)	\$(0.67)
Fully Diluted	\$(0.52)	\$(0.67)
Common Shares:		
Full Diluted	92,825	85,008
Year-end	96,049	87,829

MONROE CAPITAL CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	18,734	16,656
Net income	19,009	17,129
Earnings common share		
Primary	\$1.05	\$1.24
Fully Diluted	\$1.05	\$1.24
Common Shares:		
Full Diluted	18,081	13,864
Year-end	20,240	16,578

MOTORCAR PARTS OF AMERICA INC

Annual Meeting Development On Nov. 20, 2017, Co. announced that its Annual Meeting of Shareholders will be held on Dec. 18, 2017 at 10:00 a.m. (PT) at Co.'s offices at 2929 California Street, Torrance, CA 90503.

MUELLER (PAUL) CO

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Net Sales	125,512	130,801
Cost & expenses	120,767	133,448
Operating income	4,745	(2,647)
Interest expense	248	185
Other income (expense), net	(563)	(160)
Net before taxes	3,934	(2,992)
Net income	2,316	(1,526)
Earnings common share		
Primary	\$1.94	\$(1.26)
Fully Diluted	\$1.94	\$(1.26)
Common Shares:		
Year-end	1,196	1,202

MYOKARDIA INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	16,875	10,649
Cost & expenses	56,409	38,139
Operating income	(39,534)	(27,490)
Net income	(38,557)	(27,411)

NANOMETRICS, INC.

Co. Repurchasing Certain Securities On Nov. 14, 2017, Co.'s board of directors has authorized the repurchase of up to \$50,900,000 of Co.'s common stock.

NANTHEALTH INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	64,378	62,558
Cost & expenses	111,875	158,593
Operating income	(50,660)	(99,197)
Interest expense	12,049	4,760
Other income (expense), net	(46,045)	(7,352)
Net before taxes	(108,754)	(111,309)
Income taxes	85	(19,203)
Income contin. oper.	(108,839)	(92,106)
Net income	(153,577)	(124,151)
Earnings common share		
Primary	\$(1.28)	\$(1.19)
Fully Diluted	\$(1.28)	\$(1.19)
Common Shares:		
Full Diluted	119,745	108,360
Year-end	106,964	...

NATERA INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	157,174	167,775
Cost & expenses	246,285	226,550
Operating income	(89,111)	(58,775)
Other income (expense), net	450	1,403
Net before taxes	(90,539)	(57,755)
Income taxes	273	103
Net income	(90,812)	(57,858)
Earnings common share		
Primary	\$(1.71)	\$(1.13)
Fully Diluted	\$(1.71)	\$(1.13)
Common Shares:		
Full Diluted	53,100	51,301
Year-end	53,708	52,383

NATIONAL COMMERCE CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	63,166	44,511
Operating income	30,509	20,930
Net before taxes	30,509	20,930
Income taxes	9,950	6,794
Net income	20,559	14,136
Earnings common share		
Primary	\$1.42	\$1.19
Fully Diluted	\$1.38	\$1.17
Common Shares:		
Full Diluted	13,854	11,081
Year-end	14,777	10,920

NATIONAL VISION HOLDINGS INC**Annual Report**

Consolidated Income Statement, Years Ended (\$000):

	12/31/16	01/02/16	01/03/15
Revenue - net product sales	980,953	870,463	603,085
Revenue - net sales of services & plans	215,242	192,065	132,595
Total net revenue	1,196,195	1,062,528	735,680
Costs applicable to revenue - products	390,369	353,894	266,627
Costs applicable to revenue - services & plans	154,412	137,206	99,849
Total costs applicable to revenue	544,781	491,100	366,476
Selling, general & administrative			

expense	524,238	474,053	331,475
Depreciation & amortization	51,993	44,069	31,566
Asset impairment	7,132	7,716	4,672
Acquisition related costs	13,742
Other expense (income), net	1,667	913	691
Total operating expenses	585,030	526,751	382,146
Income (loss) from operations	66,384	44,677	(12,942)
Interest expense, net	39,092	36,741	26,823
Debt issuance costs	...	2,551	...
Earnings (loss) before income taxes	27,292	5,385	(39,765)
Current income tax provision (benefit)			
- federal	51	38	(599)
Current income tax provision (benefit) - state	1,302	202	(100)
Deferred income tax provision (benefit)			
- federal	10,058	1,360	(8,297)
Deferred income tax provision (benefit) - state	1,123	168	(3,719)
Income tax provision (benefit)	12,534	1,768	(12,715)
Net income (loss)	14,758	3,617	(27,050)
Weighted average shares outstanding			
- basic	56,185	55,962	55,807
Weighted average shares outstanding - diluted	57,001	55,962	55,807
Year end shares outstanding	56,202	56,088	55,831
Net earnings (loss) per share - basic	\$0.26	\$0.06	\$(0.48)
Net earnings (loss) per share - diluted	\$0.26	\$0.06	\$(0.48)
Total number of employees	10,360

□ Successor; □ The period from March 13, 2014 to January 3, 2015; □ As of July 1, 2017

Consolidated Balance Sheet, Years Ended (\$000):

	12/31/16	01/02/16
Cash & cash equivalents	4,945	5,595
Trade receivables	20,817	16,635
Credit card receivables	9,398	8,437
Tenant improvement allowances	3,308	3,962
Other receivables	2,430	1,881
Allowance for uncollectible accounts	1,583	1,568
Accounts receivable, net	34,370	29,347
Raw materials & work in process	42,266	36,159
Finished goods	44,798	38,858
Inventory	87,064	75,017
Prepaid expenses & other current assets	20,880	17,836
Total current assets	147,259	127,795
Land & building	3,607	3,607
Equipment	161,714	117,837
Furniture & fixtures	36,046	31,394
Leasehold improvements	121,963	90,117
Construction in progress	28,099	19,286
Property under capital leases	3,244	2,240
Property & equipment, gross	354,673	264,481
Less: Accumulated depreciation	98,259	57,281
Property & equipment, net	256,414	207,200
Goodwill	793,229	796,573
America's Best Contacts		

& Eyeglasses	200,547	200,547
Eyeglass World	40,000	40,000
Trademarks & trade names	240,547	240,547
Other intangible assets, net	81,338	91,811
Other assets	12,330	11,669
Total non-current assets	1,383,858	1,347,800
Total assets	1,531,117	1,475,595
Accounts payable	39,400	33,784
Accrued employee compensation & benefits	19,009	18,148
Self-insurance reserves	7,209	6,189
Accrued capital expenditures	9,202	5,956
Accrued advertising	1,058	5,610
Reserves for customer returns & remakes	4,611	3,783
Amounts payable to legacy partner	3,369	3,322
Fair value of derivative liabilities	8,218	...
Accrued rental expenses	2,172	2,256
Accrued management fees	1,222	1,372
Sales & use taxes	954	1,127
Accrued professional fees	1,298	1,116
Amounts payable to charitable organizations	1,000	1,000
Accrued interest on debt & derivatives	190	290
Miscellaneous & other	9,890	6,397
Other payables & accrued expenses	69,402	56,566
Unearned revenue	25,600	20,835
Deferred revenue	57,996	50,086
Current maturities of long-term debt	7,285	7,048
Total current liabilities	199,683	168,319
First Lien term loan	633,598	640,114
Second Lien term loan	125,000	125,000
Term loans before unamortized discount	758,598	765,114
Unamortized discount	(15,661)	(19,559)
Total term loans	742,937	745,555
Less current maturities	6,515	6,515
Term loans - non-current portion	736,422	739,040
Capitalized lease obligations	2,688	2,270
Less current maturities	770	533
Long-term debt, less current portion & debt discount	738,340	740,777
Deferred revenue	29,432	27,792
Fair value of derivative liabilities	15,518	18,620
Tenant improvements	21,089	17,644
Deferred rental expenses	6,256	4,884
Self-insurance reserves	3,908	3,700
Above market leases	1,705	3,230
Amounts payable to charitable organizations	1,000	2,000
Other liabilities	1,021	1,079
Deferred income taxes, net	111,278	101,320
Total other non-current liabilities	191,207	180,269
Common stock	562	561
Additional paid-in capital	424,789	420,386
Accumulated other comprehensive income (loss)	(14,556)	(11,284)
Retained earnings (accumulated deficit)	(8,675)	(23,433)
Treasury stock	233	...
Total stockholders' equity (deficit)	401,887	386,230

☐ Successor

NATURAL ALTERNATIVES INTERNATIONAL, INC.

Earnings, 3 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	28,074,000	34,067,000

Cost & expenses	26,191,000	30,531,000
Operating income	1,883,000	3,536,000
Interest income	250,000	116,000
Other income (expense), net	1,000	(7,000)
Foreign currency	(143,000)	(59,000)
Net before taxes	1,991,000	3,586,000
Income taxes	557,000	1,096,000
Net income	1,434,000	2,490,000
Earnings common share		
Primary	\$0.22	\$0.38
Fully Diluted	\$0.21	\$0.37
Common Shares:		
Full Diluted	6,831,230	6,646,963
Year-end	7,436,284	6,872,591

Consolidated Balance Sheet Items, as of (\$):

Assets:	2017	2016
Cash & equivalents	27,706,000	27,706,000
Inventories	18,996,000	18,996,000
Current assets	59,784,000	59,784,000
Net property & equip.	18,369,000	18,369,000
Total assets	80,949,000	80,949,000
Liabilities:		
Current liabilities	17,204,000	17,204,000
Stockholders' equity	61,904,000	61,904,000
Net current assets	42,580,000	42,580,000

NEOS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	62,582	65,253
Operating income	(45,351)	(59,602)
Interest expense	7,250	4,746
Other income (expense), net	578	(612)
Net income	(52,023)	(64,960)
Earnings common share		
Primary	\$(2.22)	\$(4.05)
Fully Diluted	\$(2.22)	\$(4.05)
Common Shares:		
Full Diluted	23,405	16,049
Year-end	28,081	16,025

NETWORK CN INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	263,366	324,074
Operating income	(263,366)	(324,074)
Net income	(669,316)	(706,654)
Earnings common share		
Primary	\$(0.08)	\$(0.09)
Fully Diluted	\$(0.08)	\$(0.09)
Common Shares:		
Full Diluted	8,041,995	8,041,995
Year-end	8,041,995	8,041,995

NEUROTROPE INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	8,370,510	7,918,584
Operating income	(8,270,156)	(7,913,134)
Other income (expense), net	53,599	...
Gains or losses	(34,274)	...
Net income	(8,304,430)	(7,913,134)
Balance for common	(8,304,430)	(9,450,283)
Earnings common share		
Primary	\$(1.08)	\$(6.13)
Fully Diluted	\$(1.08)	\$(6.13)
Common Shares:		
Full Diluted	7,674,600	1,540,469
Year-end	7,895,859	1,554,369

NEVADA CANYON GOLD CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	20,000	...
Cost & expenses	63,748	230,713
Other income (expense), net	...	(8,000)
Gains or losses	2,262,519	...
Net income	2,218,771	(238,794)
Earnings common share		
Primary	\$0.05	...
Fully Diluted	\$0.05	...
Common Shares:		
Full Diluted	44,050,000	103,828,284
Year-end	44,050,000	44,050,000

NEXUS ENTERPRISE SOLUTIONS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	763,273	964,702
Cost & expenses	862,335	1,018,830
Operating income	(99,062)	(54,128)
Interest expense	22,286	46,495
Other income (expense), net	(357,907)	8,692
Net income	(479,255)	(91,931)
Earnings common share		
Primary	\$(0.02)	...
Fully Diluted	\$(0.02)	...
Common Shares:		
Full Diluted	19,280,974	19,092,053
Year-end	19,542,144	19,242,144

NII HOLDINGS INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	680,897	736,606
Cost & expenses	883,421	2,047,093
Operating income	(232,152)	(1,469,511)
Interest income	35,956	29,725
Interest expense	91,245	81,854
Other income (expense), net	(5,104)	(7,763)
Foreign currency	12,197	77,777
Income taxes	(5,778)	(2,469)
Income contin. oper.	(274,570)	(1,449,157)
Net income	(272,003)	(1,465,402)
Earnings common share		
Primary	\$(2.71)	\$(14.65)
Fully Diluted	\$(2.71)	\$(14.65)
Common Shares:		
Full Diluted	100,314	100,054
Year-end	100,384	100,150

NOODLES & CO

Earnings, 9 mos. to (Consol. - \$000):

	10/03/17	09/27/16
Total Revenues	343,718	358,074
Cost & expenses	358,926	360,304
Operating income	(33,937)	(23,213)
Interest expense	2,828	1,964
Net before taxes	(36,765)	(25,177)
Income taxes	230	1,124
Net income	(36,995)	(26,301)
Balance for common	(44,962)	(26,301)
Earnings common share		
Primary	\$(1.23)	\$(0.95)
Fully Diluted	\$(1.23)	\$(0.95)
Common Shares:		
Full Diluted	36,639	27,787
Year-end	41,119	27,868

NORTHERN TECHNOLOGIES INTERNATIONAL CORP.

Annual Meeting Development On Nov. 15, 2017, 2017, Co. scheduled its Annual Meeting of Shareholders for Friday, Jan. 12, 2018, at 2:00 p.m., Central Standard Time, at Co.'s corporate executive offices located at 4201 Woodland Road, Circle Pines, MN 55014.

NVIDIA CORP

Earnings, 9 mos. to (Consol. - \$000):

	10/29/17	10/30/16
Total Revenues	6,803,000	4,737,000
Cost & expenses	4,666,000	3,536,000
Operating income	2,137,000	1,201,000
Other income (expense), net	(22,000)	(19,000)
Net before taxes	2,117,000	1,180,000
Income taxes	189,000	168,000
Net income	1,928,000	1,012,000
Earnings common share		
Primary	\$3.23	\$1.89
Fully Diluted	\$3.05	\$1.59
Common Shares:		
Full Diluted	633,000	636,000
Year-end	606,000	539,000

OCULAR THERAPEUTIX INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	1,436	1,376
Cost & expenses	50,643	32,230
Operating income	(49,207)	(30,854)
Interest income	320	236

Interest expense	1,402	1,262
Other income (expense), net	5	(1)
Net income	(50,284)	(31,881)
Earnings common share		
Primary	\$(1.76)	\$(1.29)
Fully Diluted	\$(1.76)	\$(1.29)
Common Shares:		
Full Diluted	28,601	24,792
Year-end	29,388	24,880

OFS CAPITAL CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	25,134	22,885
Cost & expenses	13,076	12,476
Net income	12,058	10,409
Earnings common share		
Primary	\$1.00	\$1.07
Fully Diluted	\$1.00	\$1.07
Common Shares:		
Full Diluted	12,090	9,693
Year-end	13,335	9,697

OMNITEK ENGINEERING CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	814,210	946,948
Cost & expenses	1,339,050	1,633,882
Deprec., depl. & amort.	18,594	21,081
Operating income	(543,434)	(708,015)
Interest expense	6,245	4,351
Other income (expense), net		5,574
Net before taxes	(549,679)	(706,792)
Income taxes	800	800
Net income	(550,479)	(707,592)
Earnings common share		
Primary	\$(0.03)	\$(0.04)
Fully Diluted	\$(0.03)	\$(0.04)
Common Shares:		
Full Diluted	20,281,082	20,095,681
Year-end	20,281,082	20,281,082

ONCOMED PHARMACEUTICALS INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	17,515	18,935
Cost & expenses	66,733	99,931
Operating income	(49,218)	(80,996)
Net before taxes	(48,513)	(80,749)
Income taxes	12	15
Net income	(48,525)	(80,764)
Earnings common share		
Primary	\$(1.29)	\$(2.57)
Fully Diluted	\$(1.29)	\$(2.57)
Common Shares:		
Full Diluted	37,521	31,435
Year-end	37,758	37,085

ONLINE VACATION CENTER HOLDINGS CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	11,457,254	11,391,505
Cost & expenses	11,281,560	10,119,454
Deprec., depl. & amort.	551,982	547,818
Operating income	(376,288)	724,233
Other income (expense), net	(1,736)	1,645
Net before taxes	(378,024)	725,878
Income taxes	(106,448)	308,203
Net income	(271,576)	417,676
Earnings common share		
Primary	\$(0.02)	\$0.04
Fully Diluted	\$(0.02)	\$0.04
Common Shares:		
Full Diluted	11,261,878	11,317,352
Year-end	11,261,878	

OREXIGEN THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	61,404	19,826
Cost & expenses	174,049	32,444
Operating income	(118,598)	(14,026)
Interest income	444	525
Interest expense	2,830	5,878

Other income (expense), net	(10,352)	17,700
Foreign currency	10,902	1,764
Net income	(120,434)	85
Earnings common share		
Primary	\$(7.94)	\$0.01
Fully Diluted	\$(7.94)	\$0.01
Common Shares:		
Full Diluted	15,164	14,570
Year-end	15,601	14,587

OSL HOLDINGS INC

Trading Suspension Development On June 7, 2017, the U.S. Securities and Exchange Commission ("Commission") announced the temporary suspension of trading in the securities of Co., commencing at 9:30 a.m. EDT on June 8, 2017 and terminating at 11:59 p.m. EDT on June 21, 2017. The Commission temporarily suspended trading in the securities of Co. due to a lack of current and accurate information about Co. because it has not filed certain periodic reports with the Commission. This order was entered pursuant to Section 12(k) of the Securities Exchange Act of 1934 ("Exchange Act"). The Commission cautions brokers, dealers, shareholders and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by Co. Brokers and dealers should be alert to the fact that, pursuant to Exchange Act Rule 15c2-11, at the termination of the trading suspension, no quotation may be entered relating to the securities of Co. unless and until the broker or dealer has strictly complied with all of the provisions of the rule. If any broker or dealer is uncertain as to what is required by the rule, it should refrain from entering quotations relating to the securities of Co. that have been subject to a trading suspension until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. Any broker or dealer with questions regarding the rule should contact the staff of the Securities and Exchange Commission in Washington, DC at (202) 551-5777. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.

OTC MARKETS GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	26,021,000	24,473,000
Deprec., depl. & amort.	1,094,000	1,215,000
Operating income	13,653,000	12,315,000
Interest income	12,000	1,000
Other income (expense), net	29,000	5,000
Net before taxes	13,694,000	12,321,000
Income taxes	4,050,000	4,485,000
Net income	9,644,000	7,836,000
Earnings common share		
Primary	\$0.84	\$0.69
Fully Diluted	\$0.81	\$0.67
Common Shares:		
Full Diluted	11,542,704	11,426,468
Year-end	11,414,238	11,375,330

OTONOMY INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Net Sales	966	410
Cost & expenses	73,197	85,038
Operating income	(72,231)	(84,628)
Interest income	934	618
Other income (expense), net		(1)
Net income	(71,297)	(84,011)
Earnings common share		
Primary	\$(2.35)	\$(2.81)
Fully Diluted	\$(2.35)	\$(2.81)
Common Shares:		
Full Diluted	30,280	29,878
Year-end	30,337	30,190

OURPET'S COMPANY

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	19,625,770	18,872,791
Cost & expenses	18,282,650	17,435,856
Operating income	1,343,120	1,436,935
Other income (expense), net	(9,395)	58,593
Net before taxes	1,258,963	1,411,322
Income taxes	196,061	494,440
Net income	1,062,902	916,882
Earnings common share		

Primary	\$0.06	\$0.05
Fully Diluted	\$0.05	\$0.05
Common Shares:		
Full Diluted	19,009,304	19,489,855
Year-end	19,539,230	17,712,348

PACIFIC GOLD CORP

Trading Suspension Development On July 26, 2017, The U.S. Securities and Exchange Commission announced the temporary suspension of trading in the securities of the following issuers, commencing at 9:30 a.m. EDT on July 27, 2017 and terminating at 11:59 p.m. EDT on Aug. 9, 2017. The Commission temporarily suspended trading in the securities of Co. due to a lack of current and accurate information about Co. because it has not filed certain periodic reports with the Commission. This order was entered pursuant to Section 12(k) of the Securities Exchange Act of 1934 (Exchange Act). The Commission cautions brokers, dealers, shareholders and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by Co. Brokers and dealers should be alert to the fact that, pursuant to Exchange Act Rule 15c2-11, at the termination of the trading suspensions, no quotation may be entered relating to the securities of Co. unless and until the broker or dealer has strictly complied with all of the provisions of the rule. If any broker or dealer is uncertain as to what is required by the rule, it should refrain from entering quotations relating to the securities of Co. that have been subject to trading suspensions until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. Any broker or dealer with questions regarding the rule should contact the staff of the Securities and Exchange Commission in Washington, DC at (202) 551-5720. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action.

PACIFIC SANDS INC

Trading Suspension Development On Sept. 22, 2017, the U.S. Securities and Exchange Commission ("Commission") announced the temporary suspension of trading in the securities of Co., commencing at 9:30 a.m. EDT on Sept. 26, 2017 and terminating at 11:59 p.m. EDT on Oct. 9, 2017. The Commission temporarily suspended trading in the securities of the foregoing companies due to a lack of current and accurate information about the companies because they had not filed certain periodic reports with the Commission. This order was entered pursuant to Section 12(k) of the Securities Exchange Act of 1934 ("Exchange Act"). The Commission cautions brokers, dealers, shareholders and prospective purchasers that they should carefully consider the foregoing information along with all other currently available information and any information subsequently issued by these companies. Brokers and dealers should be alert to the fact that, pursuant to Exchange Act Rule 15c2-11, at the termination of the trading suspension, no quotation may be entered relating to the securities of the subject companies unless and until the broker or dealer has strictly complied with all of the provisions of the rule. If any broker or dealer is uncertain as to what is required by the rule, it should refrain from entering quotations relating to the securities of these companies that have been subject to a trading suspension until such time as it has familiarized itself with the rule and is certain that all of its provisions have been met. Any broker or dealer with questions regarding the rule should contact the staff of the Securities and Exchange Commission in Washington, DC at (202) 551-5777. If any broker or dealer enters any quotation which is in violation of the rule, the Commission will consider the need for prompt enforcement action. If any broker, dealer or other person has any information which may relate to this matter, they should immediately communicate it to the Delinquent Filings Group of the Division of Enforcement at (202) 551-5466, or by e-mail at DelinquentFilings@sec.gov.

PAPA MURPHY'S HOLDINGS INC

Offering On Nov. 14, 2017, Co. announced a public offering pursuant to Common Stock, \$0.01 par value per share, reserved for issuance pursuant to awards issued under the Papa Murphy's Holdings, Inc. Amended 2010 Management Incentive Plan. Co. proposed to offer (i) 167,373 Outstanding options at a proposed maximum offering price per share of \$5.81, which amounted to a proposed maximum aggregate offering price of \$972,437.13. The amount of registration fee is \$121.07; and (ii) 56,094 Remaining shares available for issuance at a proposed maximum offering price per share of \$5.61, which amounted to a proposed maximum aggregate offering price of \$314,687.34. The amount of registration fee is \$39.18.

PAYPAL HOLDINGS INC

Interest Sale Development On Nov. 16, 2017, Co. and Synchrony Financial ("Synchrony") announced an agreement to

significantly expand their strategic consumer credit relationship. Under the terms of the transaction Synchrony's wholly-owned bank subsidiary, Synchrony Bank, will acquire the U.S. consumer credit receivables portfolio held by Co.'s indirect wholly-owned subsidiaries, Bill Me Later, Inc. and PayPal (Europe) S.A R.L. et CIE, S.C.A., consisting of \$6,800,000,000 in receivables, including Co.'s U.S. consumer credit receivables portfolio, which totaled approximately \$5,800,000,000 in receivables as of Oct. 31, 2017, and approximately \$1,000,000,000 in participation interests in receivables held by certain investors and a chartered financial institution. Terms of the transaction were not disclosed. Subject to regulatory approval and other customary conditions, this transaction is expected to close in the third quarter of 2018.

PC-TEL INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	68,136,000	61,383,000
Cost & expenses	67,186,000	62,650,000
Operating income	578,000	(1,675,000)
Other income (expense), net	(9,000)	1,000
Foreign currency	(98,000)	(24,000)
Net before taxes	652,000	(1,626,000)
Income taxes	(68,000)	6,603,000
Income contin. oper.	720,000	(8,229,000)
Net income	572,000	(12,354,000)
Earnings common share		
Primary	\$0.03	\$(0.77)
Fully Diluted	\$0.03	\$(0.77)
Common Shares:		
Full Diluted	16,830,000	16,136,000
Year-end	17,762,694	

PCM, INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Net Sales	1,629,988	1,663,960
Cost & expenses	1,618,506	1,638,376
Operating income	11,482	25,584
Interest expense	5,589	4,533
Other income (expense), net	424	
Net before taxes	6,317	21,051
Income taxes	631	8,168
Net income	5,686	12,883
Earnings common share		
Primary	\$0.46	\$1.09
Fully Diluted	\$0.43	\$1.04
Common Shares:		
Full Diluted	13,325	12,398
Year-end	11,775	11,813

PDC ENERGY INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	732,100,000	274,818,000
Cost & expenses	591,285,000	219,092,000
Operating income	(219,752,000)	261,603,000
Interest income	1,487,000	1,875,000
Interest expense	58,359,000	42,759,000
Net before taxes	(276,624,000)	302,487,000
Income taxes	(71,483,000)	112,198,000
Net income	(205,141,000)	190,289,000
Earnings common share		
Primary	\$(3.12)	\$(4.16)
Fully Diluted	\$(3.12)	\$(4.16)
Common Shares:		
Full Diluted	65,825,000	45,741,000
Year-end	65,865,523	56,254,690

PERCEPTRON, INC.**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Net Sales	19,269	17,520
Cost & expenses	17,724	19,499
Operating income	1,545	(1,979)
Other income (expense), net	30	1
Foreign currency	(22)	49
Net before taxes	1,511	(1,986)
Income taxes	(47)	369
Net income	1,558	(2,355)
Earnings common share		
Primary	\$0.16	\$(0.25)
Fully Diluted	\$0.16	\$(0.25)
Common Shares:		
Full Diluted	9,502	9,371
Year-end	9,487	9,371

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2017
Cash & equivalents	5,177
Inventories	13,196
Current assets	49,433
Net property & equip.	7,429
Total assets	70,127
Liabilities:	
Current liabilities	24,470
Stockholders' equity	42,449
Net current assets	24,963

PERNIX THERAPEUTICS HOLDINGS INC

Offering On Nov. 20, 2017, Co. announced a public offering pursuant to 2017 Omnibus Incentive Plan Common Stock, par value \$0.01 per share. Co. proposed to offer (i) 200,000 at a proposed maximum offering price per share of \$2.97, which amounted to a proposed maximum aggregate offering price of \$594,000.00. The amount of registration fee is \$73.96; and (ii) 2,069,572 at a proposed maximum offering price per share of \$2.96, which amounted to a proposed maximum aggregate offering price of \$6,125,933.12. The amount of registration fee is \$762.68.

PERSHING GOLD CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Cost & expenses	9,130,709	10,004,293
Operating income	(9,130,709)	(10,004,293)
Other income (expense), net	9,673	
Foreign currency	(9,981)	
Net income	(9,129,929)	(10,008,561)
Balance for common	(9,129,929)	(13,608,126)
Earnings common share		
Primary	\$(0.32)	\$(0.54)
Fully Diluted	\$(0.32)	\$(0.54)
Common Shares:		
Full Diluted	28,396,928	25,049,831
Year-end	28,402,389	26,206,570

PIONEER POWER SOLUTIONS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total Revenues	87,953,000	85,889,000
Cost & expenses	84,570,000	82,199,000
Operating income	3,383,000	3,690,000
Other income (expense), net	(647,000)	(554,000)
Net before taxes	1,074,000	1,985,000
Income taxes	396,000	900,000
Net income	678,000	1,085,000
Earnings common share		
Primary	\$0.08	\$0.12
Fully Diluted	\$0.08	\$0.12
Common Shares:		
Full Diluted	8,727,000	8,708,000
Year-end	8,726,045	8,699,712

PIXELWORKS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2017	2016
Total Revenues	62,189	37,403
Cost & expenses	61,180	48,185
Operating income	1,009	(10,782)
Net before taxes	281	(11,087)
Income taxes	902	357
Net income	(621)	(11,444)
Earnings common share		
Primary	\$(0.02)	\$(0.41)
Fully Diluted	\$(0.02)	\$(0.41)
Common Shares:		
Full Diluted	30,545	28,139
Year-end	34,252	28,656

PLEXUS CORP.**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	09/30/17	10/01/16	¹ 10/03/15
Net sales	2,528,052	2,556,004	(revised)
Cost of sales	2,272,197	2,328,645	(revised)
Gross profit	255,855	227,359	239,550
Selling & administrative expenses	125,947	120,886	122,423
Restructuring &			

other charges	7,034	1,691	
Operating income (loss)	129,908	99,439	115,436
Interest expense	13,578	14,635	13,964
Interest income	5,042	4,242	3,499
Miscellaneous income (expense)	451	(1,652)	1,324
Income (loss) before income taxes			
- U.S.	(35,209)	(26,796)	(32,480)
Income (loss) before income taxes - foreign	157,032	114,190	138,775
Income (loss) before income taxes	121,823	87,394	106,295
Current income tax expense (benefit) - federal	78		
Current income tax expense (benefit) - state	33	(15)	(397)
Current income tax expense (benefit) - foreign	10,016	11,312	12,957
Total current income tax expense (benefit)	10,127	11,297	12,560
Deferred income tax expense (benefit) - federal	77		
Deferred income tax expense (benefit) - state	38	24	(399)
Deferred income tax expense (benefit) - foreign	(481)	(354)	(198)
Total deferred income tax expense (benefit)	(366)	(330)	(597)
Income tax expense (benefit)	9,761	10,967	11,963
Net income (loss)	112,062	76,427	94,332
Weighted average shares outstanding - basic	33,612	33,374	33,618
Weighted average shares outstanding - diluted	34,553	34,098	34,379
Year end shares outstanding	33,464	33,457	33,500
Net earnings (loss) per share - basic	\$3.33	\$2.29	\$2.81
Net earnings (loss) per share - diluted	\$3.24	\$2.24	\$2.74
Number of full time employees	² 16,000	² 14,000	² 14,000
Number of common stockholders	³ 447	³ 478	³ 498
Foreign currency translation adjustments	4,155	(14,035)	(13,830)

¹ Reclassified to conform with 2016 presentation; ² Approximately; ³ As is; ⁴ As of November 13, 2017; ⁵ As of November 14, 2016; ⁶ As of November 16, 2015

Consolidated Balance Sheet, Years Ended (\$000):

	09/30/17	¹ 10/01/16
Cash	264,222	175,396
Money market funds & other cash equivalents	304,638	257,568
Restricted cash	394	
Accounts receivable, gross	366,493	419,256
Allowances	980	2,368
Accounts receivable, net	365,513	416,888
Raw materials	477,921	414,303
Work-in-process	86,367	69,423
Finished goods	90,354	80,405
Inventories	654,642	564,131
Prepaid expenses & other current assets	28,046	19,364
Total current assets	1,617,455	1,433,347

Land, buildings & improvements	262,428	247,806
Machinery & equipment	348,593	336,378
Computer hardware & software	117,404	107,239
Construction in progress	12,790	4,298
Total property, plant & equipment, gross	741,215	695,721
Less: accumulated depreciation	426,550	404,496
Property, plant & equipment, net	314,665	291,225
Deferred income taxes	5,292	4,834
Other assets	38,770	36,413
Total non-current assets	358,727	332,472
Total assets	1,976,182	1,765,819
Current portion of long-term debt & capital lease obligations	286,934	78,507
Accounts payable	413,999	397,200
Customer deposits	107,837	84,637
Accrued salaries & wages	49,376	41,806
Other accrued liabilities	49,445	48,286
Total current liabilities	907,591	650,436
Borrowings under the credit facility	108,000	75,000
Senior notes	175,000	175,000
Capital lease & other financing obligations	30,901	13,614
Unamortized deferred financing fees	(794)	(1,105)
Total obligations	313,107	262,509
Less: current portion	286,934	78,507
Other liabilities	16,479	14,584
Total non-current liabilities	42,652	198,586
Total liabilities	950,243	849,022
Common stock	519	513
Additional paid-in capital	555,297	530,647
Common stock held in treasury, at cost	574,104	539,968
Retained earnings (accumulated deficit)	1,049,206	937,144
Foreign currency translation adjustments	(7,482)	(11,637)
Cumulative change in fair value of derivative instruments	2,503	98
Accumulated other comprehensive income (loss)	(4,979)	(11,539)
Total shareholders' equity	1,025,939	916,797

□ Reclassified to conform with 2017 presentation

PRESIDIO INC

Secondary Offering On Nov. 16, 2017, Co. announced the commencement of a proposed secondary public offering of 8,000,000 shares of the Company's common stock at \$14.25 per share by certain funds affiliated with Apollo Global Management, LLC (the "Selling Stockholder"). The underwriters will have a 30-day option to purchase up to an additional 1,200,000 shares of common stock from the Selling Stockholder. Co. is not selling any shares and will not receive any proceeds from the proposed offering.

PROTAGENIC THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	1,656,541	1,677,225
Operating income	(1,656,541)	(1,677,225)
Gains or losses	81,509	(29,332)
Invest. income	963	
Net income	(1,563,512)	(1,719,749)
Earnings common share		
Primary	\$(0.15)	\$(0.45)
Fully Diluted	\$(0.15)	\$(0.45)
Common Shares:		
Full Diluted	10,261,419	3,826,068
Year-end	10,261,419	8,307,915

PROTAGONIST THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Cost & expenses	43,165	21,269
Operating income	(34,384)	(21,269)
Interest income	479	93
Other income (expense), net		(4,753)
Net income	(33,905)	(25,929)
Balance for common	(33,905)	(26,487)
Earnings common share		
Primary	\$(2.01)	\$(8.62)
Fully Diluted	\$(2.01)	\$(8.62)
Common Shares:		
Full Diluted	16,852	3,071
Year-end	16,944	16,714

PROTEON THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Cost & expenses	24,772	21,839
Operating income	(24,772)	(21,839)
Other income (expense), net	198	120
Gains or losses	161	155
Net income	(24,413)	(21,564)
Balance for common	(31,160)	(21,564)
Earnings common share		
Primary	\$(1.82)	\$(1.30)
Fully Diluted	\$(1.82)	\$(1.30)
Common Shares:		
Full Diluted	17,158	16,550
Year-end	17,619	16,583

PROTEOSTASIS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Total Revenues	3,719	4,324
Cost & expenses	50,185	32,180
Operating income	(46,466)	(27,856)
Interest income	515	56
Other income (expense), net	(57)	(15)
Net income	(46,008)	(27,815)
Balance for common	(46,008)	(29,193)
Earnings common share		
Primary	\$(1.84)	\$(1.75)
Fully Diluted	\$(1.84)	\$(1.75)
Common Shares:		
Full Diluted	25,052	16,672
Year-end	25,113	24,945

PULSE BEVERAGE CORP (THE)

Earnings, 9 mos. to Sep 30(Consol. - \$):

Net Sales	1,184,310	2,299,757
Cost & expenses	2,300,933	3,341,075
Operating income	(1,116,623)	(1,129,583)
Other income (expense), net	(2,096,473)	(463,007)
Income contin. oper.	(1,713,120)	
Income discount. oper.	(103,680)	
Net income	(3,465,377)	(1,816,800)
Earnings common share		
Primary	\$(0.01)	\$(0.03)
Fully Diluted	\$(0.01)	\$(0.03)
Common Shares:		
Full Diluted	303,180,000	69,791,000
Year-end	694,258,030	70,924,980

Q2EARTH INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

Total Revenues	55,933	40,000
Cost & expenses	1,135,167	1,734,525
Operating income	(1,079,234)	(1,694,525)
Interest expense	245,779	181,425
Other income (expense), net	(112,764)	692,719
Net income	(1,437,777)	(1,183,231)
Balance for common	(1,464,703)	(1,210,075)
Earnings common share		
Primary	\$(0.03)	\$(0.04)
Fully Diluted	\$(0.03)	\$(0.04)
Common Shares:		
Full Diluted	43,793,353	28,028,380
Year-end	48,422,386	29,551,431

QUADRANT 4 SYSTEM CORP

Bankruptcy Proceedings On Nov. 20, 2017, the U.S. Bankruptcy Court approved the motion of Co.'s wholly-owned

subsidiary, Stratitude, for entry of an order authorizing the Debtor to pay retention bonuses to three key non-insider employees and granting shortened notice in connection therewith. As previously reported, "By this Motion, the Debtor requests the entry of an order authorizing it to pay Retention Bonuses to the Key Employees. In order to insure the Key Employees' willingness to remain under the employ of the Debtor, the Debtor proposes to pay the Retention Bonuses on the earlier of either: (a) the closing of a sale of substantially all assets of the Debtor; or (b) the 90th day after the entry of an order approving this Motion. Each of the Key Employees played an integral role in the Debtor's maintenance and operation prior to the Petition Date and throughout the pendency of the Chapter 11 Case. It is in the Debtor's judgment that the work performed by each of the Key Employees was necessary to preserve the Debtor's going concern value and for the successful solicitation of the Stalking Horse Offer."

QUALCOMM INC

Annual Meeting Development On Nov. 16, 2017, Co. announced that its Annual Meeting of Stockholders will be held on Mar. 6, 2018.

RADIUS HEALTH INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Cost & expenses	196,677	131,906
Operating income	(182,228)	(131,906)
Interest income	1,983	1,996
Interest expense	2,763	
Other income (expense), net	(212)	(174)
Net income	(183,220)	(130,084)
Balance for common	(183,220)	(130,084)
Earnings common share		
Primary	\$(4.21)	\$(3.02)
Fully Diluted	\$(4.21)	\$(3.02)
Common Shares:		
Full Diluted	43,536	43,050
Year-end	44,532	43,110

RAPID7 INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Total Revenues	143,209	112,403
Cost & expenses	178,618	151,507
Operating income	(35,409)	(39,104)
Other income (expense), net	349	184
Net before taxes	(34,475)	(38,865)
Income taxes	(2,009)	361
Net income	(32,466)	(39,226)
Earnings common share		
Primary	\$(0.76)	\$(0.96)
Fully Diluted	\$(0.76)	\$(0.96)
Common Shares:		
Full Diluted	42,693	41,033
Year-end	43,857	42,480

REAL INDUSTRY INC

Bankruptcy Proceedings On Nov. 17, 2017, Co. and Real Alloy Intermediate Holding, LLC, Real Alloy Holding, Inc. and its U.S. wholly owned subsidiaries (collectively, "Real Alloy" and, together with Co., the "Debtors") filed voluntary petitions in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") seeking relief under Chapter 11 of the Bankruptcy Code lead case number 17-12464. The assets were valued at \$645,500,000. Real Alloy's Germany, United Kingdom, Norway, Canada and Mexico operations and its Goodyear, Arizona joint venture are not included in these filings. These cases (the "Chapter 11 Cases") are being jointly administered. The Debtors will continue to operate their businesses as "debtors-in-possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. In connection with the Chapter 11 Cases, the Debtors filed various "first day" motions seeking Bankruptcy Court approval, including, without limitation, approval of debtor-in-possession financing on the terms set forth in (i) that certain term sheet for a Senior Secured Super-Priority Debtor-in-Possession Note Purchase Agreement (the "Note Purchase Agreement"), by and among Real Alloy Holding, Inc. as issuer and certain holders of Real Alloy Holding's outstanding senior secured 10.0% notes (the "Existing Notes") as purchasers (the "Purchasers"), and (ii) that certain Debtor-in-Possession ABL Credit Agreement (the "ABL Credit Agreement"), and together with the Note Purchase Agreement, the "DIP Financing Agreements") by and among Real Alloy as borrowers and Bank of America N.A. as lender (the "Lender" or "Bank of America"). The DIP Financing Agreements will provide for approximately

\$365,000,000 in debtor-in-possession financing (the "DIP Financing"), which includes the conversion of Real Alloy's existing ABL facility with the Lender (as set forth in the Revolving Credit Agreement, dated as of Mar. 14, 2017, by and among Real Alloy and the other borrowers thereunder and Bank of America; such facility, the "Existing ABL Facility"), up to \$85,000,000 in new notes and the "roll-up" of \$170,000,000 in Existing Notes into new notes ("Roll-Up Notes"). Up to \$50,000,000 of the DIP Financing will become available upon the satisfaction of customary conditions precedent thereto, including the entry of an order of the Bankruptcy Court approving the DIP Financing on an interim basis, which such interim approval was sought on the Petition Date and is expected to be heard by the Bankruptcy Court on Nov. 20, 2017, with the balance of the DIP Facility due upon entry of a final order. For the avoidance of doubt, Co. is not a borrower, guarantor or credit party under the DIP Financing. The proceeds of the DIP Financing will be used by Real Alloy for (i) general working capital and operational expenses; (ii) administration of the Chapter 11 Cases (other than the Chapter 11 case of Co.); (iii) refinancing certain existing prepetition debt; and (iv) costs, expenses, and all other payment amounts contemplated in the DIP Financing Agreement, in any such case, in accordance with a 13-week cash flow and operating forecast in form and substance approved by the Lender and Purchasers (subject to any variances permitted by the DIP Financing Agreement). The maturity date of the loans and notes made under the DIP Financing is the earlier of six months from the Petition Date and the closing date of a sale of the Real Alloy business. The outstanding principal on the notes under the Note Purchase Agreement will bear interest at a rate of 11.5% per annum payable monthly in cash in arrears. The Roll-Up Notes will bear interest at a rate of 10.0% per annum accrued monthly and payable at maturity. The outstanding principal on the loans under the ABL Credit Agreement will bear interest at a rate of either (1) the Base Rate (as defined below) plus 2.25% or (2) the LIBOR plus 3.25%. The "Base Rate" is equal to the greater of (a) the prime rate, (b) the federal funds rate plus 0.50%, and (c) the LIBOR rate for a 30-day interest period. "LIBOR" means the per annum rate of interest equal to the London Interbank Offered Rate or comparable or successor rate as published on the applicable Reuters screen page for such interest period. The DIP Financing is subject to certain customary covenants and events of default as set forth in the DIP Financing Agreement.

REAL INDUSTRY INC

Bankruptcy Proceedings On Nov. 21, 2017, Co. filed with the U.S. Bankruptcy Court a D.I.P. notes purchase agreement and D.I.P. ABL agreement. According to documents filed with the Court, "Subject to the terms and conditions of this Agreement and the Financing Order and in reliance upon the representations and warranties of the Credit Parties contained herein, each Lender severally and not jointly agrees to make Loans to the Borrowers (collectively, the 'Revolving Loans' and individually, a 'Revolving Loan') from time to time on any Business Day during the period from the Closing Date through the Final Availability Date, in an aggregate amount not to exceed at any time outstanding such Lender's Revolving Loan Commitment, which Revolving Loan Commitment, as of the Closing Date, is set forth opposite such Lender's name on Schedule 1.1(a) under the heading 'Revolving Loan Commitments'. Borrower Representative may request that one or more L/C Issuers Issue, in accordance with such L/C Issuers' usual and customary business practices and for the account of the Borrowers, Letters of Credit and an applicable L/C Issuer (a 'Letter of Credit'), from time to time on any Business Day during the period from the Closing Date through the earlier of (x) the Final Availability Date and (y) 7 days prior to the Revolving Termination Date; provided, however, that no L/C Issuer shall Issue any Letter of Credit upon the occurrence of any of the following or, if after giving effect to such Issuance: the aggregate outstanding principal balance of Revolving Loans would exceed the Maximum Revolving Loan Amount or (b) the Letter of Credit Obligations for all Letters of Credit would exceed \$20,000,000." Also on Nov. 21, 2017, Co. filed with the U.S. Bankruptcy Court a motion for entry of interim and final orders authorizing the Debtors to obtain post-petition secured financing, authorizing post-petition use of cash collateral and other pre-petition collateral and scheduling a final hearing. The Debtors also filed an exhibit to the proposed D.I.P. financing order. The motion explains, "The DIP Facilities consist of a senior secured debtor-in-possession revolving credit facility in the amount of \$110,000,000 provided by Bank of America, the Real Alloy Debtors' prepetition ABL lender, and an agreement for issuance and purchase of up to \$255,000,000 in senior secured debtor-in-possession notes backstopped by the largest prepetition holder of the Real Alloy Debtors' prepetition Senior Secured Notes including up to \$85,000,000 in new liquidity, comprised of (A) \$65,000,000 of New Money DIP Notes,

the proceeds of which shall be used exclusively to fund the operations of the Debtors (the 'DIP Notes Facility'), and (B) an amount of New Money DIP Notes determined by the required DIP Noteholders in their sole discretion, up to \$20,000,000 the proceeds of which shall be used exclusively to fund the operations of the Debtors' foreign subsidiaries (the 'Discretionary Foreign Subsidiary DIP Notes Facility'); and authorizing (i) the DIP Notes Issuer at any time prior to the earlier of (A) 35 calendar days after the Petition Date and (B) the entry of the Final Order to issue DIP Notes in an aggregate outstanding principal amount that will not exceed \$40,000,000 under the Debtor DIP Notes Facility and \$10,000,000 under the Discretionary Foreign Subsidiary DIP Notes Facility, (ii) upon entry of the Final Order, the remainder of the DIP Notes Facilities, (iii) the DIP ABL Borrowers at any time prior to the earlier of (A) 35 calendar days after the Petition Date and (B) the entry of the Final Order to borrow under the DIP ABL Facility in an aggregate outstanding principal amount that will not exceed the sum of (x) \$20,000,000 plus (y) the aggregate amount of all prepetition letters of credit deemed letters of credit under the DIP ABL Loan Documents, plus (c) the aggregate amount of all Prepetition ABL Obligations repaid from the proceeds of DIP ABL Priority Collateral during the Interim Period." The interest rate for new money D.I.P. notes is 11.5%. Also on Nov. 21, 2017, the U.S. Bankruptcy Court issued an interim order approving Co.'s motion to obtain post-petition secured financing, authorizing post-petition use of cash collateral and other pre-petition collateral and scheduling a final hearing. As previously reported, "The DIP Facilities consist of a senior secured debtor-in-possession revolving credit facility in the amount of \$110,000,000 provided by Bank of America, the Real Alloy Debtors' prepetition ABL lender, and an agreement for issuance and purchase of up to \$255,000,000 in senior secured debtor-in-possession notes backstopped by the largest prepetition holder of the Real Alloy Debtors' prepetition Senior Secured Notes including up to \$85,000,000 in new liquidity, comprised of (A) \$65,000,000 of New Money DIP Notes, the proceeds of which shall be used exclusively to fund the operations of the Debtors (the 'DIP Notes Facility'), and (B) an amount of New Money DIP Notes determined by the required DIP Noteholders in their sole discretion, up to \$20,000,000 the proceeds of which shall be used exclusively to fund the operations of the Debtors' foreign subsidiaries (the 'Discretionary Foreign Subsidiary DIP Notes Facility'); and authorizing (i) the DIP Notes Issuer at any time prior to the earlier of (A) 35 calendar days after the Petition Date and (B) the entry of the Final Order to issue DIP Notes in an aggregate outstanding principal amount that will not exceed \$40,000,000 under the Debtor DIP Notes Facility and \$10,000,000 under the Discretionary Foreign Subsidiary DIP Notes Facility, (ii) upon entry of the Final Order, the remainder of the DIP Notes Facilities, (iii) the DIP ABL Borrowers at any time prior to the earlier of (A) 35 calendar days after the Petition Date and (B) the entry of the Final Order to borrow under the DIP ABL Facility in an aggregate outstanding principal amount that will not exceed the sum of (x) \$20,000,000 plus (y) the aggregate amount of all prepetition letters of credit deemed letters of credit under the DIP ABL Loan Documents, plus (c) the aggregate amount of all Prepetition ABL Obligations repaid from the proceeds of DIP ABL Priority Collateral during the Interim Period."

REAL INDUSTRY INC

Bankruptcy Proceedings On Nov. 27, 2017, Co. filed with the U.S. Bankruptcy Court a notice of filing of a final D.I.P. notes purchase agreement and D.I.P. ABL agreement. Exhibit 1 is a final version of the D.I.P. ABL agreement; Exhibit 2 is blackline comparing the final D.I.P. ABL agreement with the previous version; Exhibit 3 is a final version of the revised D.I.P. notes purchase agreement. According to documents filed with the Court, "Co. will authorize the issue and sale of up to \$85,000,000 aggregate principal amount of its 11.5% Senior Secured Super-Priority Debtor-in-Possession Notes due on the Maturity Date. The Notes issued pursuant hereto constitute the 'New Money DIP Notes' and shall be afforded the rights and protections set forth in the DIP Order. The purchase price for all Notes shall be deposited into the Proceeds Account pursuant to Section 3.1; provided, that \$35,000,000 in proceeds from the initial sale of the Notes shall be directed to Co.'s disbursement account (pursuant to wire instructions provided to the Purchasers) and/or to pay down the ABL DIP Facility and otherwise used in accordance with Section 9. Co. may withdraw amounts from the Proceeds Account in minimum increments of \$500,000 solely to pay expenses and other amounts permitted to be paid pursuant to the Approved DIP Budget for the next 7 days from the time of such withdrawal."

REATA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	38,094	37,355

Cost & expenses	68,142	39,464
Deprec., depl. & amort.	336	537
Operating income	(30,991)	(2,533)
Interest expense	956	
Other income (expense), net	(3)	
Gains or losses	352	113
Net before taxes	(30,991)	(2,533)
Income taxes	2	(442)
Net income	(30,993)	(2,091)
Earnings common share		
Primary	\$(1.34)	\$(0.11)
Fully Diluted	\$(1.34)	\$(0.11)
Common Shares:		
Full Diluted	23,196	18,970
Year-end	26,114	22,336

RED ROCK RESORTS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	1,221,595	1,057,873
Cost & expenses	969,238	706,585
Operating income	117,636	237,185
Interest expense	100,127	104,421
Other income (expense), net	749	(5,797)
Net before taxes	18,258	126,967
Income taxes	1,230	12,292
Net income	17,028	114,675
Earnings common share		
Primary	\$0.08	\$0.55
Fully Diluted	\$0.07	\$0.55
Common Shares:		
Full Diluted	115,877	27,174
Year-end	116,141	115,895

REGENXBIO INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	8,353	2,893
Cost & expenses	67,640	47,764
Operating income	(59,287)	(44,871)
Gains or losses	2,115	1,512
Net income	(57,172)	(43,359)
Balance for common	(57,172)	(43,359)
Earnings common share		
Primary	\$(1.94)	\$(1.64)
Fully Diluted	\$(1.94)	\$(1.64)
Common Shares:		
Full Diluted	29,440	26,386
Year-end	31,109	26,475

RIBBON COMMUNICATIONS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2016	2015	2014
Revenue - product	195,181	170,183	244,810
Revenue - service	231,913	246,853	274,291
Total revenue	427,094	417,036	519,101
Cost of revenue - product	106,068	93,680	135,459
Cost of revenue - service	103,941	125,895	140,007
Amortization of acquired technology	2,855	6,175	12,101
Total cost of revenue	212,864	225,750	287,567
Gross profit (loss)	214,230	191,286	231,534
Research & development expense	102,162	119,444	128,179
Sales & marketing expense	69,744	86,737	91,795
General & administrative expense	36,810	38,245	46,643
Legal costs for patent litigation	11,391	22,223	4,078
Revaluation of contingent consideration		(2,891)	
Revaluation of contingent consideration			
Restructuring	14	2,076	1,301

expense	7,449	9,676	1,405
Amortization of acquired intangibles	4,565	6,679	8,423
Total operating expenses	232,135	282,189	281,824
Income (loss) before interest expense, other expense (income), net, & income tax provision (benefit)	(17,905)	(90,903)	(50,290)
Interest expense	5,197	1,327	787
Other income (expense), net	(772)	4,478	1,487
Income (loss) before income taxes	(23,874)	(87,752)	(49,590)
Current income tax provision (benefit) - U.S. federal	18	424	368
Current income tax provision (benefit) - US State & local	(205)	26	354
Current income tax provision (benefit) - Non-US	3,878	2,103	348
Total current income tax provision (benefit)	3,691	2,553	1,070
Deferred income tax provision (benefit) - U.S. federal	(191)	1,865	(1,017)
Deferred income tax provision (benefit) - US State & local	(57)	141	(129)
Deferred income tax provision (benefit) - Non-US	(95)	(642)	(633)
Total deferred income tax provision (benefit)	(343)	1,364	(1,779)
Income tax provision (benefit)	3,348	3,917	(709)
Net income (loss)	(27,222)	(91,669)	(48,881)
Year end shares outstanding	2,456,842	2,504,901	2,586,334

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):
2016 2015

Cash & cash equivalents	32,759	34,228
Billed accounts receivable, gross	104,880	100,085
Unearned accounts receivable, gross	11,822	9,982
Total trade receivables, gross	116,702	110,067
Less: Allowance for doubtful accounts	3,861	2,638
Accounts receivable, net	112,841	107,429
Finished goods	10,330	13,617
Raw materials	7,368	8,463
Less: provision for excess & obsolescence	8,216	6,279
Inventory	9,482	15,801
Deferred costs	19,987	17,668
Prepaid expenses & other	7,144	9,138
Total current assets	182,213	184,264
Lab equipment	62,026	60,838
Software - internal use	48,216	44,244
Computer equipment	30,806	28,961
Leasehold improvements	17,474	13,296
Furniture & equipment	4,295	4,187
Manufacturing equipment	2,014	2,050
Construction in progress	1,232	1,496
Capital leases	336	317
Property & equipment, gross	166,399	155,389
Less: Accumulated depreciation	140,438	127,202
Property & equipment, net	25,961	28,187
Goodwill	41,655	41,733
Intangible assets, net	20,186	28,215

Deferred income taxes	9,180	7,016
Other assets	2,594	1,408
Total assets	281,789	290,823
Current portion of long-term debt	...	3,112
Revolving credit facility	17,000	16,500
Accounts payable	44,723	41,791
Accrued compensation & benefits	20,966	24,168
Accrued expenses, shareholder	10,302	8,552
Professional fees	9,006	10,464
Income & other taxes	2,094	2,126
Other accrued liabilities	10,820	11,573
Accrued restructuring	7,388	6,388
Deferred revenue	95,657	92,108
Total current liabilities	217,956	216,782
Revolving credit facility	17,000	16,500
Term debt, related party	40,000	30,000
Other term debt	...	3,112
Total debt outstanding	5,700	49,612
Amount classified as short term	17,000	19,612
Long-term debt, related party	40,000	30,000
Deferred revenue, net of current portion	11,152	12,643
Deferred income taxes	2,311	891
Employee retirement benefits	6,271	5,217
Deferred rent	4,676	2,476
Accrued interest, related party	4,245	431
Uncertain tax positions	2,009	1,564
Other long-term liabilities	1,858	2,017
Total liabilities	290,478	272,021
Convertible preferred stock	561,657	497,043
Class A common stock	17	18
Class B common stock	1	1
Class E common stock	6	6
Additional paid-in capital	330,478	393,815
Retained earnings (accumulated deficit)	(881,179)	(853,957)
Employee retirement benefits	(1,145)	(633)
Foreign currency translation adjustment	(18,524)	(17,491)
Accumulated other comprehensive income (loss)	(19,669)	(18,124)
Total stockholders' equity (deficit)	(570,346)	(478,241)

ROCKY BRANDS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	186,202,989	193,308,286
Cost & expenses	178,093,343	195,213,081
Operating income	8,109,646	(1,904,795)
Other income (expense), net	35,064	82,876
Net before taxes	7,863,886	(2,281,150)
Income taxes	2,674,000	(776,000)
Net income	5,189,886	(1,505,150)
Earnings common share		
Primary	\$0.70	\$(0.20)
Fully Diluted	\$0.70	\$(0.20)
Common Shares:		
Full Diluted	7,441,378	7,531,308
Year-end	7,403,195	7,447,331

ROKU INC

Offering On Nov. 14, 2017, Co. announced a public offering pursuant to Class A common stock, par value \$0.0001 per share. Co. proposed to offer 18,018,200 at a proposed maximum offering price per share of \$14.00, which amounted to a proposed maximum aggregate offering price of \$252,254,800. The amount of registration fee is \$29,237.

ROKU INC

Securities Registration On Nov. 14, 2017, Co. announced a public offering pursuant to Class A common stock, \$0.0001 par

value per share, which amounted to a proposed maximum aggregate offering price of \$100,000,000. The amount of registration fee is \$11,590.00.

SAGE THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	202,706	103,785
Operating income	(202,706)	(103,785)
Other income (expense), net	(48)	(18)
Net income	(200,698)	(103,086)
Earnings common share		
Primary	\$(5.37)	\$(3.20)
Fully Diluted	\$(5.37)	\$(3.20)
Common Shares:		
Full Diluted	37,368	32,218
Year-end	37,222	37,165

SAGE THERAPEUTICS INC

Secondary Offering On Nov. 13, 2017, Co. announced that it has commenced an underwritten public offering of \$300,000,000 of its common stock. Co. also intends to grant the underwriters a 30-day option to purchase up to an additional \$45,000,000 of its common stock offered in the public offering. All the shares in the offering are to be sold by Co.

SAKER AVIATION SERVICES, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	8,743,913	10,872,366
Cost & expenses	7,994,350	9,502,608
Operating income	749,563	1,369,758
Interest expense	17,091	21,506
Other income (expense), net	(10,000)	...
Net before taxes	722,472	1,348,252
Income taxes	414,241	681,000
Net income	308,231	667,252
Earnings common share		
Primary	\$0.01	\$0.02
Fully Diluted	\$0.01	\$0.02
Common Shares:		
Full Diluted	34,415,005	33,305,833
Year-end	33,422,995	33,157,610

SANGUI BIOTECH INTERNATIONAL, INC.

Earnings, 3 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	16,636	9,711
Cost & expenses	78,919	79,604
Operating income	(62,283)	(69,893)
Net income	(64,151)	(71,675)
Earnings common share		
Common Shares:		
Full Diluted	185,764,406	170,022,916
Year-end	187,261,503	174,467,747

Consolidated Balance Sheet Items, as of (\$):

Assets:	2017
Cash & equivalents	52,072
Current assets	87,847
Total assets	87,847
Liabilities:	
Current liabilities	377,851
Stockholders' equity	322,063
Net current assets	(290,004)

SANMINA CORP

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	09/30/17	10/01/16	10/03/15
		(revised)	(revised)
Net sales	6,868,619	6,481,181	6,374,541
Cost of sales	6,348,708	5,966,899	5,890,685
Gross profit	519,911	514,282	483,856
Selling, general & administrative expenses	251,568	244,604	239,288
Research & development expenses	33,716	37,746	33,083
Restructuring	1,339	2,701	13,683
Amortization of intangible assets	3,672	3,446	2,054
Asset impairment	4,600	1,000	3,454
Gain (loss) on sale of long-lived assets	1,451	...	10,807

Fully Diluted	\$(2.31)	\$(3.39)
Common Shares:		
Full Diluted	19,804	7,882
Year-end	22,121	18,188

SERES THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2017	2016
Total Revenues	29,044	18,730
Cost & expenses	90,664	85,896
Operating income	(61,620)	(67,166)
Interest income	1,892	1,483
Other income (expense), net	(699)	(620)
Net income	(60,427)	(66,303)
Earnings common share		
Primary	\$(1.49)	\$(1.67)
Fully Diluted	\$(1.49)	\$(1.67)
Common Shares:		
Full Diluted	40,420	39,676
Year-end	40,513	40,356

SIENTRA INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2017	2016
Net Sales	25,477	14,246
Cost & expenses	70,957	46,167
Operating income	(45,480)	(31,921)
Interest income	112	47
Interest expense	603	118
Other income (expense), net	(151)	(54)
Net before taxes	(46,122)	(32,046)
Income taxes	70	48
Net income	(46,192)	(32,094)
Earnings common share		
Primary	\$(2.42)	\$(1.77)
Fully Diluted	\$(2.42)	\$(1.77)
Common Shares:		
Full Diluted	19,080	18,112
Year-end	19,365	18,594

SIERRA ONCOLOGY INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2017	2016
Cost & expenses	31,814	38,842
Operating income	(31,814)	(38,842)
Other income (expense), net	506	259
Net before taxes	(31,308)	(38,583)
Income taxes	108	36
Net income	(31,416)	(38,619)
Balance for common		
Earnings common share		
Primary	\$(0.64)	\$(1.28)
Fully Diluted	\$(0.64)	\$(1.28)
Common Shares:		
Full Diluted	49,080	30,198
Year-end	52,268	30,351

SMG INDIUM RESOURCES LTD**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2017	2016
Total Revenues	1,802,486	308,452
Cost & expenses	2,067,770	(265,284)
Operating income	(265,284)	(308,452)
Interest income	635	
Net income	(342,416)	(307,817)
Earnings common share		
Primary	\$(0.21)	\$(0.18)
Fully Diluted	\$(0.21)	\$(0.18)
Common Shares:		
Full Diluted	1,665,192	1,744,569
Year-end	7,700,190	1,744,569

SOLAR SENIOR CAPITAL LTD**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2017	2016
Cost & expenses	6,168	7,364
Net income	16,952	12,667
Earnings common share		
Primary	\$1.07	\$1.55
Fully Diluted	\$1.07	\$1.55
Common Shares:		
Full Diluted	16,030	11,811
Year-end	16,034	16,025

SORRENTO TECH INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2017	2016
Total Revenues	6,087	5,336
Cost & expenses	27,709	24,628
Operating income	(24,433)	(22,110)
Net before taxes	(25,282)	(23,310)
Income taxes	13	14
Net income	(25,295)	(23,324)
Balance for common		
Earnings common share		
Primary	\$(5.07)	\$(14.37)
Fully Diluted	\$(5.07)	\$(14.37)
Common Shares:		
Full Diluted	4,987	1,754
Year-end	5,006	1,788

SOTHERLY HOTELS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2017	2016
Total Revenues	116,106,987	116,910,412
Cost & expenses	90,054,545	89,950,725
Deprec., depl. & amort.	12,708,548	11,260,987
Operating income	13,343,894	15,698,700
Interest income	126,241	63,523
Interest expense	11,827,061	13,872,129
Other income (expense), net	(258,835)	(1,224,255)
Gains or losses	1,119,622	
Net before taxes	2,503,861	665,839
Income taxes	(581,890)	(308,398)
Net income	3,085,751	974,237
Balance for common	597,385	527,971
Earnings common share		
Primary	\$0.04	\$0.04
Fully Diluted	\$0.04	\$0.04
Common Shares:		
Full Diluted	13,885,290	14,897,595
Year-end	13,823,459	14,949,651

SOTHERLY HOTELS LP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2017	2016
Total Revenues	116,106,987	116,910,412
Cost & expenses	90,054,545	89,950,725
Deprec., depl. & amort.	12,708,548	11,260,987
Operating income	13,343,894	15,698,700
Interest income	126,241	63,523
Interest expense	11,827,061	13,872,129
Other income (expense), net	782,980	(1,224,255)
Gains or losses	77,807	
Net before taxes	2,503,861	665,839
Income taxes	(581,890)	(308,398)
Net income	3,085,751	974,237
Earnings common share		
Primary	\$0.04	\$0.04
Fully Diluted	\$0.04	\$0.04
Common Shares:		
Full Diluted	16,256,713	16,723,557
Year-end	16,258,691	16,727,791

SPARK ENERGY INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2017	2016
Total Revenues	563,279	378,021
Net Sales	563,960	378,063
Cost & expenses	490,176	303,781
Deprec., depl. & amort.	30,435	23,337
Operating income	42,668	50,903
Interest expense	8,760	2,855
Net before taxes	34,010	48,388
Income taxes	5,265	6,852
Net income	28,745	41,536
Balance for common	3,590	6,697
Earnings common share		
Primary	\$0.27	\$0.62
Fully Diluted	\$0.27	\$0.52
Common Shares:		
Full Diluted	13,315	12,099
Year-end	34,631	33,443

SPARK THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2017	2016
Total Revenues	4,657,275	3,880,046
Cost & expenses	200,364,928	91,858,112
Operating income	(195,707,653)	(87,978,066)
Interest income	2,230,306	1,162,833
Net before taxes	(193,477,347)	
Income taxes	(1,816,323)	
Net income	(191,661,024)	(86,815,233)
Earnings common share		
Primary	\$(5.89)	\$(3.08)
Fully Diluted	\$(5.89)	\$(3.08)
Common Shares:		
Full Diluted	32,516,829	28,218,850
Year-end	36,926,603	30,757,156

	2017	2016
Total Revenues	4,657,275	3,880,046
Cost & expenses	200,364,928	91,858,112
Operating income	(195,707,653)	(87,978,066)
Interest income	2,230,306	1,162,833
Net before taxes	(193,477,347)	
Income taxes	(1,816,323)	
Net income	(191,661,024)	(86,815,233)
Earnings common share		
Primary	\$(5.89)	\$(3.08)
Fully Diluted	\$(5.89)	\$(3.08)
Common Shares:		
Full Diluted	32,516,829	28,218,850
Year-end	36,926,603	30,757,156

SPARTANNASH CO.

Co. Repurchasing Certain Securities On Nov. 15, 2017, Co.'s Board of Directors has authorized the repurchase of up to \$50,000,000 of Co.'s common stock from time to time on the open market or in privately negotiated transactions.

SPERO THERAPEUTICS INC**Annual Report
Consolidated Income Statement, Years Ended Dec. 31
(\$000):**

	2016	2015
Revenue	335	...
Research & development	26,333	11,125
General & administrative expenses	7,223	2,202
Total operating expenses	33,556	13,327
Income (loss) from operations	(33,221)	(13,327)
Change in fair value of derivative liabilities	580	174
Total other income (expense), net	580	174
Income before income taxes - Domestic	(27,148)	(12,832)
Income before income taxes - Foreign	(5,493)	(321)
Income from cont operations before income tax	(32,641)	(13,153)
Net income (loss)	(32,641)	(13,153)
Less: Net loss attributable to non-controlling interests	7,150	2,999
Net income (loss) attributable to Spero Therapeutics, Inc.	(25,491)	(10,154)
Cumulative dividends on redeemable convertible preferred shares	3,441	932
Accretion of bridge units & redeemable convertible preferred shares to redemption value	996	2,341
Net loss attributable to common stockholders of Spero Therapeutics, Inc.	(29,928)	(13,427)
Weighted average shares outstanding - basic	312	253
Weighted average shares outstanding - diluted	312	253
Year end shares outstanding	335	61,918
Net earnings (loss) per share - basic	\$(95.87)	\$(53.11)
Net earnings (loss) per share - diluted	\$(95.87)	\$(53.11)
Number of full time employees	29	...

□ As of September 30, 2017; □ As is

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2016	2015
Cash & cash equivalents	10,315	5,691
Other receivables	304	10
Prepaid expenses & other current assets	1,253	287
Total current assets	11,872	5,988
Tax incentive receivables	144	...

Laboratory equipment	484	85	Interest Sale Development On Nov. 20, 2017, Co. and Churchill Downs LLC, ("Buyer"), entered into an Asset Purchase Agreement (the "Agreement") pursuant to which Co. has agreed to sell substantially all of its assets to Buyer and Buyer has agreed to acquire such assets and assume certain liabilities of Co. as specified in the Agreement (the "Asset Sale"). As consideration for the Asset Sale, Buyer has agreed to (i) pay to Co. \$11,500,000 in cash (the "Cash Consideration"), (ii) enter into a subordinated secured promissory note payable to Co. in the principal amount of \$4,600,000 (the "Note") and (iii) assume substantially all of the liabilities of Co. as specified in the Agreement and Holdings will issue to Co. a 5% equity interest in Holdings (the "Equity Consideration"). In connection with the signing of the Agreement, Buyer delivered \$750,000 into escrow (the "Escrowed Funds") to serve as a deposit towards the Cash Consideration or to fund the termination fee payable to Co. if the Agreement is terminated under certain circumstances.	expense (benefit)	121,200	351,300	56,500
Computer software & equipment	185	109		Deferred United States state & local income taxes expense (benefit)	14,200	25,800	4,000
Office furniture & equipment	201	...		Deferred foreign income taxes expense (benefit)	(21,200)	(86,500)	(40,100)
Leasehold improvements	920	727		Total deferred income taxes expense (benefit)	114,200	290,600	20,400
Construction in progress	...	39		Income tax expense (benefit)	1,432,600	1,379,700	1,143,700
Total property & equipment, gross	1,790	960		Net earnings (loss) including noncontrolling interests	2,884,900	2,818,900	2,759,300
Less: Accumulated depreciation	290	11		Net earnings (loss) attributable to noncontrolling interests	(200)	(1,200)	(1,900)
Property & equipment, net	1,500	949		Net earnings attributable to Starbucks Corporation	2,884,700	2,817,700	2,757,400
Deferred offering costs	...	36		Weighted average shares outstanding - basic	1,449,500	1,471,600	1,495,900
Deposits	206	153		Weighted average shares outstanding - diluted	1,461,500	1,486,700	1,513,400
Restricted cash	50	50		Year end shares outstanding	1,431,600	1,460,500	1,485,100
Total assets	13,772	7,176		Net earnings (loss) per share - basic	\$1.99	\$1.91	\$1.84
Accounts payable	1,139	1,794		Net earnings (loss) per share - diluted	\$1.97	\$1.90	\$1.82
Accrued external research & development expenses	627	111		Cash dividends declared per share	\$1.05	\$0.85	\$0.68
Accrued payroll & related expenses	1,018	423		Total number of employees	277,000	254,000	238,000
Accrued professional fees	1,062	55		Number of common stockholders	18,100	18,100	17,900
Accrued other	221	17		Foreign currency translation adjustments	(38,300)	85,500	(222,700)
Accrued expenses & other current liabilities	2,928	606					
Derivative liabilities	2,708	3,384					
Advance payments from collaborator	...	512					
Deferred rent	143	125					
Total current liabilities	6,918	6,421					
Deferred rent, net of current portion	493	595					
Advance payments from collaborator, net of current portion	...	417					
Total liabilities	7,411	7,433					
Bridge units	7,924	...					
Redeemable convertible preferred stock	47,685	18,296					
Retained earnings (accumulated deficit)	(45,440)	(18,100)					
Total stockholders' equity (deficit)	(45,440)	(18,100)					
Non-controlling interests	(3,808)	(453)					
Total stockholders' equity (deficit)	(49,248)	(18,553)					

STARBUCKS CORP.**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	10/01/17	10/02/16	09/27/15 (revised)			
Company-operated stores revenues	17,650,700	16,844,100	15,197,300			
Licensed stores revenues	2,355,000	2,154,200	1,861,900			
Global consumer products group (CPG), foodservice & other revenues	2,381,100	2,317,600	2,103,500			
Total net revenues	22,386,800	21,315,900	19,162,700			
Cost of sales including occupancy costs	9,038,200	8,511,100	7,787,500			
Store operating expenses	6,493,300	6,064,300	5,411,100			
Other operating expenses	553,800	545,400	522,400			
Depreciation & amortization expenses	1,011,400	980,800	893,900			
General & administrative expenses	1,393,300	1,360,600	1,196,700			
Restructuring & impairments	153,500			
Income from equity investees	391,400	318,200	249,900			
Operating income (loss)	4,134,700	4,171,900	3,601,000			
Gain resulting from acquisition of joint venture	390,600			
Loss on extinguishment of debt	(61,100)			
Interest income & other income, net	275,300	108,000	43,000			
Interest expense	92,500	81,300	70,500			
Earnings (loss) before income taxes - United States	3,393,000	3,415,700	2,837,200			
Earnings (loss) before income taxes - foreign	924,500	782,900	1,065,800			
Earnings (loss) before income taxes	4,317,500	4,198,600	3,903,000			
Current United States federal income taxes expense (benefit)	931,000	704,100	801,000			
Current United States state & local income taxes expense (benefit)	170,800	166,500	150,100			
Current foreign income taxes expense (benefit)	216,600	218,500	172,200			
Total current income taxes expense (benefit)	1,318,400	1,089,100	1,123,300			
Deferred United States federal income taxes						

SPORTSMAN'S WAREHOUSE HOLDINGS INC**Earnings, 9 mos. to (Consol. - \$000):**

	10/28/17	10/29/16
Net Sales	566,506	558,580
Cost & expenses	536,517	519,006
Operating income	29,989	39,574
Interest expense	10,081	10,132
Net before taxes	19,908	29,442
Income taxes	8,053	10,313
Net income	11,855	19,129
Earnings common share		
Primary	\$0.28	\$0.45
Fully Diluted	\$0.28	\$0.45
Common Shares:		
Full Diluted	42,501	42,465
Year-end	42,579	42,245

STANLEY FURNITURE CO., INC.**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/17	10/01/16
Net Sales	33,231	34,772
Cost & expenses	33,998	38,960
Operating income	(767)	(4,188)
Interest expense	103	16
Other income (expense), net	25	16
Net before taxes	(742)	(4,275)
Income taxes	(35)	682
Net income	(707)	(4,957)
Earnings common share		
Primary	\$(0.05)	\$(0.35)
Fully Diluted	\$(0.05)	\$(0.35)
Common Shares:		
Full Diluted	14,203	14,143
Year-end	15,083	14,732

STANLEY FURNITURE CO., INC.

As is; ² Approximately; ³ As of November 11, 2016; ⁴ As of November 6, 2015

Consolidated Balance Sheet, Years Ended (\$000):

	10/01/17	10/02/16
Cash & cash equivalents	2,462,300	2,128,800
Short-term investments - available-for-sale securities	151,700	65,700
Short-term investments - trading securities	76,900	68,700
Short-term investments - Accounts receivable, gross	228,600	134,400
Allowance for doubtful accounts	880,200	778,200
Accounts receivable, net	9,800	9,400
Coffee - unroasted	870,400	768,800
Coffee - roasted	541,000	561,600
Other merchandise held for sale	301,100	300,400
Packaging & other supplies	301,100	308,600
Inventories	220,800	207,900
Prepaid expenses & other current assets	1,364,000	1,378,500
Total current assets	358,100	350,000
Long-term investments	5,283,400	4,760,500
Equity method investments	542,300	1,141,700
Cost method investments	432,800	305,700
Land	48,800	48,800
Buildings	46,900	46,600
Leasehold improvements	481,700	458,400
Store equipment	6,401,000	5,892,900
Roasting equipment	2,110,700	1,931,700
Furniture, fixtures &	619,800	605,400

other property, plant & equipment	1,514,100	1,366,900
Work in progress	409,800	271,400
Accumulated depreciation	6,664,500	6,039,500
Property, plant & equipment, net	4,919,500	4,533,800
Deferred income taxes, net	795,400	885,400
Other long-term assets	362,800	417,700
Other intangible assets	441,400	516,300
Goodwill	1,539,200	1,719,600
Total assets	14,365,600	14,329,500
Accounts payable	782,500	730,600
Accrued compensation & related costs	524,500	510,800
Accrued occupancy costs	151,300	137,500
Accrued taxes	226,600	368,400
Accrued dividend payable	429,500	365,100
Accrued capital & other operating expenditures	602,600	617,300
Insurance reserves	215,200	246,000
Stored value card liability	1,288,500	1,171,200
Current portion of long-term debt	...	400,000
Total current liabilities	4,220,700	4,546,900
Senior notes	3,955,300	3,600,000
Aggregate unamortized premium (discount)	(17,500)	2,200
Hedge accounting fair value adjustment	(5,200)	...
Less: current portion of long-term debt	...	400,000
Other long-term liabilities	755,300	689,700
Total liabilities	8,908,600	8,438,800
Common stock	1,400	1,500
Additional paid-in capital	41,100	41,100
Retained earnings (accumulated deficit)	5,563,200	5,949,800
Available-for-sale securities	(2,500)	1,100
Cash flow hedges	(4,100)	10,900
Net investment hedges	14,000	1,300
Translation adjustment & other accumulated comprehensive income	(163,000)	(121,700)
Accumulated other comprehensive income (loss)	(155,600)	(108,400)
Total shareholders' equity	5,450,100	5,884,000
Noncontrolling interests	6,900	6,700
Total equity	5,457,000	5,890,700

STATE NATIONAL COMPANIES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	179,027	156,996
Cost & expenses	117,395	102,320
Operating income	61,632	54,676
Net before taxes	61,632	54,676
Income taxes	22,213	19,695
Net income	39,419	34,981
Earnings common share		
Primary	\$0.95	\$0.83
Fully Diluted	\$0.92	\$0.83
Common Shares:		
Full Diluted	42,967	42,216
Year-end	42,174	42,197

STATE NATIONAL COMPANIES INC

Merger Completed On Nov. 17, 2017, Markel Corp. ("Markel") wholly-owned subsidiary, Markelverick Corp. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Markel. As the result of the merger, each issued and outstanding share of common stock of Co. ("Co. Common Stock") (other than shares of Co. Common Stock held by Co. as treasury shares or held by subsidiaries of Co., dissenting shares or share of performance-based restricted stock, which were treated as described below) was automatically canceled and converted into the right to receive \$21.00 in cash, without interest and less

any required withholding tax (the "Merger Consideration"). In addition, each option to acquire Co. Common Stock outstanding and unexercised as of immediately prior to the effective time of the Merger (whether or not vested) became fully vested, and each such option was immediately canceled, with the holder thereof thereafter having only the right to receive the excess of the Merger Consideration over the exercise price of such option. In the event that the exercise price of any such option was equal to or greater than the Merger Consideration, such option was canceled without payment therefor. At the Effective Time, each restricted share of Co. Common Stock ("Co. Restricted Stock") that was outstanding immediately prior to the Effective Time (whether or not vested) became fully vested, in the case of a time-based vesting Co. Restricted Stock, or became vested at the target level of performance, in the case of a performance-based vesting Co. Restricted Stock ("Performance-Based Restricted Stock"), and was automatically converted, to the extent vested as described in this sentence, into the right to receive the Merger Consideration. Any Performance-Based Restricted Stock that did not become vested at the Effective Time as described in the previous sentence was forfeited automatically without payment therefor.

STEREOTAXIS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	23,588,433	24,856,095
Cost & expenses	25,758,271	29,156,630
Operating income	(2,169,838)	(4,300,535)
Interest income	15	362
Interest expense	135,351	2,466,803
Other income (expense), net	(1,029,479)	(4,053,679)
Net income	(3,334,653)	(10,820,655)
Balance for common	(4,405,465)	(16,958,131)
Earnings common share		
Primary	\$(0.20)	\$(0.78)
Fully Diluted	\$(0.20)	\$(0.78)
Common Shares:		
Full Diluted	22,551,496	21,758,529
Year-end	22,783,121	21,891,191

STITCH FIX INC

Offering On Nov. 17, 2017. Co. announced a public offering pursuant to Class B common stock, par value \$0.00002 per share and Class A common stock, par value \$0.00002 per share. Co. proposed to offer (i) 10,210,695 shares 2011 Equity Incentive Plan under Class B common stock, par value \$0.00002 per share at a proposed maximum offering price per share of \$8.84, which amounted to a proposed maximum aggregate offering price of \$90,238,539.00. The amount of registration fee is \$11,234.70; (ii) 6,927,129 shares 2017 Incentive Plan under Class A common stock, par value \$0.00002 per share at a proposed maximum offering price per share of \$15.00, which amounted to a proposed maximum aggregate offering price of \$103,906,935.00. The amount of registration fee is \$12,936.42; and (iii) 10,210,695 shares 2011 Equity Incentive Plan under Class A common stock, par value \$0.00002 per share.

STRATEGIC ENVIRONMENTAL & ENERGY RESOURCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	6,668,700	6,048,300
Cost & expenses	9,103,200	7,834,300
Operating income	(2,434,500)	(1,786,000)
Interest expense	1,212,500	255,200
Other income (expense), net	34,100	(51,900)
Income contin. oper.	(3,612,900)	(2,093,100)
Income discont. oper.	3,366,600	397,600
Net income	(246,300)	(1,679,800)
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	54,902,947	54,263,765
Year-end	56,338,575	...

STRAYER EDUCATION, INC.

Offering On Nov. 20, 2017. Co. announced a public offering pursuant to Common Stock, par value \$0.01 per share. Co. proposed to offer 10,750,000, which amounted to a proposed maximum aggregate offering price of \$1,004,049,976.65. The amount of registration fee is \$125,004.23.

SUCAMPO PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	177,445,000	157,032,000

Cost & expenses	321,219,000	136,649,000
Operating income	(143,774,000)	20,383,000
Interest income	38,000	67,000
Interest expense	8,762,000	18,141,000
Other income (expense), net	(948,000)	5,216,000
Net before taxes	(153,446,000)	7,525,000
Income taxes	12,729,000	4,321,000
Net income	(166,175,000)	3,204,000
Earnings common share		
Primary	\$(3.67)	\$0.08
Fully Diluted	\$(3.67)	\$0.07
Common Shares:		
Full Diluted	45,338,000	43,334,000
Year-end	46,409,658	45,828,775

SUNRUN INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	383,256	333,314
Cost & expenses	510,815	496,437
Operating income	(130,713)	(166,277)
Interest expense	49,586	38,535
Other income (expense), net	(589)	460
Net before taxes	(180,888)	(204,352)
Income taxes	37,625	13,146
Net income	(218,513)	(217,498)
Balance for common	65,631	62,655
Earnings common share		
Primary	\$0.62	\$0.61
Fully Diluted	\$0.61	\$0.60
Common Shares:		
Full Diluted	107,893	104,698
Year-end	106,677	103,438

SURGERY PARTNERS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	132,258	839,437
Cost & expenses	117,002	682,378
Deprec., depl. & amort.	3,330	28,984
Operating income	11,926	128,075
Interest expense	15,883	74,863
Other income (expense), net	...	(3,733)
Gains or losses	1,098	...
Net before taxes	(2,859)	49,479
Income taxes	(211)	2,496
Net income	(2,648)	46,983
Earnings common share		
Primary	\$(0.57)	\$(0.15)
Fully Diluted	\$(0.57)	\$(0.15)
Common Shares:		
Full Diluted	48,315	48,019
Year-end	48,769	48,512

SYNACOR, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	94,025	92,457
Cost & expenses	97,439	92,558
Operating income	(10,418)	(6,883)
Interest expense	328	227
Other income (expense), net	172	206
Gains or losses	1,902	...
Net before taxes	(8,672)	(6,904)
Income taxes	999	783
Net income	(9,671)	(7,687)
Earnings common share		
Primary	\$(0.27)	\$(0.26)
Fully Diluted	\$(0.27)	\$(0.26)
Common Shares:		
Full Diluted	35,591	30,109
Year-end	38,636	30,468

SYNAPTICS INC

Offering On Nov. 15, 2017. Co. announced a public offering pursuant to Common Stock, par value \$0.001 per share. Co. proposed to offer 2,000,000 at a proposed maximum offering price per share of \$37.93, which amounted to a proposed maximum aggregate offering price of \$75,860,000.00. The amount of registration fee is \$9,444.57.

SYNCHRONOUS TECHNOLOGIES INC

Interest Sale Completed On Nov. 14, 2017, Co. sold all the issued and outstanding shares of its wholly-owned subsidiary, Intralinks Holdings, Inc. ("Intralinks"), to Impala Private Holdings II, LLC ("Impala"), an affiliate of Siris Capital Group, LLC

("Siris"), for approximately \$991,000,000 in cash, subject to post-closing adjustments for changes in cash, debt and working capital. If, in the future, Impala receives net cash proceeds in excess of \$440,000,000 from any sale of equity or assets of Intralinks, or a dividend or distribution in respect of the shares of Intralinks, then Impala is required to pay Co. up to an additional \$25,000,000 in cash or publicly traded securities. Immediately following the consummation of the Intralinks Transaction, Co. paid to Impala \$5,000,000 as partial reimbursement of the out-of-pocket fees and expenses incurred by Impala, Siris and their respective affiliates in connection with the execution of the Share Purchase Agreement and the Intralinks Transaction. As the result, Intralinks would operate as an independent, privately owned portfolio company of investment funds affiliated with Siris. Also as of Nov. 14, 2017, investment funds affiliated with Siris owned 5,994,667 shares of Co.'s common stock, par value \$0.0001 per share (the "Common Stock"), or approximately 12.6% of the issued and outstanding Common Stock as of such date.

SYNDAX PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2017	2016
Total Revenues	915	915
Cost & expenses	43,380	33,540
Operating income	(42,465)	(32,625)
Other income (expense), net	(193)	(1,720)
Net income	(41,699)	(33,657)
Balance for common	(41,699)	(36,255)
Earnings common share		
Primary	\$(2.08)	\$(2.70)
Fully Diluted	\$(2.08)	\$(2.70)
Common Shares:		
Full Diluted	20,004	13,420
Year-end	22,313	18,180

SYNOLOGIC INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2017	2016
Total Revenues	2,333	2,333
Cost & expenses	31,239	17,708
Operating income	(28,906)	138
Interest income	272	272
Interest expense	22	22
Other income (expense), net	248	248
Gains or losses	(138)	(138)
Net income	(28,680)	(17,574)
Balance for common	(28,680)	(17,574)
Earnings common share		
Primary	\$(7.87)	\$(5.88)
Fully Diluted	\$(7.87)	\$(5.88)
Common Shares:		
Full Diluted	3,642	2,976
Year-end	16,285	2,977

SYROS PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2017	2016
Total Revenues	1,101	1,101
Cost & expenses	40,267	36,918
Operating income	(39,166)	(36,918)
Other income (expense), net	458	140
Net income	(38,708)	(36,778)
Balance for common	(38,708)	(40,459)
Earnings common share		
Primary	\$(1.54)	\$(4.44)
Fully Diluted	\$(1.54)	\$(4.44)
Common Shares:		
Full Diluted	25,100	9,111
Year-end	26,292	23,370

T2 BIOSYSTEMS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2017	2016
Total Revenues	3,005	3,171
Cost & expenses	42,491	41,143
Operating income	(39,486)	(37,972)
Interest expense	5,008	2,416
Other income (expense), net	260	133
Net income	(44,234)	(40,255)
Earnings common share		
Primary	\$(1.43)	\$(1.64)
Fully Diluted	\$(1.43)	\$(1.64)
Common Shares:		
Full Diluted	30,874	24,525
Year-end	35,797	30,431

TACTILE SYSTEMS TECHNOLOGY INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2017	2016
Total Revenues	74,397	56,064
Cost & expenses	75,426	55,084
Operating income	(1,029)	980
Other income (expense), net	204	20
Net before taxes	(825)	1,000
Income taxes	(4,450)	500
Net income	3,625	500
Balance for common	3,625	(747)
Earnings common share		
Primary	\$0.21	\$(0.12)
Fully Diluted	\$0.19	\$(0.12)
Common Shares:		
Full Diluted	18,819	6,318
Year-end	17,651	16,747

TAPIMMUNE INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2017	2016
Cost & expenses	8,982,701	6,900,949
Operating income	(8,982,701)	(6,900,949)
Other income (expense), net	683,929	6,022,388
Net income	(8,298,772)	(878,561)
Earnings common share		
Primary	\$(0.91)	\$(0.14)
Fully Diluted	\$(0.91)	\$(0.54)
Common Shares:		
Full Diluted	9,081,678	6,935,000
Year-end	10,539,057	8,395,768

TCP CAPITAL CORP**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2017	2016
Total Revenues	128,862,576	108,653,443
Cost & expenses	45,376,638	36,984,286
Net income	83,485,938	71,669,157
Earnings common share		
Primary	\$0.96	\$1.06
Fully Diluted	\$0.96	\$1.06
Common Shares:		
Full Diluted	56,390,954	50,245,035
Year-end	58,792,364	53,041,751

TD AMERITRADE HOLDING CORP**Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$):**

	2017	2016	2015
			(revised)
Commissions & transaction fees	1,384,000,000	1,372,000,000	1,401,000,000
Bank deposit account fees	1,107,000,000	926,000,000	839,000,000
Net interest revenue	690,000,000	595,000,000	622,000,000
Investment product fees	423,000,000	374,000,000	334,000,000
Other revenues	72,000,000	60,000,000	51,000,000
Employee compensation & benefits expenses	962,000,000	839,000,000	807,000,000
Clearing & execution costs	149,000,000	136,000,000	148,000,000
Communications expenses	131,000,000	137,000,000	125,000,000
Occupancy & equipment costs	181,000,000	171,000,000	163,000,000
Depreciation & amortization	102,000,000	92,000,000	91,000,000
Amortization of acquired intangible assets	79,000,000	86,000,000	90,000,000
Professional services	260,000,000	178,000,000	159,000,000
Advertising	254,000,000	260,000,000	248,000,000
Other operating expenses	92,000,000	110,000,000	91,000,000
Total operating expenses	2,210,000,000	2,009,000,000	1,922,000,000
Operating income	1,466,000,000	1,318,000,000	1,325,000,000
Interest on borrowings	71,000,000	53,000,000	43,000,000
Gain (loss) on debt			

refinancing	(1,000,000)		
Gain (loss) on investments			7,000,000
Other revenues (expenses)			(1,000,000)
Total other income (expense)	(72,000,000)	(53,000,000)	(37,000,000)
Pre-tax income	1,394,000,000	1,265,000,000	1,288,000,000
Current income taxes - federal	484,000,000	435,000,000	470,000,000
Current income taxes - state	49,000,000	(4,000,000)	28,000,000
Total current income taxes	533,000,000	431,000,000	498,000,000
Deferred income taxes - federal	(11,000,000)	(5,000,000)	(22,000,000)
Deferred income taxes - state		(3,000,000)	(1,000,000)
Total deferred income taxes	(11,000,000)	(8,000,000)	(23,000,000)
Provision for (benefit from) income taxes	522,000,000	423,000,000	475,000,000
Net income (loss)	872,000,000	842,000,000	813,000,000
Weighted average shares outstanding			
- basic	529,000,000	531,000,000	543,000,000
Weighted average shares outstanding - diluted	531,000,000	534,000,000	547,000,000
Year end shares outstanding	567,000,000	526,000,000	537,000,000
Earnings (loss) per share - basic	\$1.65	\$1.59	\$1.50
Earnings (loss) per share-diluted	\$1.64	\$1.58	\$1.49
Dividends declared per share	\$0.72	\$0.68	\$0.60
Number of full time employees	10,412	6,010	5,690
Number of common stockholders	631	655	685
Number of beneficial stockholders	67,000	68,000	70,000

□ Full-time equivalent; □ As of November 2, 2017; □ As of November 3, 2016; □ As of November 3, 2015; □ Approximately

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

	2017	2016
Cash & cash equivalents	1,472,000,000	1,855,000,000
Cash & investments segregated & on deposit for regulatory purposes	10,446,000,000	8,729,000,000
Deposits paid for securities borrowed	1,154,000,000	1,051,000,000
Clearing organizations	151,000,000	116,000,000
Broker-dealers	21,000,000	16,000,000
Securities failed to deliver	8,000,000	7,000,000
Receivable from clients, gross	17,162,000,000	11,950,000,000
Allowance for doubtful accounts	11,000,000	9,000,000
Receivable from clients, net	17,151,000,000	11,941,000,000
Receivable from affiliates	137,000,000	106,000,000
Other receivables, net	174,000,000	160,000,000
Securities owned, at fair value	503,000,000	331,000,000
Investments available-for-sale, at fair value	746,000,000	757,000,000
Buildings & building components	351,000,000	269,000,000
Computer equipment	270,000,000	240,000,000
Software	215,000,000	187,000,000
Leasehold improvements	173,000,000	159,000,000
Building construction in process	101,000,000	12,000,000
Land	77,000,000	44,000,000

Other property & equipment	83,000,000	75,000,000
Property & equipment, gross	1,270,000,000	986,000,000
Less accumulated depreciation & amortization	518,000,000	460,000,000
Property & equipment at cost, net	752,000,000	526,000,000
Goodwill	4,213,000,000	2,467,000,000
Acquired intangible assets, net	1,470,000,000	575,000,000
Other assets	229,000,000	181,000,000
Total assets	38,627,000,000	28,818,000,000
Deposits received for securities loaned	2,449,000,000	1,990,000,000
Clearing organizations	32,000,000	27,000,000
Securities failed to receive	21,000,000	21,000,000
Broker-dealers	2,000,000	2,000,000
Payable to clients	25,107,000,000	19,055,000,000
Accounts payable & other liabilities	815,000,000	565,000,000
Payable to affiliates	109,000,000	9,000,000
Securities sold under agreements to repurchase	97,000,000	...
Senior notes	2,555,000,000	1,817,000,000
Deferred income taxes	193,000,000	281,000,000
Total liabilities	31,380,000,000	23,767,000,000
Common stock	7,000,000	6,000,000
Additional paid-in capital	3,369,000,000	1,670,000,000
Retained earnings (accumulated deficit)	6,011,000,000	5,518,000,000
Treasury stock, common, at cost	2,116,000,000	2,121,000,000
Deferred compensation	(1,000,000)	...
Cash flow hedging instruments	(25,000,000)	(22,000,000)
Accumulated other comprehensive income (loss)	(25,000,000)	(22,000,000)
Total stockholders' equity	7,247,000,000	5,051,000,000

□ Including securities pledged as collateral for repurchase agreements - Investments available-for-sale, at fair value: \$99,000,000

TERRAFORM GLOBAL INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2017	2016
Total Revenues	186,413	159,171
Cost & expenses	125,797	83,271
Operating income	8,071	34,929
Interest expense	88,578	95,797
Other income (expense), net	1,487	25,523
Gains or losses	30,051	21,963
Net before taxes	(48,969)	(13,382)
Income taxes	7,440	5,040
Net income	(56,409)	(18,422)
Earnings common share		
Primary	\$(0.31)	\$(0.15)
Fully Diluted	\$(0.31)	\$(0.15)
Common Shares:		
Full Diluted	112,487	107,135
Year-end	173,193	174,251

TERRAFORM POWER INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2017	2016
Total Revenues	474,932	519,336
Cost & expenses	226,592	195,539
Operating income	62,301	145,771
Interest expense	206,749	243,111
Other income (expense), net	4,882	(692)
Gains or losses	5,695	(845)
Foreign currency	(96,755)	(4,161)
Net before taxes	(4,982)	3,115
Income taxes	(91,773)	(106,153)
Net income	(50,890)	(47,559)
Balance for common		
Primary	\$(0.62)	\$(0.53)
Fully Diluted	\$(0.62)	\$(0.53)

Common Shares:		
Full Diluted	92,228	89,140
Year-end	140,611	139,549

TERRAFORM POWER INC

Offering On Nov. 16, 2017, Co. announced a public offering pursuant to Class A Common Stock, \$0.01 par value per share. Co. proposed to offer 34,273,879 at a proposed maximum offering price per share of \$12.16, which amounted to a proposed maximum aggregate offering price of \$416,770,368. The amount of registration fee is \$51,888.

TETRA TECH INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	10/01/17	10/02/16	10/09/27/15
Revenue	2,753,360	2,583,469	2,299,321
Subcontractor costs	(719,350)	(654,264)	(580,606)
Other costs of revenue	1,680,372	1,598,994	1,402,925
Gross profit	353,638	330,211	315,790
Selling, general & administrative expenses	177,219	171,985	170,456
Acquisition & integration expenses	...	19,548	...
Contingent consideration - fair value adjustments	(6,923)	2,823	(3,113)
Impairment of goodwill & other intangible assets	60,763
Operating income (loss)	183,342	135,855	87,684
Interest income	729	996	680
Interest expense	12,310	12,385	8,043
Income before income taxes - United States	166,074	113,576	118,822
Income before income taxes - foreign	5,687	10,890	(38,501)
Income (loss) before income taxes expense	171,761	124,466	80,321
Current federal income tax expense (benefit)	45,604	22,277	23,836
Current state income tax expense (benefit)	8,860	5,634	5,072
Current foreign income tax expense (benefit)	9,337	6,651	3,773
Total current income tax expense (benefit)	63,801	34,562	32,681
Deferred federal income tax expense (benefit)	(4,251)	6,231	7,218
Deferred state income tax expense (benefit)	(945)	(16)	2,335
Deferred foreign income tax expense (benefit)	(4,761)	(164)	(1,141)
Total deferred income tax expense (benefit)	(9,957)	6,051	8,412
Income tax expense (benefit)	53,844	40,613	41,093
Net income (loss) including noncontrolling interests	117,917	83,853	39,228
Net income attributable to noncontrolling interests	(43)	(70)	(154)
Net income (loss) attributable to Tetra Tech, Inc.	117,874	83,783	39,074
Weighted average			

shares outstanding - basic	56,911	58,186	60,913
Weighted average shares outstanding - diluted	57,913	58,966	61,532
Year end shares outstanding	55,873	57,042	59,381
Net earnings (loss) per share - basic	\$2.07	\$1.44	\$0.64
Net earnings (loss) per share - diluted	\$2.04	\$1.42	\$0.64
Cash dividends paid per share	\$0.38	\$0.34	\$0.30
Total number of employees	16,000	16,000	13,000
Number of common stockholders	1,394	1,484	1,555
Foreign currency translation adjustments	...	14,392	(98,287)

□ Reclassified to conform with 2016 presentation; □ As is; □ Approximately; □ As of October 31, 2017; □ As of November 7, 2016; □ As of November 9, 2015

Consolidated Balance Sheet, Years Ended (\$000):

	10/01/17	10/02/16
Cash & cash equivalents	189,975	160,459
Billed receivables	376,287	364,287
Unbilled receivables	404,899	356,147
Contract retentions	39,840	29,135
Less allowance for doubtful accounts	32,259	35,233
Accounts receivable - net	788,767	714,336
Prepaid expenses & other current assets	49,969	46,262
Income taxes receivable	13,312	14,371
Total current assets	1,042,023	935,428
Land & buildings	3,680	3,683
Equipment, furniture & fixtures	150,026	180,750
Leasehold improvements	27,689	30,261
Total property & equipment	181,395	214,694
Less: accumulated depreciation	124,560	146,867
Property & equipment - net	56,835	67,827
Investments in & advances to unconsolidated joint ventures	2,700	2,064
Goodwill	740,886	717,988
Intangible assets - net	26,688	48,962
Deferred income taxes	1,763	630
Other long-term assets	31,850	27,880
Intangible & other assets, net	0	...
Total assets	1,902,745	1,800,779
Accounts payable	177,638	158,773
Accrued compensation	143,408	129,184
Billings in excess of costs on uncompleted contracts	117,499	88,223
Current portion of long-term debt	15,588	15,510
Contingent earn-out liabilities	2,024	4,296
Other current liabilities	81,511	85,100
Total current liabilities	537,668	481,086
Deferred income taxes	43,781	60,348
Credit facilities	356,438	346,813
Other long-term debt	433	198
Less current portion of long-term debt	15,588	15,510
Long-term debt	341,283	331,501
Long-term contingent earn-out liabilities	414	4,461
Other long-term liabilities	50,975	53,980
Common stock	559	570
Additional paid-in capital	193,835	260,340

Foreign currency translations adjustment	(98,946)	(126,840)
Gain (loss) on derivative instruments	446	(1,168)
Accumulated other comprehensive income (loss)	(98,500)	(128,008)
Retained earnings (accumulated deficit)	832,559	736,357
Total Tetra Tech, Inc. stockholders' equity (deficit)	928,453	869,259
Noncontrolling interests	171	144
Total equity	928,624	869,403

Reclassified to conform with 2017 presentation

THERAPEUTICSMD INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	12,653,495	14,869,023
Cost & expenses	68,444,623	82,097,598
Operating income	(55,948,071)	(67,312,894)
Other income (expense), net	442,322	265,879
Net income	(55,498,050)	(67,039,165)
Earnings common share		
Primary	\$(0.27)	\$(0.34)
Fully Diluted	\$(0.27)	\$(0.34)
Common Shares:		
Full Diluted	203,282,335	195,912,173
Year-end	216,429,642	196,580,212

TICC CAPITAL CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	24,877,428	33,028,461
Net income	23,097,902	17,382,340
Earnings common share		
Primary	\$0.45	\$0.33
Fully Diluted	\$0.45	\$0.33
Common Shares:		
Full Diluted	59,727,707	62,018,689
Year-end	51,479,409	51,479,409

TNR TECHNICAL, INC.

Earnings, 3 mos. to Sep 30(Consol. - \$):

	2017	2016
Net Sales	1,985,026	2,135,982
Cost & expenses	1,910,327	2,001,295
Operating income	74,699	134,687
Other income (expense), net	1,411	11
Net before taxes	76,110	134,698
Income taxes	17,000	53,000
Net income	59,110	81,698
Earnings common share		
Primary	\$0.19	\$0.27
Fully Diluted	\$0.19	\$0.27
Common Shares:		
Full Diluted	315,978	307,128
Year-end	318,978	309,101

Consolidated Balance Sheet Items, as of (\$):

Assets:	2017	2016
Cash & equivalents	1,194,706	
Inventories	2,211,316	
Current assets	5,039,157	
Net property & equip.	55,396	
Total assets	5,100,192	
Liabilities:		
Current liabilities	555,297	
Stockholders' equity	4,538,895	
Net current assets	4,483,860	

TONIX PHARMACEUTICALS HOLDING CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	15,748,000	31,459,000
Operating income	(15,748,000)	(31,459,000)
Net income	(15,630,000)	(31,360,000)
Earnings common share		
Primary	\$(2.49)	\$(14.50)
Fully Diluted	\$(2.49)	\$(14.50)
Common Shares:		
Full Diluted	6,287,062	2,160,157
Year-end	7,581,700	2,935,272

TPI COMPOSITES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Net Sales	683,142	569,303
Cost & expenses	626,083	535,499
Operating income	57,059	33,804
Interest income	78	76
Interest expense	9,215	12,709
Other income (expense), net	968	192
Gains or losses	(2,575)	(700)
Net before taxes	46,315	20,663
Income taxes	8,514	4,565
Net income	37,801	16,098
Balance for common	37,801	10,627
Earnings common share		
Primary	\$1.12	\$0.88
Fully Diluted	\$1.09	\$0.88
Common Shares:		
Full Diluted	34,748	12,133
Year-end	33,994	33,737

TRACON PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	20,611	22,733
Operating income	(11,856)	(19,901)
Interest expense	681	871
Other income (expense), net	(6)	78
Net income	(12,543)	(20,694)
Balance for common	(12,543)	(20,694)
Earnings common share		
Primary	\$(0.76)	\$(1.70)
Fully Diluted	\$(0.76)	\$(1.70)
Common Shares:		
Full Diluted	16,551	12,201
Year-end	17,393	13,056

TRANSACT TECHNOLOGIES INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Net Sales	43,117	43,632
Cost & expenses	37,804	40,356
Operating income	5,313	3,276
Other income (expense), net	(8)	13
Net before taxes	5,280	3,271
Income taxes	1,657	1,010
Net income	3,623	2,261
Earnings common share		
Primary	\$0.49	\$0.29
Fully Diluted	\$0.48	\$0.29
Common Shares:		
Full Diluted	7,504	7,724
Year-end	7,366	7,383

TREVENA INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	3,750,000	
Cost & expenses	56,272,000	70,197,745
Operating income	(56,272,000)	(66,447,745)
Interest income	505,000	585,221
Interest expense	2,041,000	1,306,997
Other income (expense), net	681,000	284,376
Gains or losses	1,000	(8,808)
Foreign currency	(19,000)	
Net income	(57,145,000)	(66,893,953)
Balance for common	(57,145,000)	(66,893,953)
Earnings common share		
Primary	\$(0.98)	\$(1.29)
Fully Diluted	\$(0.98)	\$(1.29)
Common Shares:		
Full Diluted	58,475,079	51,911,107
Year-end	61,688,322	52,242,647

TRIMBLE INC

Co. Repurchasing Certain Securities On Nov. 15, 2017, Co. announced that its Board of Directors has approved a new share repurchase program authorizing up to \$600,000,000 in repurchases of Co.'s common stock. The authorization does not have an expiration date and replaces the prior authorization of \$400,000,000, which was recently completed. The new repurchase program goes into effect immediately and shares may be purchased from time to time, subject to business and market conditions and other investment opportunities, through open market

transactions, privately-negotiated transactions, or by other means. The program may be suspended, modified or discontinued at any time at Co.'s discretion. As of Nov. 15, 2017, Co. repurchased approximately 3,600,000 shares of its common stock for a total of approximately \$130,000,000.

TRONC INC

Earnings, 9 mos. to (Consol. - \$000):

	09/24/17	09/25/16
Total Revenues	1,088,998	1,180,956
Cost & expenses	1,009,782	1,126,894
Operating income	37,220	11,263
Other income (expense), net	(2,310)	(723)
Net before taxes	15,485	(9,576)
Income taxes	9,577	3,303
Net income	5,908	(12,879)
Earnings common share		
Primary	\$0.17	\$(0.39)
Fully Diluted	\$0.17	\$(0.39)
Common Shares:		
Full Diluted	34,333	32,908
Year-end	33,550	36,428

TRUPANION INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Total Revenues	176,122	136,890
Cost & expenses	177,602	141,934
Operating income	(1,480)	(5,044)
Interest expense	370	137
Other income (expense), net	1,239	39
Net before taxes	(611)	(5,142)
Income taxes	54	31
Net income	(665)	(5,173)
Earnings common share		
Primary	\$(0.02)	\$(0.18)
Fully Diluted	\$(0.02)	\$(0.18)
Common Shares:		
Full Diluted	29,501	28,362
Year-end	30,033	29,250

ULTRAGENYX PHARMACEUTICAL INC

Merger Completed On Nov. 7, 2017, Co.'s wholly-owned subsidiary, Mystic River Merger Sub Inc. ("Purchaser"), merged with and into Dimension Therapeutics, Inc. ("Dimension"), with Dimension continuing as the surviving corporation and became a wholly-owned subsidiary of Co. As the result of the merger, each share issued and outstanding of Dimension's common stock, par value \$0.0001 per share, immediately prior to the Effective Time was converted into the right to receive \$6.00 per Share, (the "Offer Price"), in cash, without interest thereon and subject to any required tax withholding, other than (i) Shares held by Dimension as treasury stock, or by Co. or Purchaser or (ii) Shares held by stockholders who properly exercised appraisal rights under the DGCL. The aggregate consideration paid by Co. was approximately \$152,300,000, not including related transaction fees and expenses.

ULTRALIFE CORP

Earnings, 9 mos. to (Consol. - \$):

	10/01/17	09/25/16
Total Revenues	63,022,000	60,835,000
Cost & expenses	58,596,000	58,716,000
Operating income	4,426,000	2,119,000
Other income (expense), net	(53,000)	46,000
Net before taxes	4,226,000	1,952,000
Income taxes	370,000	213,000
Net income	3,856,000	1,739,000
Earnings common share		
Primary	\$0.25	\$0.12
Fully Diluted	\$0.24	\$0.11
Common Shares:		
Full Diluted	15,818,000	15,446,000
Year-end	15,590,917	15,231,661

UNITED HEALTH PRODUCTS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	336,543	83,525
Cost & expenses	518,828	424,581
Operating income	(182,285)	(341,056)
Net income	(203,285)	(353,254)
Earnings common share		
Common Shares:		
Full Diluted	153,989,270	151,501,149
Year-end	156,697,207	152,875,394

UNIVERSAL HOSPITAL SERVICES, INC.**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2017	2016
Total Revenues	382,633,000	357,692,000
Cost & expenses	349,239,000	326,664,000
Operating income	33,394,000	31,028,000
Net before taxes	(6,402,000)	(8,182,000)
Income taxes	888,000	677,000
Net income	(7,290,000)	(8,859,000)
Earnings common share		
Common Shares:		
Year-end	1,000	1,000

UPLAND SOFTWARE INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2017	2016
Total Revenues	70,105	55,393
Cost & expenses	74,740	59,057
Deprec., depl. & amort.	4,111	4,270
Operating income	(8,746)	(7,934)
Interest expense	4,372	1,932
Other income (expense), net	(260)	(1,105)
Net before taxes	(13,378)	(10,971)
Income taxes	1,553	569
Net income	(14,931)	(11,540)
Earnings common share		
Primary	\$(0.83)	\$(0.71)
Fully Diluted	\$(0.83)	\$(0.71)
Common Shares:		
Full Diluted	18,043	16,340
Year-end	20,761	17,840

UPLAND SOFTWARE INC

Merger Completed On Nov. 16, 2017, Co.'s wholly-owned subsidiary, Quest Acquisition Corporation I, merged with and into Qvidian Corp. ("Qvidian"), a Massachusetts-based provider of cloud-based RFP and sales-proposal automation software, with Qvidian continuing as the surviving corporation and became a wholly-owned subsidiary of Co. As the result of the merger, Co. paid Qvidian Security-holders \$50,000,000 in cash.

USA TECHNOLOGIES INC**Earnings, 3 mos. to Sep 30**(Consol. - \$):

	2017	2016
Total Revenues	25,617,000	21,588,000
Cost & expenses	25,924,000	22,330,000
Deprec., depl. & amort.	245,000	208,000
Operating income	(552,000)	(950,000)
Other income (expense), net		(1,490,000)
Net before taxes	(681,000)	(2,579,000)
Income taxes	(468,000)	(115,000)
Net income	(213,000)	(2,464,000)
Balance for common	(547,000)	(2,798,000)
Earnings common share		
Primary	\$(0.01)	\$(0.07)
Fully Diluted	\$(0.01)	\$(0.07)
Common Shares:		
Full Diluted	47,573,364	38,488,005
Year-end	50,194,731	40,295,425

Consolidated Balance Sheet Items, as of (\$):

	2017
Assets:	
Cash & equivalents	51,870,000
Inventories	8,240,000
Current assets	74,602,000
Net property & equip.	11,850,000
Total assets	135,219,000
Liabilities:	
Current liabilities	27,913,000
Long-term debt	1,049,000
Stockholders' equity	106,096,000
Net current assets	46,689,000

USA TECHNOLOGIES INC

Merger Completed On Nov. 9, 2017, Co.'s wholly-owned subsidiary, USAT, Inc. ("Merger Sub"), merged with and into Cantaloupe Systems, Inc. ("Cantaloupe"), a premier provider of cloud and mobile solutions for vending, micro markets, and office coffee service, with Cantaloupe continuing as the surviving corporation and became a wholly-owned subsidiary of Co. As the result of the merger, Co. paid \$65,000,000 in cash (the "Cash Consideration"), issued 3,423,367 shares of Co.'s common stock (the "USAT Shares") valued at \$19,810,000 as determined under the Merger Agreement, and assumed \$1,800,000 of certain notes payable of Cantaloupe (collectively, the "Merger Consideration"), subject to certain adjustments set forth in the Merger Agreement,

as consideration for all of the issued and outstanding shares of stock, options, and warrants of Cantaloupe. In addition, each former stockholder and warrant-holder of Cantaloupe who was entitled to receive USAT Shares under the Merger Agreement (a "Cantaloupe Equity-holder") was restricted from selling or otherwise disposing of the USAT Shares for a period of six months following the Merger ("Lock-Up Period"). Additionally, during each trading day during the twelve (12) month period following the expiration of the Lock-Up Period, each Cantaloupe Equity-holder may sell USAT Shares in an aggregate amount not to exceed 5% of the average daily trading volume of Co.'s common stock for each of the trading days occurring during the three-month period ending on the trading day immediately prior to the day on which such sale is to be effected, with exceptions for privately negotiated, off-market block trades. Pursuant to the Escrow Agreement among Co., American Stock Transfer & Trust Company, LLC, as escrow agent, and Shareholder Representative Services LLC, as Stockholders' Representative ("Stockholders' Representative") dated Nov. 9, 2017, 1,496,707 of the USAT Shares, with a value of \$8,660,000 as determined under the Merger Agreement, were not delivered to the Cantaloupe Equity-holders but would be held in escrow for a minimum of fifteen months following the Merger as partial security for certain indemnification obligations of the former stockholders and warrant-holders of Cantaloupe under the Merger Agreement. In addition, an amount of \$300,000 of the Cash Consideration was not delivered to the former Cantaloupe stockholders and warrant-holders and would be held in escrow for the purpose of compensating Co. in the event of a post-closing adjustment to certain items, including Cantaloupe's working capital.

VERITONE INC

Offering On Nov. 17, 2017, Co. announced a public offering pursuant to Common Stock, \$0.001 par value per share. Co. proposed to offer 201,250 at a proposed maximum offering price per share of \$23.00, which amounted to a proposed maximum aggregate offering price of \$4,628,750. The amount of registration fee is \$577.

VERITONE INC

Secondary Offering On Nov. 16, 2017, Co. announced the pricing of an underwritten public offering of 975,000 shares of its common stock at a public offering price of \$23.00 per share. The gross proceeds to Co. from this offering are expected to be approximately \$22,425,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Co. The offering is expected to close on or about Nov. 21, 2017, subject to the satisfaction of customary closing conditions. Co. has also granted the underwriters a 30-day option to purchase up to an additional 146,250 shares of its common stock, to cover over allotments, if any.

VERMILLION INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2017	2016
Total Revenues	2,323	1,837
Cost & expenses	9,824	13,959
Operating income	(7,501)	(12,122)
Other income (expense), net	(9)	16
Net income	(7,542)	(12,122)
Balance for common	(8,484)	(12,122)
Earnings common share		
Primary	\$(0.15)	\$(0.23)
Fully Diluted	\$(0.15)	\$(0.23)
Common Shares:		
Full Diluted	55,910	52,168
Year-end	59,999	52,268

VIACOM INC**Annual Report****Consolidated Income Statement, Years Ended Sept. 30****(\$000):**

	2017	2016	2015
Revenues	13,263,000	12,488,000	13,268,000
Operating expense	7,436,000	6,684,000	6,868,000
Selling, general & administrative expense	3,005,000	2,851,000	2,860,000
Depreciation & amortization expenses	223,000	221,000	222,000
Restructuring	237,000	206,000	206,000
Total expenses	10,901,000	9,962,000	10,156,000
Gain on asset sale	127,000
Operating income	2,489,000	2,526,000	3,112,000
Interest expense, net	(618,000)	(616,000)	(657,000)

Equity in earnings

(losses) of investee companies	81,000	87,000	102,000
Gain on sale of EPIX	285,000
Other items, net	25,000	7,000	54,000
Earnings (loss) from continuing operations before provision for income taxes - United States	1,647,000	1,479,000	2,047,000
Earnings (loss) from continuing operations before provision for income taxes - international	565,000	511,000	456,000
Earnings (loss) from continuing operations before provision for income taxes	2,212,000	1,990,000	2,503,000
Current federal provision for income taxes	312,000	112,000	404,000
Current state & local provision for income taxes	43,000	31,000	65,000
Current international provision for income taxes	112,000	122,000	114,000
Total current provision for income taxes	467,000	265,000	583,000
Deferred provision (benefit) for income taxes	(174,000)	254,000	(82,000)
Provision for income taxes	293,000	519,000	501,000
Net earnings from continuing operations	1,919,000	1,471,000	2,002,000
Discontinued operations, net of tax	3,000	2,000	...
Net earnings (Viacom & noncontrolling interests)	1,922,000	1,473,000	2,002,000
Net losses (earnings) attributable to noncontrolling interests	(48,000)	(35,000)	(80,000)
Net earnings attributable to Viacom	1,874,000	1,438,000	1,922,000
Weighted average shares outstanding-basic	399,900	396,500	402,200
Weighted average shares outstanding-diluted	400,600	398,000	406,000
Year end shares outstanding	402,400	397,000	398,100
Earnings (loss) per share from continuing operations-basic	\$4.68	\$3.62	\$4.78
Earnings (loss) per share-discontinued operations-basic	\$0.01	\$0.01	...
Net earnings (loss) per share-basic	\$4.69	\$3.63	\$4.78
Earnings (loss) per share from continuing operations-diluted	\$4.67	\$3.61	\$4.73
Earnings (loss) per share-discontinued operations-diluted	\$0.01
Net earnings (loss)

per share-diluted	\$4.68	\$3.61	\$4.73
Dividends declared per share of Class A & Class B common stock	\$0.80	\$1.40	\$1.46
Total number of employees	11,650	9,300	9,200
Number of class A common stockholders	1,330	1,397	1,456
Number of class B common stockholders	19,524	20,802	21,905
Foreign currency translation adjustments	29,000	(101,000)	(237,000)

□ Reclassified to conform with 2017 presentation; □ Approximately; □ As is; □ As of October 31, 2017; □ As of October 31, 2016; □ As of November 4, 2015

Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):

	2017	2016
Cash & cash equivalents	1,389,000	379,000
Receivables, gross	3,098,000	2,849,000
Sales returns & allowances	(79,000)	(93,000)
Allowance for doubtful accounts	49,000	44,000
Receivables, net	2,970,000	2,712,000
Inventory, net	919,000	844,000
Prepaid & other assets	523,000	587,000
Total current assets	5,801,000	4,522,000
Land	261,000	239,000
Buildings	491,000	432,000
Capital leases	201,000	204,000
Equipment & other property & equipment	2,020,000	1,958,000
Gross property & equipment	2,973,000	2,833,000
Less: accumulated depreciation	1,995,000	1,901,000
Property & equipment, net	978,000	932,000
Inventory, net	3,982,000	4,032,000
Goodwill	11,665,000	11,400,000
Intangibles, net	313,000	315,000
Other assets	959,000	1,307,000
Total assets	23,698,000	22,508,000
Accounts payable	431,000	453,000
Accrued expenses	869,000	773,000
Participants' share & residuals	825,000	801,000
Program obligations	712,000	692,000
Deferred revenue	463,000	419,000
Current portion of debt	19,000	17,000
Other liabilities	434,000	517,000
Total current liabilities	3,753,000	3,672,000
Senior notes	5,045,000	6,704,000
Senior debentures	4,736,000	5,089,000
Junior debentures	1,284,000	...
Capital leases & other obligations	54,000	120,000
Less current portion	19,000	17,000
Noncurrent portion of debt	11,100,000	11,896,000
Participants' share & residuals	384,000	358,000
Program obligations	477,000	311,000
Deferred tax liabilities, net	294,000	381,000
Other liabilities	1,323,000	1,349,000
Redeemable noncontrolling interest	248,000	211,000
Additional paid-in capital	10,119,000	10,139,000
Treasury stock	20,590,000	20,798,000
Retained earnings	17,124,000	15,628,000
Foreign currency translation adjustments	(405,000)	(435,000)
Defined benefit pension plans	(221,000)	(258,000)
Cash flow hedges	8,000	1,000
Accumulated other comprehensive income		

(loss)	(618,000)	(692,000)
Total Viacom stockholders' equity	6,035,000	4,277,000
Non-controlling interests	84,000	53,000
Total equity	6,119,000	4,330,000

VIEWRAY INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	14,122,000	6,112,000
Cost & expenses	49,430,000	39,779,000
Operating income	(35,308,000)	(33,667,000)
Interest income	3,000	2,000
Interest expense	5,372,000	4,166,000
Other income (expense), net	(6,853,000)	(1,798,000)
Net income	(47,530,000)	(39,629,000)

Earnings common share

Primary	\$(0.85)	\$(1.02)
Fully Diluted	\$(0.85)	\$(1.02)
Common Shares:		
Full Diluted	56,064,562	38,915,156
Year-end	59,071,653	43,354,677

VIKING THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	14,642,937	10,109,751
Operating income	(14,642,937)	(10,109,751)
Other income (expense), net	(287,700)	444,083
Net income	(16,493,192)	(11,087,213)

Earnings common share

Primary	\$(0.67)	\$(0.74)
Fully Diluted	\$(0.67)	\$(0.74)

Common Shares:

Full Diluted	24,665,941	15,052,139
Year-end	28,498,847	19,895,749

VIRTU FINANCIAL INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	563,461,000	531,625,000
Cost & expenses	545,179,000	367,791,000
Operating income	(17,421,000)	140,990,000
Net before taxes	(17,421,000)	140,990,000
Income taxes	(2,918,000)	17,325,000
Net income	(14,503,000)	123,665,000

Earnings common share

Primary	\$(0.17)	\$0.66
Fully Diluted	\$(0.17)	\$0.66

Common Shares:

Full Diluted	53,520,346	38,264,139
Year-end	187,211,676	138,776,180

VOYAGER THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2017	2016
Cost & expenses	63,305	39,315
Operating income	(59,515)	(27,457)
Interest income	799	2,069
Other income (expense), net	(184)	(435)
Net before taxes	(58,900)	(25,823)
Income taxes	(31)	(303)
Net income	(58,869)	(25,520)

Earnings common share

Primary	\$(2.27)	\$(1.01)
Fully Diluted	\$(2.27)	\$(1.01)

Common Shares:

Full Diluted	25,969	25,227
Year-end	26,250	25,419

VWR CORP

Merger Completed On Nov. 21, 2017, Avantor, Inc. ("Parent"), a global supplier of ultra-high-purity materials for the life sciences and advanced technology industries, wholly-owned subsidiary, Vail Acquisition Corp. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each share of common stock, par value \$0.01 per share (the "Common Stock"), of Co. (other than shares of Common Stock subject to stock options and restricted stock units, owned by Co., its subsidiaries, Parent or Merger Sub, or that are held by any stockholder who is entitled to demand and has properly demanded appraisal of such Common Stock and has not failed to perfect,

waived, withdrawn or lost the right to appraisal under Delaware law) was cancelled and converted into the right to receive \$33.25 in cash (the "Merger Consideration") without interest. In addition, each stock option outstanding immediately prior to the Closing Date, whether or not exercisable or vested, was cancelled and converted into the right to receive (i) an amount in cash determined by multiplying (A) the excess (if any) of the Merger Consideration over the exercise price per share of Common Stock underlying such stock option by (B) the number of shares of Common Stock subject to such Stock Option immediately prior to the Closing Date. Each restricted stock unit outstanding immediately prior to the Closing Date was converted into a vested right to receive cash in an amount equal to the Merger Consideration. Each share of Common Stock issued pursuant to Co.'s 2014 Equity Incentive Plan that is subject to specified vesting criteria outstanding immediately prior to the Closing Date was deemed fully vested and treated in accordance with the foregoing. The Merger reflected an enterprise value of approximately \$6,500,000,000 for Co.

VYCOR MEDICAL INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Cost & expenses	1,852,997	2,033,378
Operating income	(949,211)	(1,121,500)
Other income (expense), net	(120,788)	...
Foreign currency	986	(877)
Net income	(1,101,909)	(1,164,822)
Balance for common	(1,426,279)	(1,344,549)

Earnings common share

Primary	\$(0.08)	\$(0.12)
Fully Diluted	\$(0.08)	\$(0.12)

Common Shares:

Full Diluted	17,895,269	11,012,689
Year-end	19,738,189	11,220,856

VYSTAR CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues	11,723	37,264
Cost & expenses	876,389	918,259
Operating income	(864,666)	(880,995)
Interest income	1	1
Other income (expense), net	78,513	(14,456)
Net income	(872,714)	(986,476)

Earnings common share

Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)

Common Shares:

Full Diluted	122,514,759	104,995,141
Year-end	130,495,927	111,954,708

WHOLE FOODS MARKET INC

Annual Report

Consolidated Income Statement, Years Ended (\$):

	09/24/17	09/25/16 (revised)	09/27/15 (revised)
Sales	16,030,000,000	15,724,000,000	15,389,000,000
Cost of goods sold & occupancy costs	10,633,000,000	10,313,000,000	9,973,000,000
Gross profit	5,397,000,000	5,411,000,000	5,416,000,000
Selling, general & administrative expense	4,627,000,000	4,477,000,000	4,472,000,000
Merger-related expenses	156,000,000
Pre-opening expenses	60,000,000	64,000,000	67,000,000
Relocation, store closure & lease termination cost	95,000,000	13,000,000	16,000,000
Operating income	459,000,000	857,000,000	861,000,000
Interest expense	49,000,000	41,000,000	...
Investment & other income	7,000,000	11,000,000	17,000,000
Income before income taxes	417,000,000	827,000,000	878,000,000
Current federal income taxes	168,000,000	223,000,000	310,000,000
Current state income taxes	58,000,000	52,000,000	76,000,000
Current foreign income taxes	1,000,000	(1,000,000)	(1,000,000)
Total current income taxes	227,000,000	274,000,000	385,000,000
Deferred federal			

income taxes (benefit).....	(56,000,000)	41,000,000	(40,000,000)
Deferred state income taxes (benefit).....	2,000,000	8,000,000	(2,000,000)
Deferred foreign income taxes (benefit).....	(1,000,000)	(3,000,000)	(1,000,000)
Total deferred income taxes (benefit).....	(55,000,000)	46,000,000	(43,000,000)
Provision for income taxes.....	172,000,000	320,000,000	342,000,000
Net income (loss)	245,000,000	507,000,000	536,000,000
Weighted average shares outstanding - basic.....	326,100,000	358,500,000	
Weighted average shares outstanding - diluted.....	326,900,000	360,800,000	
Year end shares outstanding.....	100	318,323,000	348,900,000
Net income (loss) per share - basic.....	\$1.55	\$1.49	
Net income (loss) per share - diluted.....	\$1.55	\$1.48	
Dividends declared per common share.....	\$0.46	\$0.54	\$0.52
Number of full time employees.....			61,700
Number of part time employees.....			27,100
Number of temporary employees.....			2,100
Total number of employees.....	89,000,000	87,000	90,900
Number of common stockholders.....		1,326	1,343
Foreign currency translation adjustments.....	(4,000,000)	(21,000,000)	

¹ Reclassified to conform with 2017 presentation; ² Shares decreased due to the effect of the merger with Walnut Merger Sub, Inc. where each share was converted into the right to receive \$42.00 per share in cash.; ³ Approximately; ⁴ As of November 11, 2016; ⁵ As of November 11, 2015

Consolidated Balance Sheet, Years Ended (\$):

	09/24/17	09/25/16 (revised)
Cash & cash equivalents.....	322,000,000	351,000,000
Short-term investments - available-for-sale.....		
Securities.....	504,000,000	379,000,000
Restricted cash.....	124,000,000	122,000,000
Accounts receivable.....	242,000,000	242,000,000
Merchandise inventories.....	471,000,000	517,000,000
Prepaid expenses & other current assets.....	143,000,000	167,000,000
Receivable from parent.....	124,000,000	
Deferred income taxes.....	215,000,000	197,000,000
Total current assets.....	2,145,000,000	1,975,000,000
Land.....	156,000,000	161,000,000
Buildings & leasehold improvements.....	3,641,000,000	3,390,000,000
Capitalized real estate leases.....	120,000,000	80,000,000
Fixtures & equipment.....	2,615,000,000	2,499,000,000
Construction in progress & equipment not yet in service.....	265,000,000	284,000,000
Gross property & equipment.....	6,797,000,000	6,414,000,000
Less accumulated depreciation & amortization.....	3,283,000,000	2,972,000,000
Property & equipment, net of accumulated depreciation and amortization.....	3,514,000,000	3,442,000,000
Long-term investments - available-for-sale securities.....	121,000,000	

Goodwill.....	710,000,000	710,000,000
Intangible assets, net of accumulated amortization.....	68,000,000	74,000,000
Deferred income taxes.....	74,000,000	100,000,000
Other assets.....	44,000,000	40,000,000
Total assets.....	6,676,000,000	6,341,000,000
Current installments of long-term debt & capital lease obligations.....	2,000,000	3,000,000
Accounts payable.....	371,000,000	307,000,000
Accrued payroll, bonus & other benefits due team members.....	397,000,000	407,000,000
Dividends payable.....		43,000,000
Other current liabilities.....	585,000,000	581,000,000
Total current liabilities.....	1,355,000,000	1,341,000,000
Senior unsecured notes.....	999,000,000	1,000,000,000
Less: unamortized discount and debt issuance costs related to senior notes.....	(6,000,000)	(7,000,000)
Carrying value of senior notes.....	993,000,000	993,000,000
Capital lease obligations.....	90,000,000	58,000,000
Less: current installments.....	2,000,000	3,000,000
Long-term debt & capital lease obligations, less current installments.....	1,081,000,000	1,048,000,000
Deferred lease liabilities.....	690,000,000	640,000,000
Other long-term liabilities.....	120,000,000	88,000,000
Total liabilities.....	3,246,000,000	3,117,000,000
Common stock.....	2,972,000,000	2,933,000,000
Common stock in treasury, at cost.....		2,026,000,000
Accumulated other comprehensive income (loss).....	(38,000,000)	(32,000,000)
Retained earnings (accumulated deficit).....	496,000,000	2,349,000,000
Total shareholders' equity.....	3,430,000,000	3,224,000,000

¹ Reclassified to conform with 2017 presentation

WILLDAN GROUP INC

Earnings, 9 mos. to (Consol. - \$):

	09/29/17	09/30/16
Cost & expenses.....	195,585,000	140,353,000
Deprec., depl. & amort.....	2,896,000	2,308,000
Operating income.....	10,710,000	8,855,000
Interest expense.....	88,000	137,000
Other income (expense), net.....	56,000	2,000
Net before taxes.....	10,678,000	8,720,000
Income taxes.....	1,839,000	1,990,000
Net income	8,839,000	6,730,000
Earnings common share		
Primary.....	\$1.03	\$0.82
Fully Diluted.....	\$0.97	\$0.79
Common Shares:		
Full Diluted.....	9,138,000	8,516,000
Year-end.....	8,764,000	7,904,000

WINGSTOP INC

Earnings, 9 mos. to (Consol. - \$000):

	09/30/17	09/24/16
Total Revenues.....	77,267	66,607
Net Sales.....	27,063	25,144
Cost & expenses.....	47,984	43,472
Deprec., depl. & amort.....	2,407	2,187
Operating income.....	26,876	20,948
Interest expense.....	3,908	2,858
Other income (expense), net.....		(254)
Net before taxes.....	22,968	17,836
Income taxes.....	6,161	6,714
Net income	16,807	11,122
Earnings common share		
Primary.....	\$0.58	\$0.39
Fully Diluted.....	\$0.57	\$0.38
Common Shares:		
Full Diluted.....	29,362	28,991
Year-end.....	29,094	28,731

WOODSTOCK HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2017	2016
Total Revenues.....	4,850,090	4,947,432
Cost & expenses.....	5,170,903	5,207,554
Net income	(320,813)	(260,122)
Earnings common share		
Primary.....	\$(0.19)	\$(0.17)
Fully Diluted.....	\$(0.19)	\$(0.17)
Common Shares:		
Year-end.....	2,121,858	1,953,853

WOODWARD, INC.

Annual Report

Consolidated Income Statement, Years Ended Sept. 30

(\$000):

	2017	2016 (revised)	2015 (revised)
Net sales.....	2,098,685	2,023,078	2,038,303
Cost of goods sold.....	1,526,126	1,483,960	1,462,833
Selling, general & administrative expenses.....	176,633	174,017	177,121
Research & development costs.....	126,519	126,170	134,485
Interest expense.....	27,430	26,776	24,864
Interest income.....	1,725	2,025	787
Equity interest in the earnings of the joint venture (JV).....	2,568	6,204	
Net gain (loss) on sales of assets.....	3,604	4,431	626
Rent income.....	254	315	485
Net gain (loss) on investments in deferred compensation program.....	1,833	1,062	(33)
Other income (expense).....	786	294	84
Total costs & expenses.....	1,845,938	1,796,592	1,797,354
Earnings before income taxes - United States.....	192,220	175,146	172,315
Earnings (loss) before income taxes - other countries.....	60,527	51,340	68,634
Earnings (loss) before income taxes.....	252,747	226,486	240,949
Current federal income taxes (benefit).....	17,872	81,127	23,923
Current state income taxes.....	1,379	6,067	3,108
Current foreign income taxes (benefit).....	15,118	9,689	18,343
Deferred federal income taxes (benefit).....	16,907	(40,801)	19,236
Deferred state income taxes (benefit).....	(2,561)	(9,054)	751
Deferred foreign income taxes (benefit).....	3,525	(1,380)	(5,864)
Income tax expense (benefit).....	52,240	45,648	59,497
Net earnings (loss)	200,507	180,838	181,452
Weighted average shares outstanding - basic.....	61,366	61,893	64,684
Weighted average shares outstanding - diluted.....	63,512	63,556	66,056
Year end shares outstanding.....	61,221	61,586	63,197
Net earnings (loss) per share - basic.....	\$3.27	\$2.92	\$2.81
Net earnings per share - diluted.....	\$3.16	\$2.85	\$2.75
Dividends per common share.....	\$0.48	\$0.43	\$0.38
Number of full time			

employees	2,690	2,680	2,690
Number of common stockholders	2,900	2,100	2,100
Foreign currency translation adjustments	45	(6,615)	(34,989)

□ Reclassified to conform with 2017 presentation; □ As is; □ As of October 31, 2017; □ As of October 31, 2016; □ Approximate; □ As of October 31, 2015; □ As of November 3, 2017; □ As of November 10, 2016; □ As of November 6, 2015

Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):

	2017	2016	2015
Cash & cash equivalents	87,552	81,090	
Accounts receivable, gross	405,958	346,308	
Less allowance for uncollectible amounts	3,776	2,540	
Accounts receivable, net	402,182	343,768	
Raw materials	59,034	54,246	
Work in progress	103,790	109,756	
Component parts	262,755	249,307	
Finished goods	47,926	48,374	
Inventories, net	473,505	461,683	
Income taxes receivable	19,376	20,358	
Other current assets	38,574	37,525	
Total current assets	1,021,189	944,424	
Land & land improvements	88,326	87,696	
Buildings & buildings improvements	514,453	527,704	
Leasehold improvements	16,142	15,213	
Machinery & production equipment	543,641	484,315	
Computer equipment & software	124,723	117,984	
Office furniture & equipment	24,308	29,344	
Other property, plant & equipment	19,393	18,969	
Construction in progress	111,910	88,909	
Property, plant & equipment, gross	1,442,896	1,370,134	
Less accumulated depreciation	520,853	493,784	
Property, plant & equipment, net	922,043	876,350	
Goodwill	556,545	555,684	
Intangible assets, net	171,882	197,650	
Deferred income tax assets	19,950	20,194	
Other assets	65,500	48,060	
Total assets	2,757,109	2,642,362	
Short-term borrowings & current portion of long-term debt	32,600	150,000	
Accounts payable	232,788	169,439	
Income taxes payable	6,774	4,547	
Accrued salaries & other member benefits	91,285	87,197	
Accrued warranties	13,597	15,993	
Accrued interest payable	9,626	9,071	
Current portion of acquired performance obligations & unfavorable contracts	1,627	2,910	
Accrued retirement benefits	2,413	2,505	
Current portion of loss reserve on contractual lease commitments	1,343	1,840	
Current portion of deferred income from JV formation	6,451	6,552	
Deferred revenues	4,625	5,779	
Accrued taxes, other than income	14,401	14,580	
Other accrued liabilities	9,704	10,200	
Accrued liabilities	155,072	156,627	
Total current liabilities	427,234	480,613	
Revolving line of credit	32,600	156,700	
Unsecured series notes	582,080	572,544	
Less: current portion of			

long-term debt	32,600	150,000
Less: unamortized debt issuance costs	(1,794)	(2,091)
Long-term debt, less current portion	580,286	577,153
Deferred income tax liabilities	33,408	3,777
Net accrued retirement benefits, less amounts recognized within accrued liabilities	52,211	70,479
Noncurrent portion of deferred income from JV formation	236,896	238,187
Total unrecognized tax benefits, net of offsetting adjustments	20,949	17,239
Acquired unfavorable contracts	2,076	3,148
Deferred economic incentives	14,574	16,196
Loss reserve on contractual lease commitments	3,927	7,402
Other liabilities	14,165	15,573
Total liabilities	1,385,726	1,429,767
Common stock	106	106
Additional paid-in capital	163,836	141,570
Accumulated other comprehensive earnings (losses)	(53,186)	(65,705)
Deferred compensation	7,135	5,089
Retained earnings	1,820,268	1,649,506
Less treasury stock at cost	559,641	512,882
Treasury stock held for deferred compensation, at cost	(7,135)	(5,089)
Total Woodward Governor Company stockholders' equity (deficit)	1,371,383	1,212,595
Total stockholders' equity	1,371,383	1,212,595

□ Reclassified to conform with 2017 presentation

XCEL BRANDS, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$):		2017	2016
Total Revenues	24,690,000	25,793,000	
Cost & expenses	20,707,000	23,214,000	
Operating income	2,810,000	1,407,000	
Interest expense	1,040,000	1,427,000	
Net before taxes	1,770,000	(20,000)	
Income taxes	1,704,000	(3,000)	
Net income	66,000	(17,000)	
Earnings common share			
Common Shares:			
Full Diluted	18,896,418	18,608,034	
Year-end	18,468,801		

XTANT MEDICAL HOLDINGS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):		2017	2016
Total Revenues	63,279,912	65,531,879	
Cost & expenses	69,950,971	68,229,992	
Operating income	(10,775,624)	(6,388,632)	
Other income (expense), net	(2,677,625)	406,814	
Net income	(23,991,671)	(14,956,713)	
Earnings common share			
Primary	\$(1.33)	\$(1.24)	
Fully Diluted	\$(1.33)	\$(1.24)	
Common Shares:			
Full Diluted	18,065,911	12,064,782	
Year-end	18,173,007	12,193,970	

YANGTZE RIVER DEVELOPMENT LTD

Earnings, 9 mos. to Sep 30 (Consol. - \$):		2017	2016
Cost & expenses	3,915,184	4,559,561	
Operating income	(3,915,184)	(4,559,561)	
Interest income	216	174	
Interest expense	6,409,691	6,474,519	

Other income (expense), net	(857)	2,799
Net before taxes	(10,325,516)	(11,031,107)
Income taxes	(816,048)	(884,725)
Net income	(9,509,468)	(10,146,382)
Earnings common share		
Primary	\$(0.05)	\$(0.06)
Fully Diluted	\$(0.05)	\$(0.06)
Common Shares:		
Full Diluted	198,000,128	172,268,077
Year-end	172,344,446	172,269,446

ZAFGEN INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):		2017	2016
Cost & expenses	39,641	47,750	
Operating income	(39,641)	(47,750)	
Interest income	740	664	
Interest expense	157	432	
Foreign currency	115	79	
Net income	(38,943)	(47,439)	
Earnings common share			
Primary	\$(1.42)	\$(1.74)	
Fully Diluted	\$(1.42)	\$(1.74)	
Common Shares:			
Full Diluted	27,414	27,286	
Year-end	27,484	27,329	

ZONED PROPERTIES INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):		2017	2016
Total Revenues	1,580,602	1,310,870	
Cost & expenses	919,612	1,348,429	
Operating income	493,225	(163,469)	
Interest income	5,622		
Gains or losses	831,753	(1,843)	
Net income	1,188,629	(335,931)	
Earnings common share			
Primary	\$0.06	\$(0.02)	
Fully Diluted	\$0.06	\$(0.02)	
Common Shares:			
Full Diluted	18,142,071	17,136,148	
Year-end	17,311,701	17,181,375	

ZYNERBA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):		2017	2016
Total Revenues		7,250	
Cost & expenses	24,618,505	16,530,212	
Operating income	(24,618,505)	(16,522,962)	
Foreign currency	361,450	(49,668)	
Net before taxes		(16,519,387)	
Income taxes		(27,543)	
Net income	(23,893,705)	(16,491,844)	
Earnings common share			
Primary	\$(1.87)	\$(1.86)	
Fully Diluted	\$(1.87)	\$(1.86)	
Common Shares:			
Full Diluted	12,743,332	8,865,854	
Year-end	13,257,279	9,628,278	

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2017 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.